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Prostate cancer selectively metastasises to the axial skeleton where it produces
osteoblastic lesions.
Media conditioned by human osteoblast-like cells demonstrated growth stimulation of
prostate cell lines in a dose dependent manner. PC-3 cells were stimulated to a maximum of
3.5 fold greater than control levels. DU145 cells and LNCaP were stimulated to a lesser
extent, 2.3 (p<0.025) and 1.5 fold (p<0.025) respectively. This stimulatory activity was heat
and acid sensitive and its production from the osteoblast-like cells was unaffected by 1nM
dihydrotestosterone or 1 nM 1,25 (OH)2 vitamin D.
Media conditioned by red bone marrow, derived from proximal femora, did not
stimulate the growth of prostate cell lines. Prostate cell line growth was also unaffected by
media conditioned by cell lines derived from bladder, lung and kidney (diluted to 50%), which
represent other metastatic sites of prostate cancer.
To aid the characterisation of prostate mitogens in osteoblast-like cell conditioned
medium, the effect of haematopoietic growth factors (produced predominantly in the bone
environment) was tested. Results showed that PC-3 and DU145 could be significantly
(p<0.0025) stimulated by rEPO (>1mlU/ml) and rGM-CSF (>0.1IU/ml) in serum free medium.
Stimulation was dose dependent. rEPO stimulated PC-3 cell growth 2.6 fold and DU145 2.2
fold. rGM-CSF stimulated growth of the two cell lines by a greater degree, PC-3 cells were
stimulated 3 fold and DU145 2.3 fold. Growth of the same cell lines was unaffected by
incubation with rlL-3 (0.1-1000mU/ml) or rG-CSF (0.1-1000IU/ml). The LNCaP cell line was
stimulated only by rGM-CSF (>5IU/ml).
To investigate further the involvement of GM-CSF in prostate cancer the presence of
GM-CSF protein in the three prostate cell lines was determined by immunohistochemistry
and examination of cell line conditioned media with ELISA and Western blotting. These
techniques demonstrated that GM-CSF-like material was produced by DU145 and PC-3 cells
but not by LNCaP. The results from ELISA found media conditioned by DU145 cells
contained 1.7pg GM-CSF/pg protein and PC-3 conditioned medium contained 2.5pg GM-
CSF/pg protein. The presence of GM-CSF gene transcripts in DU145 and PC-3 cells was
established by reverse transcription and PCR of total RNA.
These findings suggest that osteoblast-like cell conditioned medium, GM-CSF and
EPO may be responsible for the growth stimulation of prostate cancer in skeletal metastases.
Production of GM-CSF by prostate carcinoma cells could play a role in the formation of
osteoblastic lesions and may represent an autocrine mechanism of growth.
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INTRODUCTION
Prostate cancer is a slow growing tumour, the incidence of which is
closely correlated to age (Silverberg 1987). A small percentage of these
tumours become metastatic (Berretoni & Carter 1986), and this aggressive
form of the disease has a high level of mortality since the metastases are
usually multiple and destructive. Paget (1889) was the first to observe that
cancers metastasize preferentially to selective secondary organs. He
hypothesised that the environment of that secondary organ provided a
'nutritious soil' for the cancer to grow in. This could be explained by the
presence of specific growth factors secreted by the secondary organ. The
aim of this thesis was to identify growth factors secreted by the bone
environment that can stimulate prostate cancer growth.
1.1 Prostate Cancer
Prostate cancer is now the second most common cause of cancer for
males in the European Community (Jensen et al 1990), and a major cause of
death for men over the age of 55 years. The cost of treatment is an ever
growing burden on the State and with life expectancy increasing the problem
will get worse. At the moment a successful treatment for advanced prostatic
carcinoma has not been established. An understanding of the normal




a) Normal Physiology and Function Of The Prostate
The prostate is a musculoglandular organ, surrounding the prostatic
urethra. Morphological and embryological studies by McNeal (1972, 1988a)
have led to the identification of three main zones in the prostate gland
(Figure 1):
a) the peripheral zone
b) the central zone
c) the transitional zone
The peripheral zone is responsible for 70% of the glandular mass of
the gland and the central zone a further 25%. Each zone has a separate
composition of stroma, muscle fibre, accessory cells and a population of
endocrine-paracrine cells. All possess ductal-acinar systems, lined with
columnar, secretory epithelia (McNeal 1988a). The epithelia produce
prostatic fluid which slowly collects in the gland. During emission this fluid
injects into the urethra by muscular contraction, where it combines with
spermatozoa and other seminal fluids. Prostatic fluid represents roughly
30% of the average ejaculate volume (Aumuller 1992). The main proteins
found in the fluid are prostatic acid phosphatase (Lin et al 1986), prostatic
specific antigen (Wang et al 1979) and ft-microseminoprotein (Akiyama et al
1985). Citrate is also present, creating a pH of 6.5, which is thought to
neutralise the alkalinity of cervical mucus. Other possible functions of the
prostatic fluid include liquefaction of seminal fluid (Amelar 1962), sperm
motility (by an ion-exchange reaction) and an immunosuppressive effect on
the urethra or cervix (Aumuller 1992).
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Figure 1: Diagram of adult prostate. Illustrating position of
peripheral zone (PZ), central zone (CZ), transitional zone (TZ),
pre-prostatic sphincter (PPS), verumontanum (V), seminal
vesicles (SV), vas deferens (Vas) and bladder (B).
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b) Regulation of Prostate Growth
Testicular androgens are essential for the normal functioning of the
prostate. 95% of circulating testosterone is produced in the testes, the
remaining 5% derives from adrenal androgens (Baird et al 1969).
Testosterone production from both sources depends on the hypothalamic-
pituitary-gonadal axis, illustrated in figure 2.
o
Androgen receptor
SHBG - steroid hormone binding globulin





Figure 2: Endocrine Control Of The Prostate
Higher Centres PLASMA PROSTATE CELLS
CRH LHRH
CRH - corticotrophic releasing hormone
LHRH - luteinising hormone releasing hormone
ACTH - adrenocorticotropic hormone





Testosterone is synthesised by the Leydig cells of the testes in
response to the secretion of luteinising hormone from the anterior pituitary
gland. The production of luteinising hormone is controlled by the pulsatile
secretions of luteinising hormone releasing hormone (LHRH) from
4
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hypothalamic neurones. The pulsatile nature of LHRH conveys a similar
rhythmic, secretory nature to luteinising hormone (Clarke & Cummins 1987).
Testosterone acts in a negative feedback loop on both the pituitary and the
hypothalamus. This is achieved by decreasing the pulse frequency and
amplitude of luteinising hormone secretion (Johnson and Everitt 1988).
Integration of neural and endocrine systems occurs in the higher centres of
the brain, where the secretion of LHRH can be regulated by stimulatory and
inhibitory neurotransmitters e.g. catecholamines, serotonin and opioid
systems (Clarke & Cummins 1987).
The production of adrenal androgens is dependent on the secretion of
adrenocorticotrophic hormone from the pituitary, again, under the influence
of the hypothalamus. These adrenal androgens can be metabolised by the
prostate (Harper et al 1974).
90% of the total circulating testosterone is bound to serum proteins
(albumin and steroid hormone binding globulin), the remaining 10% is
unbound and therefore available to the prostate cell (Peeling & Griffiths
1987). This available testosterone is taken into the prostate cell and reduced
by the enzyme 5a-reductase to form dihydrotestosterone (DHT). 5a-
reductase is found on the nuclear membrane, endoplasmic reticulum and in
smaller quantities in the cytoplasm (Moore et al 1974), though it may be
confined to the nuclear membrane (Houston et al 1985). DHT binds to the
hormone binding region of the androgen receptor, a protein with both
hormone and DNA binding sites. This leads to conformational changes
within the receptor which expose the DNA binding sites. The hormone-
receptor complex can then attach to specific DNA sequences (androgen
response elements) in the genome (Claessens et al 1989). Transcriptional
5
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alterations are produced, which control further gene activity and protein
production, essential for prostate growth (Katz et al 1989).
In peripheral tissues such as adipose, testosterone can be converted
to oestradiol by aromatization (Folkerd & James 1983). Oestrogens have
been found in the prostate (Ghanadian & Puah 1981) though whether or not
oestrogen receptors are present in the prostate remains undetermined (F.K.
Habib 1990). Prostate growth is also stimulated by prolactin, apparently due
to a synergistic action with luteinizing hormone, which results in enhanced
testosterone production (Hafiez et al 1972). Its stimulatory effect may also
occur by potentiating 5a-reductase activity (Yamanka et al 1975).
The normal growth of prostate is also dependent on locally produced
growth factors. Stroma and epithelium are found in close proximity to each
other within the prostate gland (Rohr & Bartsch 1980, McNeal 1988a). These
cell types are thought to closely interact by the release of paracrine growth
factors. This is illustrated by the research of Kabalin et al (1989) who
showed that fibroblasts can stimulate epithelial cell colony growth. The
paracrine interaction is further illustrated by the findings of Sugimura et al
(1986) who showed that the growth of foetal epithelium is androgen-
dependent only when androgen receptors are present in the mesenchyme,
and not in the epithelium. Androgen receptors and 5a-reductase are found in
both epithelial and stromal compartments (Schweikert et al 1985, Kyprianou
& Davies 1986), indicating both cell types could be affected by androgens.




Table 1: Prostate Derived Growth Factors
EGF 6Kd (h) (Maddy et al 1987, Jacobs et al 1988,
Fowler et al 1988)
bFGF 16Kd (h) (Mydlo et al 1988, Story et al 1989)
IGF-IS 7.5Kd (r) (Matuo et al 1988)
PDGF 30Kd (h) (Sitaras et al 1988)
TGFa 6Kd (h) (Wilding et al 1989a)
TGFG1 25Kd (r) (Steiner et al 1991, Matuo et al 1990)
TGF&2 25Kd (h) (Mori et al 1990)
Growth Hormone 20Kd (h) (Sibley et al 1984)
Prostate derived growth factor 25Kd (r) (Maehma et a11986)
Nerve Growth Factor 26Kd (h) (Djakiew et al 1991)
(h-human, r-rat model)
Some of these factors are potentially responsible for the paracrine
growth control discussed. Table 2 lists the variety of growth factors
(stimulatory and inhibitory) known to affect the prostate.
Table 2: Prostate Growth Factors
STIMULATORY INHIBITORY
Androgens (h) (Schuurmans et al 1988)
Insulin 6Kd (h) (McKeehan et al 1987)
Prolactin 23/48Kd (h) (Hafiez et al 1972)
EGF 6Kd (h) (Schuurmans et al 1988,
MacDonald et al 1990)
bFGF 16Kd (h) (Story et al 1989)
IGF-I 7Kd (h) (Fiorelli et al 1991)
TGFa 6Kd (h) (Wilding et al 1989a)
Nerve growth factor 26Kd (h)
(Djakiew et al 1991)
TGFft 25Kd (m)
(Fernandez et al 1986)
Prostate epithelium inhibitory




Generally the mitogenic influences of EGF and FGF are balanced by
the inhibitory activity of TGFf2>. EGF is both produced by and stimulates the
prostate. The presence of its receptors have been demonstrated in normal
prostate tissue (Fekete et al 1989), benign prostate (Maddy et al 1987),
cancer tissue (Fekete et al 1989) and cell lines (MacDonald et al 1990).
Studies on a prostate tumour cell line have demonstrated how EGF receptor
expression can be increased in response to androgen stimulation
(Schuurmans et al 1991), thus illustrating how growth is controlled by steroid
and growth factor interactions.
The interactions of prostate cells, growth factors and hormones are
clearly important for regulating growth of the normal gland. Progression of
malignant growth is likely to be accompanied by a breakdown in these
regulatory processes and an understanding of this may help find therapies.
c) Prostate cancer
Carcinomas of the prostate arise mainly in the peripheral zone of the
gland (McNeal et al 1988b). The tumour grows towards and outside the
prostatic capsule. This initial growth is slow and clinically unnoticed. In many
cases the disease remains as a small focus and causes no medical
problems (Carter & Coffey 1990). McNeal et al (1986) suggested 1ml is a
critical size, with subsequent growth leading to biological aggressiveness
and metastasis. The metastatic spread occurs through the lymphatics and
the venous systems, with secondaries occurring in lymph nodes, bone and
lungs (Busuttil 1990). Not until the cancer enlarges or metastasises does it
become necessary to treat. Early forms of the cancer are hormone sensitive
and if confined to the prostate can be treated with endocrine therapy,
surgery, or irradiation. However 75% of patients diagnosed already have
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metastases (Ritchie 1989) which places them beyond the effectiveness of
such treatments to fully remove the cancer (Ritchie 1989). Once the cancer
progresses to a hormone insensitive state endocrine treatments cannot slow
further progression and radiotherapy or chemotherapy are used to try and
inhibit cancer growth (Nagel & Kolln 1977, Laing et al 1991). Skeletal
metastases are usually very painful and interfere with surrounding
musculature and neural structures. They also cause weakening of the bone
leading to fractures and disrupt the bone marrow (Berrettoni and Carter
1986). Bisphosphonate compounds are used to alleviate the pain of skeletal
metastases (Adami et al 1985, Yu-Cheng et al 1992) but they also do not
present a cure, only slow progression.
Clearly preventative treatment is important for prostate cancer.
Screening men would help find the curable, early primary tumours. Since
men presented at diagnosis already have metastases such a move would be
greatly beneficial.
i) Factors Involved In Prostate Cancer Formation
Various factors are involved in the formation of prostate carcinoma.
The most striking of these is age. Figure 3 illustrates how the incidence of
both benign prostatic hyperplasia (BPH) and prostate carcinoma (CaP)
increases with age.
The incidence of benign prostatic hyperplasia increases from 20% to
80% between the ages of 40 and 80 years. Carcinoma is rarely seen before
the age of 40 and its incidence lags behind benign prostatic hyperplasia in
years (Bostwick et al 1991). The second most striking factor is the
involvement of androgens. Anti-androgens and castration can inhibit
hormone sensitive cancers (Tetu et al 1991, Huggins et al 1941), indicating
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Figure 3: Age-specific Prevalence of BPH and CaP in Human Autopsy
(After Bostwick et al 1991)
Epidemiological studies have indicated an environmental factor. The
incidence of prostate cancer is much lower in Japan and China (0.1-0.3%)
compared to the USA (12%). However Chinese and Japanese emigrants to
the USA show an increase in incidence (Carter & Coffey 1990). This maybe
due to changing diet and certain studies have demonstrated a strong
association between cancer and dairy products (Armstrong & Doll 1975).
The cancer can also be an inherited disease (Steinberg et al 1990).
Evidence shows the risk for a man increases with number of affected
relatives and how genetically close he is to an affected relative.
To investigate the mechanisms of prostate cancer formation and




Various human and animal models exist for studying prostate
carcinoma. An ideal model system should represent the human disease
exactly. Therefore these models must be capable of eliciting responses to
hormonal and chemotherapeutic manipulations, analogous to the natural
disease. They should be capable of forming metastases and also create
reproducible results. A major problem of producing such a system is that the
fundamental prostate biology is not completely understood.
Animal Models
The most well known animal model is the Dunning rat tumour, a
spontaneous tumour of the rat prostate (Lubaroff et al 1980). It is a useful
model but limited because it isn't human nor does it form skeletal metastases
(without artificial assistance). Rats, mice and hamsters are often used as
hosts for the injection of human tumour tissue. This allows tumour
progression and metastasis to be observed and manipulated. Sufficient
numbers of animals can be used, allowing better statistical analysis of the
results. The injection of human tissue can, however, lead to immunological
reactions within the animal, which can complicate results. Hormone
insensitive cells have been successfully injected into immune suppressed
mice (Mickey et al 1980) but hormone sensitive cells have had low
acceptance rates (Otto et al 1988).
Organ Culture
This technique employs whole organs cultured in tanks of culture
medium or organ fragments cultured on plasma clots in petri dishes
(Lasnitzki et al 1982). It allows functional and structural tissue preservation,
and lasts for a few hours or days. Often the organ retains its hormonal
responsiveness and secretory activities. Therefore this model allows a more
11
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physiological investigation, though the lack of systemic influences means the
model is still not true. McMahon et al (1972) successfully produced prostate
organ cultures. This allowed drug response experiments on an organ from a
patient with a known and useful medical history. However obtaining suitable
positive and negative controls can be difficult. This problem is compounded
by inconsistent availability of organs. Surgery may also cause damage or
infection of the organ and once in culture deterioration occurs within days.
Primary Culture
The problems of organ culture can be overcome with primary cultures - cells
cultured from fresh tissue. An isolated cell system allows the investigation of
specific changes in carcinogenesis (a difficult task in vivo). Primary cultures
provide a means of isolating fibroblasts and epithelial cell cultures, usually
employing collagenase digestion (Chaproniere et al 1986, Peehl 1985).
These cells are representative of the original organ because they are not
altered by prolonged in vitro serial culture. The technique allows improved
reproducibility when compared to organ culture, though the cultured cells
have a finite life span and serial dilution is not always possible. They are still
prone to bacterial and fungal contamination. It was discussed earlier that the
normal growth of the prostate is, in part, regulated by paracrine interactions
between the fibroblast and epithelia cells. Loss of this interaction may result
in unrepresentative findings. Epithelia will generally be contaminated with
fibroblasts, and malignant cultures contaminated with sub-populations of
benign cells. Therefore, exact characterisation of the culture is difficult to
determine. These latter problems are overcome using cell lines.
Cell Lines
Established cell lines have the ability to sub-culture indefinitely in
vitro. The 'infinite' life of these cells is their major advantage, allowing
12
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greater accuracy for experimental repetition than any other model. It is
unknown if these cells are immortal due to a series of mutations in culture
(Periera-Smith & Smith 1988) or the clonal expansion of an immortal cell
from the original neoplastic tissue. Diverging characteristics of the same cell
line can result from long-term culture of cloned cells, especially if culture
conditions vary between different laboratories (Labrie & Veilleux 1986). One
cell line can be easily contaminated with another cell line if tissue culture
technique is poor. Results therefore, may not be reproducible between
different laboratories. Bacterial and fungal contaminations present fewer
problems than other models, however the imperceptible contamination of
mycoplasma is a greater concern. Mycoplasma is difficult to detect and can
affect cell growth, thereby negating experimental results (McGarrity et al
1985).
Prostate cell lines are available which represent pure cultures of
malignant, epithelial prostate cells, in both hormone sensitive and insensitive
stages of malignancy. The cell line LNCaP is hormone sensitive, showing
increased growth when stimulated with DHT (Horoszewicz et al 1983,
Hasenson et al 1985). It is derived from a supraclavicu lor lymph node
metastatic lesion. Many aspects of functional differentiation are preserved
such as prostatic acid phosphatase, prostate specific antigen and androgen
receptors in the cytosol and nuclear fractions. The cell lines DU145 and PC-
3 are both hormone insensitive. DU145 was established from a brain
metastasis (Stone et al 1978, Mickey et al 1980) and PC-3 from a bone
metastasis (Kaighn et al 1979). Both exhibit fewer prostatic markers than
LNCaP with prostatic acid phosphatase present at low levels and androgen
receptors expressed at very low levels or not at all (Tilley et al 1990). PC-3
13
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and DU145 grow in very low serum and with a faster growth rate than
LNCaP (for a summary of properties see table 3).
Table 3: Characteristics ofprostate carcinoma cell lines
CELL LINE DU145 PC-3 LNCaP
ORIGIN Brain metastasis Bone metastasis Lymph node
metastasis
CELL TYPE epithelia epithelia epithelia












The three cell lines represent useful models for prostate cancer, a
disease that is originally hormone responsive but eventually becomes
unresponsive. LNCaP cells represent the early, hormone responsive stages
of prostate cancer and DU145 and PC-3 cell lines represent later poorly
differentiated stages of the cancer that are hormone insensitive and more
malignant.
These models have allowed a variety of investigations into the study




1.2 Malignancy and Growth Factors
Tumour cells have abnormal growth patterns and are unresponsive to
the normal mechanisms of growth control. The aberrant presentation,
production or mutation of a growth factor can lead to this escape from
orderly growth.
a) Normal Cell Growth
Control of growth is one of the most important and least understood
areas of biology. It is a precise and carefully regulated process allowing an
organ to grow to a specific size and combination of cell types. A balance of
inhibitory and stimulatory factors are required, together with various
differentiation factors.
A cell is either quiescent or growing. If the cell is growing it undergoes
a series of phases known as the cell cycle, illustrated in figure 4:







During the cell cycle, there is an increase of mass, DNA division and
finally cell division. G^, G2 and S phase comprise interphase during which
there is cellular growth and synthesis of cellular proteins and other
macromolecules. In G-|, cells commit themselves to initiate DNA synthesis
and the DNA content is then doubled in S phase. In G2, chromatin
condenses in preparation for mitosis (M phase) which results in the
formation of two daughter cells. A quiescent cell is classified as G0. A cell in
G0 may be resting or terminally differentiated (e.g. nerve cells) (Rees &
Steinberg 1984).
The complicated regulation of cell division depends on correctly co¬
ordinating gene transcription, protein translation and protein function.
Growth factors and hormones play an important role in this co-ordination.
b) Growth Factors
Growth factors control the growth and differentiation of cells, by
providing a basic level of inter- and intracellular communication,
predominantly within local cellular environments. They are polypeptide
molecules with varying degrees of glycosylation and can be synthesised by
a variety of cells. In contrast, hormones are produced by a specialised gland
and have endocrine actions. Growth factor action is either autocrine or
paracrine (see figure 5).
Hormones are described as endocrine since they are synthesised in
organs at distant sites to their target cell and then transported from one to
the other in the circulation (e.g. testosterone). Growth factor action is usually
local and communicates between two cells (paracrine) or exerts its action on
the cell which synthesised it (autocrine).
16
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i) Common Growth Factors
The most commonly known growth factor is epidermal growth factor
(EGF). It is a single polypeptide chain of 53 amino acids and molecular
weight, 6Kd. EGF was named due to its ability to cause proliferation of
epidermal and epithelial tissues, however it can stimulate and differentiate a
wide variety of cells (Carpenter & Cohen 1979). Similar in structure to EGF
is transforming growth factor alpha (TGFa). It too is a small polypeptide of
50 amino acids, synthesised from a larger precursor. TGFa can compete for
the EGF receptor and produce all the effects of EGF (Winkler et al 1989),
and in some circumstances can be more potent.
Transforming growth factor beta (TGFR) belongs to a large family of
molecules that share gene homology. The family includes inhibins and bone
morphogenetic proteins (Lyons & Moses 1990). Despite its name, TGFft has
no similarity to TGFa. TGFI3. is a 25Kd dimeric protein, synthesised from a
larger precursor. There are four types of TGFI3 (three in humans), which
share similar biological activities and gene homology. As a whole they have
17
Introduction
diverse biological activities over a wide range of tissues, these include:
chemotaxis, growth inhibition and extracellular matrix production (Lyons &
Moses 1990).
The fibroblast growth factors (FGF) exist in acidic and basic forms.
Although produced from different genes they are closely related and have
similar biological activities, both with a molecular weight of 16Kd
(Gospodarowicz et al 1987). They are multifunctional with the widest range
of stimulatory and differentiating activities of all the growth factors, and are
well known for their potent angiogenic functions. Platelet derived growth
factor (PDGF) is the major mitogen of connective tissues and is important for
wound healing. It is a 30Kd dimer and the products of two genes. The two
peptide chains have 60% amino acid homology (Heldin et al 1985).
The last of the common growth factor families are the insulin-like
growth factors (IGF). There are two members of this family; IGF-I
(somatomedin C) and IGF-II (skeletal growth factor), which have a molecular
weights of 7.5Kd. They share structural (the insulin fold) and functional
similarities to insulin (Dafgard et al 1985).
The above gives a general indication of the effects of the common
growth factors. Although growth factors are often named after the cell type
they were first identified to affect, their actions are often more widespread
and complex than those listed. The effect of one growth factor will depend on
the other growth factors present and their interactions together (Sporn &
Roberts 1988). For example the stimulatory effects of EGF on prostate cell
lines can be increased by androgens and decreased by TGFI3. (Schuurmans
et al 1988). The biological effects of TGFft vary (i.e., it can be stimulatory or




Recent studies have led to the discovery of cytokines, a group of
growth factors involved in inflammatory and immune processes. It includes
common factors such as TGFft and the more recently identified factors;
interleukins and colony stimulating factors. Within the group is another set of
growth factors, the haematopoietic growth factors, which control the growth
and differentiation of haematopoietic cells. Much of this thesis will look at
haematopoietic growth factors in more detail since they are likely candidates
for stimulating prostate cancer in skeletal sites,
ii) Haematopoietic Growth Factors
Haematopoietic growth factors are glycoproteins specifically involved
in the survival, differentiation and function of cells from the haematopoietic
system. Most of these factors are interleukins or colony stimulating factors.
They can be produced by T-lymphocytes, monocytes, endothelial cells and
fibroblasts. The exception to this is erythropoietin which is a hormone
produced by the kidney in response to hypoxia (Hoffbrand & Pettit 1993).
Erythropoietin stimulates the maturation of red blood cells allowing
increased oxygen delivery. Levels of haematopoietic growth factors are iow
or undetectable except during inflammation.
Haematopoietic cells (platelets, lymphocytes, erythrocytes,
monocytes, macrophages and granulocytes) may have very different
morphologies and functions but they are derived from the same precursor,
the pluripotent stem cell. Under the influence of haematopoietic growth
factors the stem cell generates the wide variety of haematopoietic cells. IL-3,
IL-4, IL-6 and GM-CSF all act on early multipotential cells whereas G-CSF,
M-CSF, IL-5 and erythropoietin act on later cells that are already committed
to one or two lineages; this work is reviewed in Whetton & Dexter 1989,
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Daniel & Dexter 1989. Figure 6 illustrates how these factors form a complex














RBC Platelets Monocyte Neutrophil Eosinophil Basophil Lymphocytes
(KEY: bfu, burst forming unit; cfu colony forming unit, e, erythroid; meg, megakaryocyte;
gm, granulocyte monocyte; o, eosinophil; b, basophil)
Figure 6: Role of Growth factors In Haemopoiesis
(After Hoffbrand & Pettit 1993)
Each haematopoietic growth factor has a unique, high-affinity
receptor. These receptors are distributed in a manner that reflects their
action (Nicola 1989) e.g., granulocyte-colony stimulating factor receptors are
found on granulocytes. The discovery of a common 210 amino acid
sequence in the extracellular domain of haematopoietic growth factor
receptors, has led to the formation of a new hematopoietin receptor
superfamily. The members of this family include: IL-2, IL-3, IL-4, IL-6, IL-7,
GM-CSF, prolactin, growth hormone, and erythropoietin (Cosman eta! 1990)
Several haematopoietic growth factors are used for cancer therapy.
The ability of GM-CSF, G-CSF, M-CSF, IL-3 and IL-1 to influence all aspects
of haematopoietic cell differentiation and proliferation has led to their clinical
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use of reviving bone marrow growth after chemotherapy. They are also used
for the treatment of myeloid leukaemia and other bone marrow disorders
(Moore 1990). The ability of erythropoietin to stimulate erythropoiesis has
led to its use in the treatment of anaemia (Adamson & Eschbach 1990, Oster
et al 1990).
iii) Pathways of Growth Factor action
Each growth factor exerts its action through a specific receptor
located in the cell membrane. The result of this binding is the activation of a
variety of secondary messenger systems which ultimately influence cell
metabolism. Two of the commonest systems are the tyrosine kinase pathway
(figure 7) and the adenylate cyclase (figure 8) pathway. These are named
according to the initial enzyme activated by each growth factor.
To give an indication of the complexity of growth factor - receptor
signalling, the tyrosine kinase pathway is explained in more detail below.
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Most growth factors use the tyrosine kinase pathway; the example used here
is EGF (figure 7). The binding of EGF to its receptor activates a tyrosine
kinase (TK) in the cytoplasmic domain of the receptor. Evidence suggests
tyrosine kinase (1) may in turn activate phospholipase C (PLC) by tyrosine
phosphorylation (Meisenhelder et al 1989). This consequently leads to the
hydrolysis (2) of phosphatidylinositol bisphosphate (PIP2) to diacylglycerol
(DG) and inositol triphosphate (IP3). The first of these secondary
messengers, diacylglycerol, activates protein kinase C (PKC). This active
kinase can desensitise the EGF receptor (3), by phosphorylation of
threonine 654 (Schlessinger 1988) and also activate (4) the sodium ion
(Na+)/proton (H+) antiporter (Pouyssegur 1985). Meanwhile, inositol
triphosphate bound to its receptor (R) on the surface of intracellular calcium
stores (5) causes the release of calcium ions (Ca++) (6). High levels of
intracellular calcium ions activates a calcium dependent potassium (K+)
channel (7) leading to hyperpolarization. The intracellular levels of calcium
oscillate when the phosphoinositide pathway is stimulated. The frequency of
these oscillations varies with agonist concentration (Berridge & Irvine 1989).
Calcium signals can spread from cell to cell through gap junctions, enabling
cell to cell communication.
The haematopoietin receptor family mediates tyrosine kinase
activation via the extracellular domains of the receptor (Chiba et al 1993).
Many hormones and neurotransmitters use the adenylate cyclase
pathway to produce cell proliferation, this is illustrated in figure 8. The
binding of the hormone to its receptor (1) leads to the activation of a G
protein (2). By a series of events adenylate cyclase (AC) can be inhibited or
stimulated (3) to catalyse the production of cAMP from ATP. cAMP acts as a
secondary messenger by activating a cAMP dependent protein kinase (4).
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The activated kinase is then capable of phosphorylating a variety of other
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Figure 8: Adenylate cyclase pathway (After Palmiter 1988)
These pathways illustrate how growth factors form complex intracellular
signals which control and co-ordinate cell metabolism and development.
The process is not infallible, and the mutation of a growth factor or
any component of the intracellular signalling process can result in
uncontrolled growth, and the development of a tumour. (Aaronson 1991).
Such mutations are the result of oncogenes and tumour suppressor genes in




c) Tumourogenesis & Genetic mutation
Tumourogenesis is thought to occur in a step wise fashion (figure 9):
The initial event of tumourogenesis is the mutation of genomic DNA.
DNA can be mutated by the inheritance of a genetic defect, radiation,
chemical carcinogen or viral alteration. This mutation, although inheritable,
may have no effect on phenotype allowing it to remain dormant for years.
However further mutation can cause aberrant protein expression and clonal
expansion of the cell. The mutation can activate either an oncogene or
deactivate a tumour suppressor gene (Bishop 1991). Additional genetic
mutations cause the tumour to progress further and attain an autoregulatory
state. Ultimately it becomes metastatic and invades other tissues.
Deletions are the most likely cause of tumour suppressor gene
deactivation and these have been observed in prostate cell lines (Bookstein
et al 1990, Brothman et al 1990, Carter et al 1990a). Oncogenes are
dominantly acting mutant genes, whose presence produces a malignant
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phenotype. Activation of an oncogene can occur through point mutation,
chromosome translocations or gene amplification. Such mutations have also
been identified in prostate cell lines and tumours (Nag and Smith 1989,
Carter et al 1990b). Figure 10 illustrates how a hypothetical series of genetic
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Figure 10: Chromosomes In Prostate Cancer (After Sanberg 1992)
Investigations of prostate cancer cells have shown the presence of
various mutations in the androgen receptor (Brinkmann et al 1991, Newmark
et al 1992), and the total absence of the receptor in the hormone insensitive
human prostate cell lines, DU145 and PC-3 (Tilley et al 1990). It is possible
that both loss or mutation of the androgen receptor (Ekman et al 1991) and
the attainment of aberrant growth factor action are involved in the
progression of prostate cancer to a hormone insensitive state (King 1990,
Davies & Eaton 1991).
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d) Malignancy and growth factors
Mutations may cause overexpression of normal proteins or normal
expression of mutated proteins, both resulting in the loss of normal growth
control. There are several ways aberrant growth factor or action may aid
tumourogenesis and these are discussed below:
i) Receptor mimicking
Sequence analysis of the avian v-erb-B oncogene product shows homology
with the human EGF receptor sequence (Downward et al 1984). v-erb-B is
thought to be a truncated form of the EGF receptor with intact membrane
and cytoplasmic regions but no extracellular EGF binding domain. The lack
of this binding domain may lead to a permanently activated receptor.
Evidence also suggests that the v-fms oncogene may represent a mutated
M-CSF receptor. The receptor still retains an M-CSF binding site but a
deletion has led to the loss of the tyrosine autophosphorylation site
important for desensitisation. As a result the receptor is constitutively
activated (Coussens et al 1986), and known to cause fibrosarcomas.
Transcripts for the fms oncogene have been identified in ovarian
adenocarcinomas (Kacinski et al 1990), breast carcinomas (Kacinski et al
1991) and lung carcinoma cell lines (Filderman et al 1992). In all cases
expression was thought to be connected to invasiveness.
ii) Autocrine stimulation
The production of a growth factor by a cell which is stimulatory for
itself is known as autocrine stimulation. In malignancy this can lead to the
loss of dependency from paracrine or endocrine sources of normal growth
stimulation and the cell grows uncontrolled (Sporn & Roberts 1985).
Research has shown that prostate carcinoma cells can produce and respond
to TGFa (Wilding et al 1989a, MacDonald et al 1990) and TGFI3>1 (Steiner &
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Barrack 1992) in an autocrine fashion. The secretion of GM-CSF by Lewis-
lung carcinoma cells was also implicated in autologous stimulation of these
cells since they also proliferate in response to exogenous GM-CSF (Young
et al 1992). Furthermore the ability of these cells to invade basement
membrane was inhibited by a GM-CSF antibody indicating a possible role in
the metastatic properties of these cells,
iii) Paracrine Influences and metastasis
Growth factors released by one cell type may increase the
tumourogenic potential of another. For example, androgens are known to
stimulate hormone sensitive prostate tumours (Schuurmans et al 1991).
Certain growth factors such as GM-CSF have been implicated in developing
a cell's invasive potential (Young et al 1992). GM-CSF gene expression has
been correlated with metastatic tumour formation in mice (Takeda et al
1991), tumour necrosis factor was found to increase the metastatic potential
of Chinese hamster ovary cells (Malik et al 1990), and the presence of M-
CSF receptors on lung carcinoma cells is linked to their metastatic ability
(Filderman et al 1992).
Paracrine influences are important for metastasis. A paracrine growth
factor can also act as a motility factor (Gherardi 1991); or have angiogenic
properties allowing the tumour to increase in size (Bicknell & Harris 1991); or
they may stimulate tumour cells within the secondary metastatic site. These




Metastasis describes the spread of cancer cells from the primary
malignant tumour to secondary sites in other organs. The tumour cell must
complete all the steps of the metastatic cascade (illustrated in figure 11) to
form a secondary tumour.
With the number of 'obstacles' to overcome it can be seen why
metastasis has been described as an inefficient process (Weiss 1990). This
was illustrated by Glaves (1983) who found that although thousands of
malignant cells may enter the blood stream only a small percentage will form
secondary tumours. Despite this inefficiency, metastasis occurs in many
cancer patients, and is invariably the cause of death.
Observations have indicated that metastases originating from a
primary tumour have a tendency to form in specific target organs, examples
of this can be seen in table 4.
Table 4: Common metastatic sites of cancer tissues (After Hill 1987)
PRIMARY TUMOUR COMMON METASTATIC SITE
Kidney carcinoma lung, bone, adrenal
Prostate carcinoma bone
Small cell lung carcinoma brain, liver, bone marrow
Melanoma of the skin liver, brain, bowel
Melanoma of the eye liver
Neuroblastoma liver, adrenal
Thyroid, follicular carcinoma bone, lung





C Invasion of circulation
D Avoid immune system
E Arrest
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Figure 11: The Metastatic Cascade
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The observation of cancers metastasising to specific secondary sites
supports the idea of Stephen Paget's 'Seed and Soil' hypothesis (Paget
1889). The hypothesis suggests that certain organs may provide a suitable
environment of growth factors (soil) for the growth of metastatic tumour cells
(seed). However it is likely that a number of factors are involved in the
formation of site specific metastases. These are now discussed by studying
the steps of metastatic cascade in detail, with particular reference to prostate
carcinoma.
a) The Metastatic Cascade
i) Detachment From The Primary Tumour
A metastatic cell must initially escape the primary tumour. This
involves the loss of cell to cell contact which may occur through a decrease
in the levels of adhesion molecules. These ideas are strengthened by results
indicating that fibronectin mRNA is lower in metastatic rat prostate cell lines
in comparison to equivalent non-metastatic lines (Schalken et al 1988). Also
the expression of E-cadherin (a calcium dependent cell adhesion molecule)
decreases with the increasing invasive potential of a series of rat prostate
cell lines (Bussemakers et al 1992).
ii) Mobility
In order to reach the circulation a metastatic cell must become mobile.
Nerve growth factor-like proteins secreted from prostate stroma have shown
the ability to stimulate prostate cancer cell line motility (Djakiew et al 1993).
Autocrine motility factors have been found, secreted from melanoma cells
(Liotta et al 1986). Degradation products of the basement membrane can
also induce cell mobility (Blood & Zetter 1990). These include molecules
such as fibronectin, collagen and laminin (Lacovara et al 1984, Mundy et al
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1981, Wewer et al 1987). Hydrolytic enzymes secreted by invading tumour
cells are responsible for the degradation of extracellular matrices,
iii) Invasion Of The Circulation
Research has led to the discovery of a variety of enzymes, secreted
by tumour cells, that are capable of degrading basement membrane. The
release of such enzymes allows the invasion of either the venous system or
the lymphatics. One such enzyme is plasminogen activator, it exists in two
forms: urokinase type (u-PA) and tissue type (t-PA). Plasminogen activator
catalyses the activation of plasminogen to plasmin. Plasmin is an enzyme
capable of degrading many proteins including laminin and fibronectin (Liotta
et al 1981). It may also activate latent collagenase (Salo et al 1982),
therefore indirectly degrading collagen.
The central zone of the prostate is a selective site for t-PA in seminal
fluid (Reese et al 1988). Elevated levels of plasminogen activator have been
found in cancerous prostate tissue. Results have shown malignant prostate
tissue extracts have higher u-PA activity than benign, and bone metastases
have higher plasminogen activator levels than the primary tumour
(Kirschheimer & Binder 1990). Plasminogen activator content has also been
linked to metastatic potential of prostate cancer cell lines LNCaP, DU145
and PC-3 (listed in order of increasing aggressiveness). Keer et al (1991)
demonstrated PC-3 cells have twice the activity of u-PA than DU145 cells.
DU145 and PC-3 cells both secrete and have receptors for u-PA, whereas
LNCaP has neither characteristic (Hoosein et al 1991). Furthermore the
invasive properties of DU145 and PC-3 can be inhibited using an urokinase
receptor agonist.
A second family of enzymes, the metalloproteinases, have also been
linked to invasion. Human matrix metalloproteinase-7 degrades gelatins,
31
Introduction
fibronectin and activates collagenases. Using Northern blots matrix
metalloproteinase-7 transcripts were found three times more frequently in
prostate adenocarcinomas than normal tissue samples. No evidence for
matrix metalloproteinase-7 transcripts in prostate cell lines were found
(Pajouh et al 1991).
These results provide good evidence for the involvement of
proteolytic enzymes in the metastasis of prostate cancer.
iv) Avoidance Of The Immune System
Once in the circulation a tumour cell must survive the immune system.
Avoidance of the body's natural defences may be achieved through the
alteration of MHC antigens - consequently the tumour cells are not
recognised by T-lymphocytes (Katzav et al 1984). Tumour cells are known to
aggregate platelets, but how this aids metastasis is unknown. Potentially, the
platelets form an embolus around the tumour cells, thereby masking them
from the immune system (Gasic 1984). These emboli may also be important
for arresting at secondary sites.
v) Arrest At A Secondary Site
Tumour cells arrest at the vascular endothelium of secondary
metastatic sites either through specific receptor interactions or adhesion
molecules, or simply where the cells become physically lodged (Johnson et
al 1991, Blood & Zetter 1990). Adhesion molecules such as laminin and
fibronectin (Terranova et al 1984, Haberern et al 1985) are thought to be
major determinants of site specific metastases (Zetter 1990). Evidence
demonstrates that tumour cells will preferentially adhere to the extracellular
matrix components of the organ they metastasise to (Doerr et al 1989). Rat
prostate adenocarcinoma cell lines have shown preferential adherence to
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bone marrow endothelial cells over bone marrow stromal cells, osteoblasts,
hepatic endothelial cells or rat fibroblasts (Haq et al 1992).
Once the tumour cell has bound to the endothelial surface, cell
retraction occurs exposing the subendothelial basement membrane.
vi) Invasion Of Secondary Organ
The basement membrane is again a barrier to the passage of
metastasising cells from the circulation into the secondary tumour. The
variety of hydrolytic enzymes originally required to escape the primary
tumour probably participate again. However the presence or absence of a
particular enzyme may correlate with a tumour cells ability to invade a
specific tissue (Zetter 1990), since the components of the extracellular matrix
differ from tissue to tissue. Experiments have also shown the organ
environment can affect the type of degradative activity produced by the
tumour cell (Nakajima et al 1990). Site specific metastasis is therefore also
governed by the type of hydrolytic enzyme a tumour produces.
vii) Growth and Proliferation At The Metastatic Site
Once at the metastatic site, tumour cells must grow and proliferate
even though this is a foreign environment. Growth factors secreted from the
secondary organ are thought to be important in maintaining growth. The
presence of distinct growth factors in different secondary organs may also
lead to site specific metastases (Nicolson et al 1986). Prostate cancer shows
a selective metastatic spread to bone (Jacobs 1983), therefore growth
factors released by the skeleton may aid the establishment and proliferation




Bone is a highly specialised connective tissue with organic and
inorganic components, that are continually remodelled.
a) Normal Structure and Function
Bone serves as a support for soft tissue and protects vital organs,
e.g., the skull protects and supports the brain. Other functions involve the
small bones of the ear for sound transmission, and the calcified skeleton
which acts as a reservoir for ionic calcium. There are two types of bone,
compact and cancellous. Compact bone is very dense and is also referred to
as cortical bone. It forms the major component of long bones providing
structural support. Microscopic cylindrical structures known as haversian
systems are an integral part of this bone. They are made of concentric
collagen lamellae, surrounding nutrient blood vessels. Cancellous bone is
also known as spongy or trabecular bone. It is composed of networks of
interconnecting plates (trabeculae) surrounded by bone marrow. The
composition makes it less dense than compact bone, though more
biologically active; for reviews see Boyce 1991, Williams & Frolik 1991.
b) Normal Growth
Since bone must endure much stress and strain, it is prone to wear
and tear and therefore constant remodelling is essential to prevent
weakening. There are three main cell types present in bone, which are




This cell is multinucleate and responsible for bone resorption. It is
generally accepted to derive from the macrophage-monocyte lineage in the
bone marrow (Kurihara et al 1990). The osteoclast is polar and has a brush
border in close contact with the bone surface forming an enclosed
extracellular space. Into this space it actively secretes degradative enzymes
(Delaisse et al 1987) and creates an acid environment (Baron et al 1985).
The enzymes are activated by the low pH enabling solubilization of the bone
matrix (Russel et al 1990).
ii) The Osteoblast
Osteoblasts are mononuclear and responsible for bone formation.
Evidence suggests they originate from stromal cells in the bone marrow
(Vaughan 1981). Osteoblasts produce an organic matrix known as osteoid
which is essential for mineralization. Collagen type I is the main component
of osteoid, though the osteoblast secretes many more factors, listed in tables
5 and 6.
Table 5: Components ofOsteoblast Extracellular Matrix
Collagen I (Owen et al 1990)
Fibronectin (Owen et al 1990)
Osteonectin (Russel et al 1990)
Osteocalcin (Aronow et al 1990)
Chondroitin sulphate (Fedarko et al 1990, Takeuchi et al 1990)
Heparan sulphate (Fedarko et al 1990, Takeuchi et al 1990)
Hyaluronan (Fedarko et al 1990)
Dematan sulphate (Fedarko et al 1990, Takeuchi et al 1990)
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(Cantrella & Canalis 1987)
(Robey et al 1987)
(Gowen et al 1990)
(Slootweg et al 1990)
(Slootweg et al 1990)
(Horowitz et al 1989)
(Felix et al 1989)
(Felix et al 1991)





9K bone resorbing protein
(Aronow et al 1990)
(Pfeilschifter et al 1990)
(Pfeilschifter et al 1990)
(Morris et al 90)
(Valentin-Opran et al 1987)
Populations enriched in osteoblasts can be cultured using sequential
digestion procedures (Wong & Cohn 1974). This relies on the fact that
osteoblasts are present in distinct areas of the bone. Osteoblasts have also
been cultured as outgrowths from small chips of trabecular bone (Beresford
et al 1984).
iii) The Osteocyte
This cell is formed from the osteoblast and is the most numerous of
the three cell types. It is in effect the osteoblast left behind, trapped, in its
own calcified matrix. It has no function in bone formation, but networks of
these cells, joined by long dendrites, maybe involved in the bone's response
to stress (Russel et al 1990).
c) Remodelling
The remodelling process is controlled by three main hormones:
parathyroid hormone, calcitonin and Vitamin D. Parathyroid hormone is
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secreted in response to decreased calcium and leads to bone resorption,
whereas calcitonin is secreted (from the thyroid) in response to increased
calcium levels and inhibits resorption (Russel et al 1990). Vitamin D
increases calcium levels by stimulating resorption (Russel et al 1990). Table
7 lists the variety of other growth factors, local or humoral which are involved
in the remodelling of bone.
Table 7: Factors Affecting Bone remodelling
Autocrine/paracrine Growth Factor Bone Formation Resorption Ref
EGF Inhibition Stimulation 1.2
aFGF, bFGF Osteoblast mitogen 3
IGF-I Bone cell mitogen 4
IGF-II Bone cell mitogen 5
IFN y Inhibition 6
TGFB Potent stimulator Inhibition 7
PDGF Bone cell mitogen 8
TNF a Stimulation 9
IL-I Stimulation 10
GM-CSF Stimulation Stimulation 11,12
HEP ! & il Proteins Osteoblast mitogen 13
Parathyroid hormone related peptide Stimulation 14
Prostaglandin E2 Stimulation 15,16
Bone morphogenic proteins Stimulation 17
Endocrine Factor
Calcitonin Inhibition 18,20
Parathyroid hormone Stimulation 19,20
1,25 dihydroxy vitamin D Stimulation 12
Glucocorticoids Stimulation 21
Growth hormone Osteoblast mitogen 22
Insulin Stimulation 23
Oestrogen Stimulation 24
References: 1) Canalis et al 1979, 2) Simpson 1984, 3) Rodan et al 1987, 4) Canalis 1980,
5) Mohan & Baylink 1991, 6) Peterlik et al 1985, 7) Robey et al 1987, 8) Canalis 1981, 9)
Bertolini et al 1986, 10) Gowen et al 1983, 11) Evans et al 1989, 12) Kurihara et al 1990, 13)
Rifas et al 1989, 14) Morris et al 1990, 15) Pfeilschifter et al 1990, 16) Peterlik et al 1985,
17) Urist et al 1984, 18) Chambers & Magnus 1982, 19) Raisz et al 1965, 20) Heath &
Reynolds 1990, 21) Russel et al 1990, 22) Slootweg et al 1988, 23) Canalis et al 1977, 24)
Slootweg et al 1992
The remodelling process is continual. The recruitment of osteoclasts
by both vitamin D and PTH leads to the release of hydrolytic enzymes.
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'Resorption bays' are formed at local sites of bone degradation. By unknown
methods, resorption is coupled to the migration and proliferation of
osteoblasts (Russel et al 1990). Osteoblasts lay down the osteoid matrix
which is subsequently mineralised by deposition of hydroxyapatite to
produce new bone (Owen et al 1990).
The osteoblast and osteoclast are coupled to the extent that often the
receptors for factors causing resorption are found on the osteoblast e.g.,
parathyroid hormone receptors are localised to the osteoblast (Newman et al
1989). The action of parathyroid hormone is thought to release soluble
growth factors from the osteoblast which then stimulate osteoclastic
resorption (McSheehy & Chambers 1986). This indicates how complex
mechanisms are likely to exist between the two cells. Various candidates
exist for a coupling factor between osteoblasts and osteoclasts, including
TGF-R (Bonewald & Mundy 1990), parathyroid hormone-related protein
(Morris et al 1990), GM-CSF (Evans et al 1989) and HEP (Rifas et al 1989)
proteins.
d) Skeletal Metastasis
Skeletal metastases are known to be common in patients dying from
advanced cancers of the prostate, breast, bronchus, kidneys and thyroid
(Galasko 1986), whereas cancers of the alimentary canal rarely produce
such metastases. Pain is the main symptom for the presence of a skeletal
metastasis. They are more often found in cancellous bone than cortical,
probably due to differences in biological activity (as detailed before).




An osteolytic metastasis causes a net destruction of bone, leading to
its weakening. The malignant cells of an osteolytic metastasis are thought to
secrete osteoclast activating factors, therefore bone destruction is indirect
(Galasko 1976, Mundy 1988). Studies have in fact shown that malignant
cells can secrete factors known to stimulate osteoclastic activity, these
include cytokines and growth factors such as TGFa, TGFI3 and EGF
(Tashjian et al 1985).
In an osteoblastic metastasis the malignant cells cause a proliferation
of osteoblasts and therefore increased bone mass. This most likely occurs
due to the production of osteoblast growth factors by the malignant cell
(Simpson et al 1985), but may also involve mechanisms separate from
normal remodelling (subsequent resorption is not seen) or a loss of the
coupling mechanism between the osteoblast and the osteoclast (Boyce
1991).
e) Prostate Skeletal Metastases
As has been stated, prostate cancer shows a selective metastatic
spread to bone. The most common sites of prostate skeletal metastases are
the spine, femur, pelvis, ribs, sternum, skull and humerus (Jacobs 1983).
These metastases are osteoblastic, though both bone formation and
degradation are seen.
Metastases appear first in the bone marrow, where they can survive
undetected for a long time. This dormant stage maybe due to angiogenesis,
or the host destroying cancer cells as fast as they divide. Eventually growth
of the tumour cells becomes dominant. Once established the cancer
expands, invades and remodels the surrounding bone. The tumour cells
must somehow activate osteoclasts to allow initial degradation. Gaiasko
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(1976) and Tashjian et al (1985) both produced results suggesting tumour
cells can produce osteoclast activating factors. After invasion, the cancer
produces a proliferation of osteoblasts, accompanied by new bone formation
(Jacobs 1983), leading to irregular and broader remodelling. The
proliferation of osteoblasts may be due to growth factors released by the
tumour. These factors may cause osteoblastic recruitment or affect their
production of osteoid.
There are at least four reasons (which are not exclusive) why prostate
cancer metastasises preferentially to the bone. The first is mechanical.
Batson (1940) suggested metastasis to a specific site depends on the
specific vasculature the cancer cell invades. He demonstrated prostate
cancer cells would invade the vertebral venous system, (a network of
longitudinal, valveless veins which run parallel to the vertebral column) and
form large anastomoses with the vertebrae, pelvis, thorax and brain venous
systems. Therefore this venous network could account for the pattern of
secondary skeletal tumours. Secondly, specific adhesion molecules in the
bone marrow maybe important for the arrest of the tumour cell. Thirdly, any
degradative enzymes secreted by the prostate cancer cells which allow the
remodelling of the surrounding bone, maybe important. Lastly, Stephen
Paget (1889) hypothesised cancers seeded at secondary sites only where
the environment was favourable for growth, due to the presence of
stimulatory growth factors. Since prostate tumour cell growth is greater in the
bone environment than in the primary tumour (Jacobs 1983, Berretoni et al




It becomes clear that factors from the bone environment and the
tumour cells are acting very closely, potentially in a paracrine manner. This
is now discussed further.
i) Growth Factors Involved In Prostate Skeletal Metastases
Bone Growth Factors Produced By Prostate Cancer Cells
Many researchers have looked for a prostatic growth factor that is
capable of producing osteoblastic metastases. There are many growth
factors known to be secreted by the prostate (see table 2), some of these
can stimulate the osteoblast (table7).
In 1979 Jacobs et al were the first to show that extracts of human
benign prostatic hyperplasia contained a mitogen for rat osteoblast cells. A
second research group used reverse phase high performance liquid
chromatography on extracts of both benign prostatic hyperplasia and
prostate carcinoma tissue, and found a peptide of 10 Kd that had selective
mitogenic activity on rat osteoblast cells (Koutsilieris et al 1987). A rat
osteoblast cell line was again stimulated by media conditioned by the
prostate cell line, PC-3 (Harrod et al 1985), this stimulatory activity was
isolated as a factor of 20Kd. PC-3 cell mRNA was purified and injected into
Xenopus laevis oocytes by Simpson et al (85). This led to the formation of
new translation products from the oocytes which were secreted into the
culture medium, this conditioned medium (CM) had mitogenic activity on rat
osteosarcoma cell lines. The CM was also capable of increasing a number of
bone formation associated activities (collagen synthesis and alkaline
phosphatase activity). The majority of this activity was shown to correspond




Perkel et al (90) were the first to use primary cultures of human
osteoblast-like cells. Their experiments demonstrated that PC-3 CM could
stimulate these cells but not human skin fibroblasts. Known growth factors
(TGFG, IGF I, IGF II) were also used to stimulate the osteoblast-like cells
with and without the CM. The CM had a cumulative effect with these factors
suggesting the stimulatory factor in the CM was not one of the common
factors tested and chromatography indicated its molecular weight to be in the
order of26-30Kd.
Bone Growth Factors Acting On Prostate Cancer Cells
It is a common occurrence that prostate cancer cells grow at a faster
rate in skeletal metastases than in primary tumours (Jacobs 1983, Berrettoni
et al 1986). Several researchers have looked for growth factors released by
the bone environment that are mitogenic for prostate cancer cells.
Charkal-Roy et al (1989) were able to stimulate the growth of the cell
lines PC-3 and DU145 using media conditioned by fresh human bone
marrow (BMCM) and by primary cultures of human bone marrow stromal
cells. These CM had little effect on cell lines derived from other metastatic
tumours. The prostate cell lines were also incubated with haematopoietic
growth factors to determine if the BMCM stimulation was due to
haematopoietic growth factors in the bone marrow. Only M-CSF was seen to
produce a 100% stimulation of growth but this did not match the 800%
stimulation from the BMCM, and no combination of haematopoietic growth
factors could achieve this. Later studies showed that transferrin was one of
the stimulatory components of BMCM (Charkal-Rossi et al 1992).
Charkal-Roy's results are in contrast to earlier results by Klose et al
(1987) who demonstrated that rat bone marrow contained a 640 Dalton
factor which inhibited a rat prostate cancer cell line and the human cell line
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DU145. The finding of a rat cell line inhibitory factor in bone marrow may
help explain the lack of skeletal metastases in the Dunning rat model of
prostate carcinoma. The result for the DU145 cells is less clearly explained
unless the inhibition was due to a cross-species effect.
Further studies by Rago et al (1991) are also contrary to Charkal-
Roy's results, Rago showed bone marrow stromal cell CM had no growth
effects on either PC-3 or DU145 cells and inhibited the growth of the
hormone sensitive cell line, LNCaP. Whether this result was due to
androgen sensitivity or not, (DU145 and PC-3 cells are androgen
insensitive), was not determined. The experiments involved a filtration step
(5000 molecular weight cut off) which could have removed Charkal Roy's
stimulatory factor.
Gleave et al (1991) coinoculated athymic nude mice with LNCaP cells
and various non-tumourogenic fibroblasts. The results indicated that a
human bone fibroblast cell line (MS) was the most effective at producing
LNCaP tumours, (followed by rat prostate fibroblasts and then embryonic rat
urogenital fibroblasts). The results were strengthened by the fact bone
fibroblast CM stimulated LNCaP growth 150% in comparison to a control, in
vitro. However CM from prostate fibroblasts and also bFGF produced similar
stimulatory effects. These results indicated the presence of a growth factor
from bone fibroblasts that stimulate LNCaP cell line growth.
As a whole, the results from all these experiments are rather
confusing, since Charkal-Roy et al (1989) demonstrated the stimulation of
prostate cell line growth by BMCM, despite contradictory experiments by
Klose et al (1987) and Rago et al (1991). Although Gleave et al (1991)
showed stimulation of LNCaP cells by bone fibroblasts this wasn't specific to
the bone and the experiment was carried out using a mouse model.
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Much evidence exists for paracrine growth factors mediating
stimulatory activity between the bone environment and prostate cancer.
Such factors could also be responsible for the selective metastasis of
prostate carcinoma to the skeleton. No-one has yet looked specifically for an
osteoblast-derived factor that can stimulate prostate cancer growth.
Another way of investigating the site specific metastasis of prostate
cancer to bone would be to test haematopoietic growth factors for growth
stimulation, since they are produced largely in the bone marrow (Nicola
1989). Although a number of researchers (EORTC 1991, Twentyman &
Wright 1991) demonstrated no growth stimulation of human carcinoma cell
lines by haematopoietic growth factors, other groups have shown stimulatory
actions of these factors on non-haematopoietic cell lines (Table 8).





GM-CSF Lung (Young et al 1992, Nakata et al 1991)
Bladder (Block et al 1992)
Breast (Dedhar et al 1988)
Colorectal (Berdel et al 1992)
IL-3 Bladder (Block et al 1992)
Colorectal (Berdel et al 1992)
The effect of haematopoietic growth factors on prostate cell line




Prostate cancer has a preferred metastatic spread to bone. A number
of events are thought to be important in the formation of a site specific
metastasis: a) mechanical i.e., vertebral venous spread; b) selective
adhesion at secondary sites due to the presence of specific adhesion
molecules; c) tumour production of hydrolytic enzymes capable of degrading
the secondary organ's extracellular matrix; d) the ability of a secondary
organ to sustain and increase growth of a tumour cell depending on the
growth factor it produces.
This study aims to investigate the latter step by examining the
influence of:
a) human osteoblast conditioned media
b) human bone marrow conditioned media
c) recombinant haematopoietic growth factors
on human prostate cell line growth.







Most general chemicals were purchased from either Fisons
(Loughborough, UK) or Sigma Chemicals (Poole, UK). Chemicals purchased
elsewhere are listed below:
Aldrich (Gillingham, UK): Hydrogen peroxide, isopropanol, sodium
hydroxide pellets,
BDH (Poole, UK): DePeX mounting medium, sodium dihydrogen
orthophosphate, tetramethylethylenediamine (TEMED).
Bio-Rad (Hemel Hempstead, UK): Bradford dye reagent concentrate.
James Buroughs (London, UK): Ethanol
MacKay & Lynn Distributors (Edinburgh, UK): Oxoid Dulbecco's A
phosphate tablets (one tablet dissolved in 100ml of distilled water)
Spectrum (Pierce Warner, Chester, UK): Spectrapore 3 dialysis tubing
(3.5Kd MW cut-off)
b) Tissue Culture
i) Cell Line Sources
Prostate carcinoma cell lines, previously discussed in the introduction,
were obtained from the sources listed in table 1. All other human cell lines
were obtained from the European Collection of Animal Cell Cultures (Porton
Down, UK). Their names and derivations are listed in table 2.
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Table 1: Prostate adenocarcinoma Cell Line Sources
Name Description Source
DU145 brain metastasis hormone
insensitive
D.Mickey, Dept. Urology,
University N. Carolina, USA









Table 2: Human Cell Lines
Name Derivation
MG63 male osteosarcoma
RT112 epithelial bladder carcinoma
HF19 female, foetal lung fibroblast
Hs578T epithelial breast carcinosarcoma
CHANG liver epithelia
ACHN male, renal adenocarcinoma, fibroblast
HEP 2 epithelial larynx carcinoma
ii) Disposables:
All the tissue culture disposables (Corning and Sterilin) were
purchased from MacKay & Lynn Distributors (Edinburgh, UK). Centricon
concentrators; -3 (MW cut-off 3Kd), -10 (MW cut-off 10Kd), -30 (MW cut-off
30Kd), -100 (MW cut-off 100Kd) were purchased from Amicon (Stonehouse,




iii) Tissue Culture Media
Tissue culture media were purchased as follows:
Flow (High Wycombe, UK): Ham's F12 Medium
Gibco (Paisley, UK): Dmem/F12 Medium, foetal calf serum (FCS), L-
glutamine (200mM), heat inactivated foetal calf serum (HIFCS),
10,000IU/ml penicillin/ 10,000pg/ml streptomycin solution, RPMI 1640
Medium, trypsin-EDTA (10x) solution.
Kyokuto Pharmaceuticals (Tokyo, Japan): WAJC 404 tissue culture
medium
iv) Chemicals
Tissue culture grade chemicals were purchased from Sigma (Poole,
UK) or from the sources listed below:
Amersham (Slough, UK): [methyl-3H] thymidine (25Ci/mmol).
Canberra Packard (Pangbourne, UK): 'Ultima Gold' scintillation fluid.
Lome Diagnostics (Bury St.Edmunds, UK): Worthington collagenase
No.4196 (SA>170U/ml)
Roche (Welwyn Garden City, UK): 1a, 25-dihydroxycholecalciferol
(1.25 (OH)2 Vitamin D). This was dissolved to 10pM in ethanol and
stored under nitrogen at -20°C.
c) Growth factors
The following haematopoietic growth factors were all human
recombinant growth factors produced from E.Co//'; erythropoietin
(125mU/pg), interleukin-3 (1000U/|jg), granulocyte colony stimulating factor
(100,000U/jjg), granulocyte macrophage-colony stimulating factor
(10,000IU/pg). All were kind gifts from the National Institute For Biological
Standards and Controls (Potters Bar, UK).
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Natural mouse, epidermal growth factor was purchased from
Collaborative research (c/o Universal biologicals, London, UK) and human
platelet, transforming growth factor from British Biotechnology (Cowley,
UK).
Transforming growth factor a (rat) was kindly donated by Dr. H.Gregory
(ICI, Macclesfield, UK).
d) Antibodies
The monoclonal mouse anti-human GM-CSF (lgG-|) was purchased
from Genzyme (West Mailing, UK) and a second GM-CSF antibody
(polyclonal sheep anti-human GM-CSF serum) was provided by the National
Institute For Biological Standards and Controls (Potters Bar, UK). The
human GM-CSF immunoassay, 'Quantikine Kit' was aquired from British
Biotechnology (Cowley, UK).
Sheep serum and monoclonal mouse anti-human a fetoprotein (lgG-|
kappa) were both provided by SAPU (Carluke, UK).
Anti-mouse Ig-POD, Fab fragments and donkey anti-sheep IgG
peroxidase conjugate were purchased from Boehringer Mannheim
Biochemica (Germany) and Sigma (Poole, UK), respectively.
e) Western Blotting
Materials and electrophoresis grade chemicals were purchased from
the sources listed below:
Amersham (Slough, UK): ECL Western blotting analysis system, Hi-bond C
extra nitrocellulose membrane, Hyperfilm ECL, Rainbow protein
molecular weight markers 2.35-46-Kd and 14.3-200Kd.
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Sigma Electrophoresis Grade Chemicals (Poole, UK): 40% acrylamide
solution, ammonium persulfate, glycine, silver nitrate, tris base.
Stratech Scientific Ltd. (Luton, UK): 'Blue Juice' sample buffer
(bromophenol blue, urea, SDS, mercaptoethanol).
f) Molecular Biology
i) Disposables
Sterile pastettes were purchased from Alpha Labs. (East Leigh, UK)
and sterile 500pl micro-test tubes from Bio-Rad (Hemel Hempstead, UK).
Elkay 1.5ml microcentrifuge tube (eppendorfs) and Elkay 50ml and 15ml
sterile falcon tubes were all bought from MacKay & Lynn Distributors
(Edinburgh, UK).
ii) Chemicals
General molecular biology grade chemicals were obtained from Sigma
(Poole, UK). Chemicals and enzymes that were purchased elsewhere are
listed below:
Appligene (Durham, UK): Aquaphenol (water saturated phenol)
Northumbria Biologicals (Cramlington, UK): Guanidine isothiocynate
Pharmacia (Milton Keynes, UK): Agarose NA, 100 base pair ladder
(reconstituted in 800pl autoclaved water+100pl loading buffer),
ultrapure solution dNTP (100mM).
Promega (Southampton, UK): AMV reverse transcriptase (25 OOOU/ml), 5x
AMV RT buffer (250mM Tris-HCI, pH 8.3, 250mM KCI, 50mM DTT,
2.5mM spermidine), Bgl I (20U/pl), 10x enzyme buffer (60mM Tris-HCI,
pH 7.9, 1.5M NaCI, 60mM MgCI2, 10mM DTT), MgCI2 (50mM),
Oligo(dT)15 primers (0.5pg/pl), RNAsin (40,000U.ml), Taq DNA
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polymerase (5U/pl), 10x polymerase buffer (500mM KCI, 100mM Tris-
HCI, pH 9.0, 1% Triton X-100).
Stratech Scientific Ltd. (Luton, UK): 'Geneclean' DNA loading gel BBXG
(bromophenol blue, xylene cyanole, glycerol),
iii) Primer Sequences
GM-CSF
GM-CSF primer sequences were designed from the human GM-CSF
gene sequence (Kaushansky et a/ 1986) and were synthesised by the
Imperial Cancer Research Fund, Clare Hall Laboratories, Potters Bar, UK:
The sequences were as follows:
5'GGCTGGCCATCATGGTCAAG3' (MW 6580)
5'GAACCTGAGTAGAGACACTG3' (MW 6597)
These two primers defined a 170bp fragment which spans two introns
(a 955bp genomic fragment). The concentration of primer in the stock
solutions was measured and a working solution (50pg/ml) was prepared.
HPRT
HPRT primer sequences were obtained from Ewan Grant (Dept.
Surgery, Western General Hospital, Edinburgh) and were designed from
Gen Bank. The sequences were as follows (defining a 240bp fragment):
5'CTTGCTCGAGATGTGATGAAG3'
5'GTCTGCATTGTTTTGCCAGTG3'
Stock solutions of primers were stored at -20°C and the working
solutions at 4°C.
Methods andMaterials
2.2 Tissue Culture Techniques
a) Routine Cell Line Culture
All cell lines were routinely cultured in sterile 75ml culture flasks in a
tissue culture incubator (37°C, humidified atmosphere and 5% CO2 in air).
The normal growth media varied according to the cell line, these are listed in
table 3.
Table 3: Growth media used for routine cell line cultures.
Cell line Normal growth medium
DU145, MG63, RT112, Hs578T,
HF19, HEP2, ACHN, CHANG
1640 RPMI + 10% FCS (v/v)
LNCaPt 1640 RPMI + 10% FCS (v/v) + 10nM |
DHT* (Horoszewicz et al 1983)
PC-3 HAM'S F12 + 7% FCS (v/v)
*DHT was prepared 10pM in ethanol and diluted 1:1000 (v/v) into medium.
tLNCaP cells showed no growth without 10nM DHT.
All the normal growth media were supplemented with 100U/ml
penicillin, 100pg/ml streptomycin and 300mg/l glutamine. Cell cultures were
twice monthly tested for mycoplasma using a kit from Boehringer Mannheim
Biochemica (Germany).
b) Passaging Cell Cultures
Cell passage was required for plating cells (e.g., into 24 or 96 well
plates), subculturing cells into two or more flasks (to increase cell number),
or to freeze cells, for storage.
Medium was removed from cells growing in 75ml flasks (or petri dishes)
and the cells were washed once with Dulbecco's A phosphate buffer. The
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cells were then incubated for 5 minutes, at 37°C with 10% trypsin (diluted v/v
with Dulbecco's A phosphate buffer). After this time (or when the cells had
rounded up) the cells were harvested by washing them from the culture flask
(or petri dish) with normal growth medium (10ml). The cell suspension was
placed in a sterile universal and centrifuged at 360 xg for 5 minutes after
which the supernatant was discarded and the pellet resuspended in the
required medium. A single cell suspension was produced by titurating with a
10ml pipette. Cell numbers were counted and the cells seeded as required.
c) Primary Cell Culture
i) Human Prostate Epithelia and Fibroblast Culture
Media and Buffers


















0.5mg insulin (from a working solution of 0.25mg/ml in distilled water)
20pg cholera toxin (from a working solution of 10pg/ml in distilled
water)
1pM dexamethasone (from a working solution of 10mM in ethanol)




The following method was based on an earlier procedure by
Chaproniere et a/ (1986) and was routinely used for the culture of fibroblasts
and epithelia from human prostate.
'Chips' of human prostate were obtained from surgery after
transurethral resections. These were collected in transport medium and
either used immediately or stored overnight at 4°C (storage in this way had
no apparent effect on culture). Parallel chips were sent to the Department of
Pathology, Western General Hospital, Edinburgh, for histological
examination.
Chips (1g) were aseptically dissected into small pieces and incubated
with collagenase solution (1500IU collagenase dissolved in 7.5ml transport
media), overnight at 37°C. The digested solution was titurated by repeated
pipetting with a 10ml pipette and then centrifuged in a sterile universal, at
360 xg for 10 minutes, in a bench top centrifuge (Denley BS400,
Billingshurst, UK). The supernatant was discarded, and the pellet was
washed (to remove collagenase) in transport medium (20ml) and centrifuged
as before. The supernatant was again discarded and the pellet was
resuspended in transport medium (10ml) and centrifuged at 60 xg for 20
seconds. The resultant pellet contained mainly epithelial acini and the
supernatant contained fibroblast aggregates.
The 'fibroblastic' supernatant was carefully collected and spun at
360 xg for 10 minutes. The resultant pellet was reconstituted with fibroblast
growth medium (15ml) in a 75ml culture flask.
The 'epithelial' pellet was reconstituted into epithelial growth medium
(15ml) and cultured in a 75ml culture flask.
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Fibroblast cultures became confluent after approximately 2 weeks, and
medium was replenished when required. Epithelial cultures usually adhered
to the plastic after 5 days, therefore media could not be replenished until
after this time. After 1 week in culture epithelial outgrowths were visible from
acini.
ii) Human Osteoblast-like Cell Culture
The following normal growth medium was prepared:
Osteoblast Normal Growth Medium: Dmem/F12 nutrient mix




Osteoblast-like cells were cultured as described by Beresford et al
(1984). Proximal femur or femoral heads were obtained from orthopaedic
surgery, conveyed in transport medium (as for prostate primary culture) and
used immediately for culture. Surgery was usually a hip replacement. Using
sterile bone cutters, 0.5cm2 chips of bone were excised. These were placed
in a sterile universal and washed thoroughly using transport medium. Six -
eight explants were placed in a sterile petri dish (10cm diameter), containing
normal growth medium (20ml) and maintained at 37°C, in a humidified
atmosphere of 5% CO2 in air.
Growth media was renewed every week by the removal of 10ml of
spent media and the addition of 10ml fresh media.
After 2 weeks, outgrowths of cells could be seen from the bone chips,
by weeks 4-6 these usually became confluent. Once confluent, the cells
were passaged into 75ml culture flasks and the remaining explants could be
recultured for further use.
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In this study individual osteoblast cultures were denoted by a capital
letter (e.g., 'OBCM (A)'),
iii) Human Skin Fibroblasts
A culture of human skin fibroblasts was kindly provided by Dr. Priestly
(Dermatology, Royal Infirmary, Edinburgh). These were grown by incubating
1cm2 sections of skin (from the buttock of an 85 year old female) in petri
dishes containing 20ml normal growth media (Dmem/F12 nutrient mix, 10%
heat inactivated FCS, 100U/ml penicillin, 100pg/ml streptomycin, 300mg/l
glutamine) and maintained at 37°C, in a humidified atmosphere of 5% CO2 in
air. After approximately 2 weeks confluent cultures of fibroblasts were
obtained.
d) Osteoblast Characterisation
The method of osteoblast cell culture used in this thesis, has already
been widely characterised by Beresford et al (1983, 1984, 1986). For the
purpose of this thesis osteoblast-like cultures were characterised, by the
stimulation of alkaline phosphatase production with 10nM 1,25 (OH)2 vitamin
D (Murray et al 1987). Skin fibroblasts were used as a negative control since
they are not sensitive to 1,25 (OH)2 vitamin D in the above manner, whilst
they have similar origins as the osteoblast i.e., both are connective tissue
fibroblasts.
i) Histochemical staining of alkaline phosphatase
Method
Cells were passaged into 24 well plates (5000 cells/well) containing
circular 1cm microscope slides. Once the cells became 50% confluent they
were fixed with acetone (1ml) for 1 minute and then stained for alkaline
phosphatase using a 'Sigma diagnostic kit'. The kit was based on the
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incubation of cells with napthol AS phosphate (pH 8.6, 0.25% w/v) as a
substrate. Phosphatase activity produced napthol AS. Subsequent
incubation of the cells with fast blue RR, diazonium salt produced a coupling
reaction which resulted in the formation of an insoluble, visible pigment at
sites of enzyme activity.
Nuclear staining was achieved by incubation with Mayer's
Haematoxylin (1ml) for 1 minute. Stained cells were then photographed
directly in the 24 well plates using an Olympus IMT-2 inverted microscope.
The following cell cultures were stained for alkaline phosphatase;
osteoblast-like cells grown in normal growth medium (plate 1a), osteoblast-
like cells from the same culture, previously incubated for 48 hours in normal
growth medium supplemented with 10nM 1,25 (OH)2 vitamin D (plate 1b),
skin fibroblasts grown in normal growth medium (plate 1c) and skin
fibroblasts previously incubated for 48 hours in normal growth medium
supplemented with 10nM 1,25 (OH)2 vitamin D (plate 1d).
Plate 1a shows very little cytoplasmic staining, only the blue nuclear
stain of haematoxylin. Plate 1b indicates cells with strong purple staining
throughout the cytoplasm, indicative of alkaline phosphatase. Both plates 1c
and 1d show very little cytoplasmic staining, only nuclear staining by
haematoxylin.
These results indicate the osteoblast-like cells were stimulated by
10nM 1,25 (OH)2 vitamin D to produce alkaline phosphatase. No such
stimulation occurred with the skin fibroblasts, indicating that the osteoblast-

















>, «> ,v . •' > MPMHt
« •' "•
. / "V
\ v'; t e * .





■ ■«." ■» a
•">>
Plate 1a: Human osteoblast-like cells stained for alkaline phosphatase.
x10 Magnification
Plate 1b: Human osteoblast-like cells incubated in the presence of 10nM 1,25
(0H)2 vitamin D and then stained for alkaline phosphatase. x10 Magnification
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Plate 1c: Human skin fibroblasts stained for alkaline phosphatase. x10
Magnification
Plate 1d: Human skin fibroblasts incubated in the presence of 10nM 1,25 (OH)2
vitamin D and then stained for alkaline phosphatase. x10 Magnification
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ii) Colourimetric Assay for Alkaline Phosphatase
The production of alkaline phosphatase from osteoblasts, in response
to 1,25 (0H)2 vitamin D, was quantified using an alkaline phosphatase
colourimetric assay.
Method
Osteoblast-like cells were plated into 24 well plates (105 cells/well) and
left overnight to adhere. The culture medium was replaced with normal
growth medium with or without 10nM 1,25 (0H)2 vitamin D. Cells were
incubated in one of these media for a further 48 hours after which the media
was aspirated and the cells frozen at -20°C for 15 minutes. The cells were
then thawed at room temperature and assay buffer (200pl of 0.1 M Glycine,
1mM MgCI2, 0.1% Triton X-100 [v/v]) was added. This suspension was
mixed by aspiration and 100pl was used to measure protein concentration,
by reading the absorbance at 280nm. The remaining 100pl was used to
assay alkaline phosphatase, by mixing with 0.01 M p-nitrophenol phosphate
(100pl, prepared in assay buffer) and incubating at 37°C for 60 minutes. The
assay was stopped by the addition of 4M NaOH (20pl) and the absorbance
of the solution was read at 405nm on a spectrophotometer (Pye Unicam 550,
Cambridge, UK). The absorbance value was converted to alkaline
phosphatase activity by comparison to a standard curve which had been
prepared by measuring the absorbance of p-nitrophenol standards diluted in
assay buffer at concentrations of 0.1-1 pmol/ml.
The results from three different osteoblast-like cultures (V, Rl and Ql)
are summarised in table 4 and compared to the quantities produced by
human osteogenic sarcoma cell lines SAOS-2 and TE-85 (Murray et al
1987). They indicate that the production of alkaline phosphatase can be
significantly stimulated by 10nM 1,25 (OH)2 vitamin D. The level of this
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activity varies with osteoblast-like cell culture, though V and Ql show activity
comparable to that of SAOS-2 cells. This confirms the histochemical results
that the osteoblast-like cell cultures possess characteristics specific to
osteoblasts.
Table 4: Colourimetric assay of vitamin D stimulated alkaline
phosphatase activity from osteoblast-like cell cultures and cell lines.
Values are expressed as means (n=3) ± sd. p values are shown if alkaline
phosphatase activity is statistically different in cells treated with 1,25 (OH)2 vitamin
D in comparison to untreated cells.
Cell Treatment Alkaline phosphatase activity
(nmol pNP/min/mg protein)
V Osteoblast-like basal 1 509 ± 202
1,25 (OH)2 vitamin D 2 252 ±235 (p<0.0005)
Rl Osteoblast-like basal 7 290 ± 290
1,25 (0H)2 vitamin D 25 200 ±734 (p<0.0005)
Ql Osteoblast-like basal 1 268±101
1,25 (OH)2 vitamin D 2 310 ±335 (p<0.005)
SAOS-2 basal 2 607 ± 139
1,25 (0H)2 vitamin D 2 712 ±30 (p<0.05)
TE-85 basal 16.8 ± 1.4
1,25 (OH)? vitamin D 34.7 ±0.8 (p<0.0005)
61
Methods andMaterials
e) Collection of Conditioned Media
i) Serum free medium (SFM)
SFM was used for collecting conditioned medium and, later, for








ii) Collection of conditioned medium from cell lines, osteoblast-like
cells and skin fibroblasts
Cells were grown to confluence in 75ml culture flasks. Growth media
was then removed and the cells rinsed once with Dulbecco's A phosphate
buffer. SFM (10ml) was exposed to the cells for 24 hours. This conditioned
media was collected, filtered through a 0.2pm sterile filter and stored at
-20°C (for no longer than 6 months) until used.
iii) Collection of Bone Marrow Conditioned Medium
The collection of bone marrow conditioned medium was based on the
method used by Charkal-Roy et al (1989).
Fragments of proximal femora were obtained from orthopaedic surgery
(as for the osteoblast culture). Using sterile bone clippers the red marrow
was carefully removed and any bone fragments were gently washed with
Dulbecco's A phosphate buffer and the washes added to the marrow. This
mixture was centrifuged at 360 xg for 5 minutes. The pellet was resuspended
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in serum free medium (10ml), placed in a 75ml culture flask and incubated
for 24 hours at 37°C, in a humidified atmosphere of 5% C02 in air.
The resulting conditioned medium was clarified by centrifugation at 360
xg for 5 minutes and the supernatant filtered through a 0.2pm filter. The
conditioned medium was then stored at -20°C (for no longer than 6 months)
until used.
f) Reconstitution of Haematopoietic Growth Factors and
Antibodies.
i) Haematopoietic Growth Factors (HGF)
All recombinant HGFs were provided in lyophilised form and were
reconstituted using SFM plus 0.1% BSA (1ml). From these solutions 50pl
aliquots were produced and stored at -70°C. The concentrations of HGFs in
these aliquots were as follows:
rlL-3 of 1pg/ml (1000U/ml)
rG-CSF of 10Ong/ml (10,000U/ml)
rGM-CSF of 1pg/ml (10,000IU/ml)
rEPO of 80pg/ml (10IU/ml)
ii) GM-CSF monoclonal antibody (Genzyme).
This antibody was purchased as 0.5mg in 0.5ml (1mg/ml), it was split
into two aliquots of 0.25ml.
One aliquot was diluted by the addition of Dulbecco's A phosphate
buffer plus 1% BSA to a concentration of 100pg/ml (1:10 dilution). These




The other 0.25ml aliquot was diluted by the addition of SFM plus 0.1%
BSA to a concentration of 100pg/ml (1:10 dilution), aliquoted into volumes of
100pl and subsequently used for cell growth assays.
All the aliquots were stored at -70°C.
g) Growth Assay of Cell lines Following Exposure to Either
Growth Factors or Conditioned Media
To assay the effect of growth factors or conditioned media on cell line
growth, cells were exposed to the factor in serum free medium. The use of
serum free medium avoided producing any unknown additive or conflicting
effects serum may have on the growth factor action. DU145 and PC-3 cells
both grew in serum free conditions however the LNCaP cell line did not.
LNCaP cells were unable to grow in serum free media even in the presence
of 10nM DHT. The LNCaP cell line showed very poor growth unless
maintained in its normal growth medium. The assay procedures used were
therefore different,
i) Plating and Preparation
DU145 and PC-3:
Cells were passaged into 96 well plates in normal growth medium
(150pl), using a multipipette dispenser, at a density of 1000 or 2000
cells/well. Any wells that were unused were filled with growth medium to
reduce evaporation. The cells were left overnight to plate, after which the
medium was changed to serum free medium (150pl). The cells were grown
for a further 48 hours to adjust to the serum free environment. After this time




- recombinant haematopoietic growth factors (rll_-3, rG-CSF, rEPO and
rGM-CSF) reconstituted and diluted in serum free medium
containing 0.1% BSA.
- conditioned media, diluted in serum free medium.
- control cells were grown in either SFM or SFM plus 0.1% BSA,
according to the test solution.
The cells were grown for a period of days in the test solutions, as detailed
below, and cell numbers were subsequently measured by tritiated thymidine
uptake.
LNCaP
Cells were passaged into 24 well plates, in normal growth medium
(1ml), at a density of 5000 cells/well and allowed to plate for 48 hours.
Plating required an extended period of time, in comparison to DU145 and
PC-3 cells, since the LNCaP cell line adhered very loosely to plastic. After
this time, test solutions (haematopoietic growth factors or conditioned media)
were added, all of which were diluted in normal LNCaP growth medium. The
cells were grown for a period of days as detailed below, with no media
change. Cell growth was measured using cell counts. Thymidine uptake
could not be used because large numbers were lost during the assay (since
as stated above the cells adhered loosely to the plastic),
ii) Growth Assays
Dose Response assay
Cells were plated and grown, as above, then test solutions were added
at varying concentrations by diluting in the appropriate medium (i.e.,
conditioned medium in SFM, haematopoietic growth factors in SFM plus
0.1% BSA and LNCaP test solutions in LNCaP normal growth medium).
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After 3 days exposure to the test solutions DU145 and PC-3 cell growth
was measured by tritiated thymidine uptake. LNCaP eel! growth was
measured by cell counts, after 5 days exposure to test solutions. At these
time points the cells were judged to be in the logarithmic phase of growth,
which for the prostate cell lines is between 30 and 80% confluence.
Time Course Studies (DU145 & PC-3)
The time dependency of stimulatory growth factor or conditioned
medium was investigated as follows: cells were plated, as above, the test
solution (150pl) was added (this was taken as day 0) and cell growth was
assessed by tritiated thymidine uptake on day 0 and every subsequent 24
hours for 4 days (after this time cells were no longer in the iogarithmic phase
of growth). The test solutions were renewed after 3 days exposure to the
cells.
Antibody Inhibition of GM-CSF Growth Stimulation
To test if the growth stimulation of DU145 cells by GM-CSF was
specific to GM-CSF, the growth factor was pre-incubated with a monoclonal
antibody raised specifically to human GM-CSF.
A solution of rGM-CSF was prepared at 200IU/ml in SFM. Several
concentrations of antibody were also prepared - 4, 40, 400, 4000 and 40
OOOng/ml (diluted with SFM plus 0.1% BSA). The rGM-CSF solution was
mixed 1:1 (v/v) with each of the antibody solutions. This produced five
solutions each containing 100IU/ml of rGM-CSF (a concentration known to
stimulate prostate cancer cell lines) and an antibody concentration of 2, 20,
200, 2000 or 20 OOOng/ml. These solutions were incubated at 37°C for one
hour before addition to DU145 cells, plated as described in 2.2-g.i). Cells
were grown for 3 days in these solutions, after which cell growth was
measured by tritiated thymidine uptake.
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The experiment was repeated exactly using mouse anti-human a
fetoprotein (SAPU) as the monoclonal antibody.
h) Measurement of Cell Growth - Thymidine Uptake
Initially three assay methods were available to measure cell growth:
i) Cell counts with a haemocytometer
Described in section 2.6a
ii) 3H-TdR Incorporation
Incorporation of tritiated thymidine into cellular material was assessed
by washing cells (in their log phase of growth) with Dulbecco's A phosphate
buffer. The cells were then incubated for 4 hours in methyl-3H thymidine
diluted to 10pCi/ml in serum free medium. After this time they were
repeatedly washed in Dulbecco's A phosphate buffer and then incubated for
5 minutes with 10% trypsin (diluted v/v in Dulbecco's A phosphate buffer),
followed by a 30 minute incubation with ice cold 10% TCA (w/v).
The cells were harvested with a 'Skatron Combi' cell harvester
(Newmarket, UK) onto filter papers. These papers were dried, then punched
into scintillation vials and dissolved in 6ml of 'Ultima Gold' scintillant.
Disintegrations per minute were measured and calculated by a 'Canberra
Packard' Tri-Carb liquid scintillation analyser.
iii) 3H-TdR uptake
The measurement of tritiated thymidine uptake into cells was carried
out on cells in their log phase of growth. The cells were washed once with
Dulbecco's A phosphate buffer and then incubated for 4 hours in methyl-3H
thymidine diluted to 10pCi/ml in serum free medium. Following this
incubation the cells were thoroughly washed in Dulbecco's A phosphate
buffer and then incubated for 5 minutes in 10% trypsin (diluted v/v in
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Dulbecco's A phosphate buffer). This produced a cell suspension which was
harvested with a 'Skatron Combi' cell harvester (Newmarket, UK) onto filter
papers. The filter papers were dried and then punched into scintillation vials
and dissolved in 6ml of'Ultima Gold' scintillant.
This scintillant completely removed all radioactivity from the filter after 5
minutes; this was confirmed by placing a filter paper with radioactive counts
in a vial of scintillant, for 5 minutes, removing the filter and placing it in a
second vial of scintillant. Counts were measured in the first vial and only
background was detected in the second.
Counts per minute were then measured by a 'Canberra Packard' Tri-
Carb liquid scintillation analyser. The analyser counted each sample for
three minutes, corrected the counts for efficiency (quench) and calculated
disintegrations per minute. The efficiency of the tritium channel remained at
approximately 66% throughout the experiments.
iv)Choice of Assay
Each of the above methods was investigated for its suitability to assay
cell growth in the experimental design.
Cell counts were not routinely used since a Coulter counter was not
available and measurements had to be made with a haemocytometer.
Counting in this way proved slow and inaccurate, due to human error.
Thymidine incorporation was found to be inaccurate at low serum
concentrations. It was noticed that counts from thymidine incorporation were
very low in serum free experiments even though there were cells in the wells.
To investigate this, DU145 cell growth in serum free or 10% FCS medium
was assayed using either thymidine uptake or incorporation. Any counts left
behind (in the culture well) after harvesting were extracted with NaOH (0.5M
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NaOH was added to the well, mixed with a pipette and removed into a
scintillation vial and counted as before). Results are shown in table 5.
Table 5: Comparison of thymidine incorporation vs. thymidine uptake
assays of DU145 cell growth in 10% FCS and serum free medium.
1000 DU145 cells were plated in normal growth medium and grown for 3 days in
either 10% FCS or serum free medium. After this time they were incubated for 4
hours in tritiated thymidine (10pCi/ml) and growth was measured either by
thymidine uptake or by thymidine incorporation. Cells were then harvested and 3H-
TdR counted on a liquid scintillation analyser. For both assays the 3H-TdR left
behind in the wells was extracted using 0.5M NaOH, which was pipetted into a
scintillation vial and counted as before. Values are expressed as means (n=6) ± sd.
Cells grown in: Thymidine 3H counts (dpm) 3H counts (dpm)
assay Thymidine NaOH Extraction
Normal Medium (10% FCS) Incorporation 2890±120 490
Normal Medium (10% FCS) Uptake 2700±77 600
Serum free medium Incorporation 435±48 1700
Serum free medium Uptake 17411130 450
When cells were grown in complete medium the dpm measured by both
thymidine assays was similar (2890 and 2700) and very few dpm were left
behind in the wells (490 and 600). However, when cells were grown in serum
free medium the dpm measured by thymidine incorporation decreased
dramatically to 435 dpm and the counts left behind in the well increased to
1700 dpm. Increasing trypsin concentration or trypsin incubation time did not
increase the size of thymidine incorporation or decrease the counts found by
NaOH extraction. Thymidine uptake still showed a high dpm count (1741)
and low counts for the cells remaining in the well (450) when cells were
grown in serum free medium. Similar experiments conducted in the absence
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of cells did not indicate any counts above background levels for any of the
three thymidine assays. These results indicate that TCA seemed to interfere
with the action of trypsin or cell attachment in serum free environments,
causing large numbers of cells to remain behind after harvesting. Therefore
thymidine uptake was used to measure cell growth in a serum free
environment.
Validation of Thymidine Uptake
To validate whether thymidine uptake could represent cell counts,
prostate cell lines were plated and grown in serum free medium (as in
section 2.2-g.i). Growth was subsequently assayed every 24 hours for a
period of 4 days by either thymidine uptake or cell counts.
Figure 1 illustrates the growth of DU145 (a) and PC-3 (b) cell lines
assayed by both thymidine uptake and cell counts. The graphs indicate that
cell line growth over a period of 4 days followed a similar pattern, whether
assayed by cell counts or thymidine uptake, i.e., as thymidine uptake
increased so did cell counts. This, demonstrated thymidine uptake is a valid










Figure 1a & 1b: Growth of Prostate Cancer Cell Lines In Serum Free Medium -
Comparison of Growth Measurement by Cell Counts and Thymidine Uptake.
DU145 [A] or PC-3 [B] cells were plated (1000/well) in normal growth medium. After
24 hours the medium was changed to SFM. The cells were incubated in SFM for 48
hours to adjust to the new medium. Growth was subsequently measured every 24
hours by both thymidine uptake (—) and cell counts (- -). Values are expressed as
means (n=6). Standard deviations were <10% of the mean.
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i) Characterisation Of Osteoblast-like Cell Conditioned
Medium
i) Acid treatment
Four aliquots of OBCM (1ml) were each incubated with 1ml of citric-
acid phosphate buffer (0.1M citric acid, 0.2M Na2HP04) at one of four pH
(2.6, 4.6, 6.6 and 7.6), for 2 hours at room temperature. At the end of the
incubation serum free medium containing 1mg/ml BSA (9ml) was added to
each solution to bring the pH back to 7.6. The mitogenic activity of acid
treated OBCM were tested by incubating DU145 cells (plated as described in
2.2-g.i). in these solutions for 3 days.
ii) Heat treatment
50% OBCM (5ml) was incubated, in a water bath, at 80°C for 1 hour,
and then cooled to room temperature.
Each treated medium was tested for DU145 mitogenic activity, by
exposing them to the cells (plated as described in 2.2-g.i) for 3 days.
iii) Molecular Weight Fractionation
OBCM was fractionated using 'centricon' filters, since gel filtration
proved unsuccessful and high performance chromatography techniques
were not available. The method is summarised in figure 2, and is described
below.
50% OBCM (5ml) was loaded into a centricon-100 concentrator and
centrifuged at 1000 xg for 10 minutes. The material retained on the filter
(>100Kd) was recovered by the addition of 5mls of serum free medium to the
sample reservoir (to run on a polyacrylamide gel this retentate was
recovered in Dulbecco's A phosphate buffer). 1ml of the filtrate (<100Kd)
was kept to assay its mitogenic activity and the rest was loaded into a
































Again, 1ml of the new filtrate (<30Kd) was kept to assay its mitogenic
properties and the rest loaded into a centricon-10 concentrator and
centrifuged at 4000 xg for 1 hour. This last step was repeated with a
centricon-3 concentrator which was centrifuged at 4000 xg for 2 hours, and
samples were retained for assay (<10Kd and <3Kd).
By the end of the filtration sequence five molecular weight fractions
were produced, these were: >100Kd, <100Kd, <30Kd, <10Kd and <3Kd.
Each fraction was tested for DU145 mitogenic activity, by exposing the cells
(plated as described in 2.2-g.i) for 3 days to these solutions.
A sample of serum free medium (5ml) was similarly fractionated to
provide five control fractions. A 1ml sample of each molecular weight fraction
was later lyophilised and run on a 7.5% reducing polyacrylamide gel.
iv) OBCM incubation with monoclonal mouse anti-human GM-CSF
To determine whether or not GM-CSF was responsible for any of the
stimulatory effects of OBCM, OBCM was pre-incubated with a monoclonal
antibody raised to human GM-CSF (Genzyme).
OBCM was serially diluted with SFM to the following concentrations;
100%, 50%, 25%, 12.5% and 6.25%. Each dilution was mixed 1:1 (v/v) with
anti-GM-CSF mAb solution (4pg/ml). This produced five solutions each
containing 2pg/ml of anti-GM-CSF mAb and a dilution of OBCM as follows;
50%, 25%, 12.5%, 6.25% and 3.125%. A solution of SFM mixed 1:1 (v/v)
with 4pg/ml of GM-CSF mAb was also prepared. All these solutions were
incubated at 37°C for one hour before addition to DU145 cells, plated as
described in 2.2-g.i). Cells were grown for 3 days in these solutions, after
which cell growth was measured by tritiated thymidine uptake.
The above method was repeated by replacing the OBCM solution with






The following solutions were prepared:
. Trls Buffered Saline (TBS), pH 7.6:
50mM Tris
140mM NaCI
0.1% Triton X-100 (v/v)
• TBS/BSA (1% Bovine serum albumin [w/v] in tris buffered saline solution)
• 0.02M Imidazole Solution prepared in distilled water.
• 1% & 3% H202 (v/v in distilled water)
• 1% formaldehyde (v/v diluted in Dulbecco's A phosphate buffer)
• 5% acetic acid (v/v in ethanol)
• Primary Antibody Solution
monoclonal mouse anti-human GM-CSF (IgG-j) was diluted in TBS/BSA,
to the required dilution.
• Secondary Antibody Solution
sheep anti-mouse (Fab fragments conjugated to peroxidase) was diluted
1:40 (v/v) in TBS/BSA solution.
• DAB Solution (diaminobenzidine hydrochloride):
DAB (2mg) was dissolved in TBS (2ml), to this was added 0.02M
imidazole (60pl) solution and the mixture was heated to 37°C. Finally
1% H202 (30pl) was mixed into the solution.
ii) Preparation and fixation of cell lines and primary cultures
Cells were passaged into 24 well plates in normal growth medium (1ml)
at a density of 10 000 cells/well. When the cells were approximately 50%
confluent they were fixed in 1% formaldehyde (250jjI) for 20 minutes at room
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temperature, followed by 5% acetic acid ( 250pl) for 10 minutes. The cells
were then washed twice in TBS, each wash was left for 3-4 minutes.
iii) Preparation of Frozen Tissue Sections
Microscope slides (Chance Propper Ltd., Warley, UK) were first
prepared by cleaning them with acid alcohol (1% HCI [v/v] in 70% Ethanol)
and then incubating in a L-lysine solution at room temperature for 5 minutes.
These were then either air dried overnight or at 60°C for 1 hour.
The slides were used to mount 5pm cryostat frozen (-70°C) tissue
sections. These were fixed by incubating in acetone for 10 minutes and then
air drying for 5 minutes and finally rinsing in TBS.
iv) Preparation of Paraffin-embedded tissue sections
Paraffin embedded tissue sections were obtained from the Pathology
Dept., at the Western General Hospital, Edinburgh. This provided prostate
tissue sections which had been examined by pathologists and their Gleason
scores (Foster 1992) obtained. In this study, well differentiated cancers have
a Gleason score <4, moderately differentiated 6 and poorly differentiated >6.
The sections were first dewaxed by heating to 60°C for 15 minutes,
after which they were washed twice in xylene for 3 minutes, at room
temperature. This was followed with repeated three minute washes in 100%
ethanol, and then repeated washes in 95% ethanol, both at room
temperature. The sections were finally rinsed in TBS.
v) Immunostaining
Fixed tissue sections or cell lines were all stained according to the
method described below.
Endogenous peroxidase was blocked by incubation in 3% hydrogen
peroxide for 30 minutes, at room temperature. Samples were then washed
twice in TBS, each for 5 minutes. Non-specific sites were blocked by
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incubation in a solution containing 20% sheep serum (v/v) and 20% human
male serum (v/v) diluted in TBS/BSA solution, for 1 hour at room
temperature. The blocking solution was drained off and the samples
incubated in primary antibody. Titration of the primary antibody, indicated
that positive staining occurred between dilutions of 1:100 and 1:800. Optimal
staining was as follows:
- Cell lines: incubated in a 1:200 dilution of primary antibody (v/v) in
TBS/BSA solution, overnight, at 4°C, inside a humidified
container.
- Tissue sections: incubated in a 1:400 dilution of primary antibody (v/v)
in TBS/BSA solution for 2 hours at room temperature, inside a
humidified container.
TBS/BSA solution was used as a negative control. After incubation with
the primary antibody, samples were washed thoroughly in TBS and then
incubated with the secondary antibody, for 1 hour, at room temperature
inside a humidified container. Samples were again washed repeatedly in
TBS and then incubated in DAB solution for 5 minutes (or until colour
developed), at room temperature.
Samples were rinsed in tap water, and then incubated in Mayer's
haematoxylin for 1 minute, at room temperature, followed by 1 minute in
saturated lithium carbonate.
Cover slides (Chance Propper Ltd.) were applied to tissue sections
using DePeX, and these were photographed using a Leitz Ortholux 2 light
transmitting microscope.
Cell lines were photographed directly in the 24 well plates using an
Olympus IMT-2 inverted microscope.
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vi) Specificity of Immunostaining
The specificity of immunostaining produced by the GM-CSF
monoclonal antibody was investigated by pre-incubating the primary
antibody with excess rGM-CSF, prior to staining the DU145 cell line. The
primary antibody was used at a dilution of 1:800. Titration had shown this to
be the lowest dilution of antibody that still produced a positive result,
therefore this reduced the amount of GM-CSF required to adsorb all the
antibody.
A 1:400 dilution of primary antibody was prepared (with TBS/BSA) and
mixed 1:1 (v/v) with a solution of rGM-CSF (1250U/ml = 125ng/ml). This
produced a final solution containing a 1:800 dilution of primary antibody and
rGM-CSF (625U/ml), this concentration of rGM-CSF was calculated to be 15
times the molar excess of the antibody. This mixture was incubated at 37°C
for one hour and then used as the primary antibody solution for
immunostaining.
In a similar experiment the antibody was also pre-incubated with
excess IL-3 (125ng/ml) and excess EPO (125ng/ml), to act as controls. As a
blank, antibody solution (1:800) was incubated 1:1 (v/v) with SFM plus 0.1%
BSA. Negative staining was achieved by replacing the antibody solution with
TBS/BSA and mixing 1:1 (v/v) with SFM plus 0.1% BSA.
b) Enzyme Linked Immunoassay (ELISA)
The concentration of GM-CSF in the conditioned media of various cells
was measured using a Quantikine Kit for human GM-CSF. The principles of




A microtiter plate was provided, previously coated with a mouse
monoclonal antibody to GM-CSF. GM-CSF standards were pipetted into the
wells along with undiluted samples of conditioned media (3 wells/sample or
standard). Any GM-CSF present in the media, bound to the plate and
unbound proteins were washed away. A second goat monoclonal antibody
(conjugated to peroxidase) was added to the cells and adsorbed to the
bound GM-CSF. After washing away unbound antibody a substrate solution
was added which contained a chromogen (tetramethylbenzidine), and colour
developed according to the amount of GM-CSF present. This was measured
as an absorbance at 450nm. The minimum detectable dose of the assay was
1.5pg/ml GM-CSF.
The antibody was cross reacted with TGFa (0.5pg/ml), TGF(3
(10.5ng/ml), EPO (80ng/ml), IL-3 (10ng/ml) and G-CSF (100ng/ml), to check
its specificity.
The ELISA kit was used to assay media conditioned by; DU145 cells,
PC-3, LNCaP, benign prostate fibroblasts, MG63 and osteoblast-like cells.
The absorbance at 450nm was measured using a Bio-Rad 450
microplate reader (Watford, UK), which used a correction wavelength of
540nm. The plate reader calculated the standard curve and data.
2.4 Western Blotting
a) Solutions
The following solutions were prepared using electrophoresis grade
chemicals:
Phosphate Buffer (pH 7.6)





i) Polyacrylamide gel electrophoresis
30ml Resolving Gel 12% (ml) 7.5% (ml)
h2o 12.9 16.2
40% acrylamide 9.0 5.6
1.5M Tris (pH 8.8) 7.5 7.6
10% sds (w/v) 0.3 0.3
10% ammonium persulfate (w/v) 0.3 0.3
TEMED 0.012 0.012
10ml, 5% Stacking Gel (ml) Tris-Glycine Electrophoresis Buffer
h20 7.3 Prepared with distilled water
40% acrylamide 1.25 25mM Tris
1.5M Tris (pH 6.8) 1.25 200mM Glycine
10% sds 0.1 3.5mM SDS









Washing Solution (pH 7.5)









Monoclonal mouse anti-human GM-CSF (Genzyme) or
polyclonal sheep anti-human GM-CSF serum (National Institute For
Biological Standards and Controls) were diluted 1:100 (v/v) with
blocking solution.
Secondary Antibody Solution
(for the primary, polyclonal sheep anti-GM-CSF)
Donkey anti-sheep IgG peroxidase conjugate (Boehringer Mannheim
Biochemica) was diluted 1:1000 with blocking solution.
iv) Silver Staining
All water used was the purest available
Silver solution
Two solutions were prepared:
a) 0.8g AgN03 in 4mls distilled Fl20
b) 1.4ml conc. NFI4OFI plus 21ml 0.36% NaOH (w/v).
Solution (a) was mixed vigorously to (b) and the volume made up to
100ml with distilled water
Developer
0.12 mis 37% formaldehyde
1,25ml 1 % citric acid (w/v)
148.63ml distilled water.
Stop Solution
50% distilled water, 45% methanol and 5% acetic acid (v/v/v)
b) Sample preparation
Conditioned media were collected from DU145, PC-3, LNCaP, MG63,
benign prostatic fibroblasts and osteoblast-like cells (as in section 2.2.e).
Salts and small molecular weight compounds were removed from the
conditioned media by dialysis against 5 litres of 10mM, pH 7.6 phosphate
buffer using Spectrapore 3 dialysis tubing (molecular weight cut off 3.5Kd).
Buffer was changed twice, over 24 hours. The protein concentrations of the
dialysed media were measured using the Bradford assay and a sample of
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each was snap frozen in liquid nitrogen and lyophilised to dryness at a
pressure of O.lmbar.
The powdered media were reconstituted in Dulbecco's A phosphate
buffer to a concentration of 0.1 -1mg protein/ml. Samples were mixed 1:1
(v/v) with 'Blue juice' sample buffer and stored at -20°C or used directly for
electrophoresis.
c) SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE)
PAGE was based on the method described by Laemmli (1970) using a
Bio-Rad Protean II apparatus. All parts of the casting mould were cleaned
with 70% ethanol before assemblage. The components of the resolving gel
were mixed in the order listed (ammonium persulfate prepared fresh) into a
50ml Falcon tube. As soon as TEMED was added the contents of the tube
were carefully mixed and poured. The gel was overlaid with water-saturated
isobutanol to a 1cm depth and the gel was left to polymerise for 45 minutes.
Once the gel had set, the overlay was removed using the edge of a clean
filter paper and rinsed with distilled water.
Components of the stacking gel were carefully mixed, in the order
listed, into a 50ml disposable falcon tube, and poured immediately onto the
resolving gel. The sample comb was carefully inserted into the stacking gel
solution and left to polymerise for a further 45 minutes. After polymerisation
was complete the comb was removed and using a squirt bottle, the wells
were washed with electrophoresis buffer to remove unpolymerised
acrylamide. The gel was then placed in the electrophoresis apparatus and
electrophoresis buffer was added to the top and bottom reservoirs.
Samples previously prepared in 'Blue juice' loading buffer were boiled
for 5 minutes to denature the proteins, and cooled. Samples (10-30pl) were
loaded into the wells with a Hamilton syringe (1-1 Opg of a polypeptide and
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50-100|jg of a protein mixture). Rainbow molecular weight markers (20pl)
were similarly loaded (range: 2.35-46Kd or 14.3-200Kd) and rGM-CSF
(25ng) was loaded as a positive control. The power source was attached and
the electrophoresis was run at 20mA until the dye reached the resolving gel
and then turned up to 40mA, until the dye was 1cm from the gel bottom. After




The gel was placed in transfer buffer and soaked for 30 minutes. After
equilibration, the gel was measured and one piece of nitrocellulose
membrane, plus four pieces of 3MM Whatman paper were cut to the same
dimensions. The membranes and papers were also equilibrated for a further
30 minutes. Blotting took place in a Bio-Rad Trans Blot semi dry
electrophoretic transfer cell. Two pieces of Whatman were placed exactly on
top of each other onto the anode and any air bubbles rolled out. The
nitrocellulose was then placed on top of the Whatmann papers, then the gel
and then the remaining 2 pieces of Whatman. The cathode was placed on
top and blotting was carried out overnight at 5V.
ii) Immunodetection
The nitrocellulose membrane was removed from the blocking apparatus
and briefly rinsed with washing solution. It was then incubated in blocking
solution for 1 hour at room temperature, on a shaking platform (0.1ml
solution/cm2 membrane) in a heat sealable bag. After this, the membrane
was washed thoroughly in washing medium and then incubated with one of
the primary antibody solutions (0.1ml solution/cm2 membrane), for 2 hours at
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room temperature. The membrane was repeatedly washed in washing
medium. Antibody detection was dependent on the primary antibody, as
follows:
• mouse monoclonal anti-GM-CSF detection was performed with the ECL
Western Blotting analysis system. Briefly, this system incubated the
membrane with a 1:1000 dilution of secondary antibody (sheep anti-
mouse and conjugated to peroxidase) for 1 hour. The membrane was
washed thoroughly and a detection reagent added for 1 minute to the
side of the membrane carrying the protein.
« polyclonal sheep anti-GM-CSF was detected by incubating the
membrane with a donkey anti-sheep secondary antibody solution for 1
hour. The membrane was then washed thoroughly and the ECL
detection reagent added for 1 minute to the side of the membrane
carrying the protein.
The membrane was wrapped in saran wrap and exposed to Hyperfilm-ECL
(placing the protein side of the membrane against the film) for 5 minutes.
Lastly the film was developed with a Kodak RP X-OMAT processor.
e) Silver Staining
The gel was fixed overnight in 50% methanol (v/v with distilled water)
followed by incubation in the silver solution for 15 minutes on an orbital
shaker, at room temperature. The gel was then washed extensively in water.
Developer was added until proteins bands were easily visible and then the
reaction was stopped by incubation with the stop solution.
The gel was finally placed in a heat sealable bag with a small amount
of stop solution and photographed immediately.
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2.5 Molecular Biology Techniques
a) Solutions
i) RNA Extraction
To destroy RNase contamination, all solutions were incubated
overnight with depc (20|jl depc/100ml of solution) followed by autoclaving.
Glassware was similarly treated with depc, by rinsing inside the glassware
with a depc solution (20pl depc/100ml water) and then autoclaving. All the
plastics used were sterile and free of RNases.
The following solutions were prepared:
GTC Denaturing Solution
0.318ml Sodium citrate (0.75M, pH 7.0)
0.476ml Sarcosyl (10% w/v)
5.54ml Depc treated H20
4.73g Guanidine isothiocynate
0.072ml Mercaptoethanol
2M Sodium Acetate (anhydrous), pH 4:
Prepared with 32% depc water and 68% glacial acetic acid (v/v)
ii) Polymerase chain reaction
Tris Borate Buffer (TBE)
90mM Tris base
90mM Boric acid
2mM EDTA (pH 8.0)
b) RNA Extraction
RNA extraction was based on a method used by Chomczynski and
Sacchi (1987). Where possible the experiments were carried out on ice to
reduce any contaminating RNAse activity.
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i) Preparation of Cell lines
Cells were grown to confluency in 75ml tissue flasks (approximately
1.5x106 cells). These were then rinsed with sterile Dulbecco's A phosphate
buffer, and drained as much as possible. Denaturing solution (2ml) was
added to the flask and incubated with the cells for 30 minutes on an orbital
shaker at 4°C. This solution was then drained into a sterile 10ml falcon tube.
ii) Preparation of Blood Cells
Total female blood (10ml) was incubated on ice with denaturing
solution (10ml) for 1 hour and then placed in a 50ml sterile falcon tube.
iii) Extraction
Cells in denaturing solution were homogenised to sheer the DNA, after
which the foam was allowed to settle on ice for 1 hour, the solution was then
transferred in 500pl aliquots to sterile eppendorfs.
Sodium acetate (50pl of 2M, pH4) was added to each eppendorf and
vortexed, then water saturated phenol (500pl) was added and vortexed.
Finally, chloroform/isoamyl alcohol (100pl, 49:1[v/v]) was added and
vortexed vigorously for 15 seconds. Finally, the eppendorfs were spun in a
bench top microfuge (MSE, Microcentaur, MacKay & Lynn Distributors,
Edinburgh, UK) for 20 minutes at 14 000 xg (4°C).
This produced two phases. Using a pasteur pipette, the top aqueous
phase was transferred to fresh sterile eppendorfs, to which isopropanol
(200pl) was added. This solution was vortexed and stored at -20°C for 1
hour to precipitate the RNA. After precipitation, the RNA was spun in a
microfuge for 20 minutes at 14 000 xg (4°C). The supernatant was carefully
removed and the pellet resuspended in denaturing solution (60pl). At this
point aliquots were pooled and isopropanol was added 1:1 (v/v). This was
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precipitated, overnight at -20°C after which it was spun for 10 minutes at 14
000 xg (4°C).
The supernatant was removed and the pellet washed in 75% ethanol.
At this point the pellet could be stored at -70°C (in 75% ethanol) or
resuspended in depc water. To re suspend in water, the RNA was spun for
10 minutes at 14 000 xg (4°C), and the ethanol removed with a pipette. The
pellet was then air dried for 1 hour (or under vacuum for 5-10 minutes). This
formed a translucent pellet which was resuspended in 11 pi of depc water.
The concentration of RNA in the solution was then calculated.
c) Reverse Transcription
Total RNA (1pg) was reverse transcribed in a reaction volume of 20pl,
by the addition of:
1pl RNA (1 pg)
2pl dNTP mix (10mM)
0.5pl RNasin (40 OOOU/ml)
1 pjl Oligo (dT)15 primers (500ng/ml)
0.8pl AMV reverse transcriptase (25 OOOU/ml)
4pl AMV RT Reaction buffer (5x)
4pl MgCI2 (25mM)
6.7pl Autoclaved water
The solution was mixed by gentle flicking and incubated at 42°C for 60 min.
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d) Polymerase Chain Reaction (PCR)
i) Reaction
Amplification of specific RNA sequences was carried out in an
microtest-tube in a reaction volume of 100pl, which contained:
20pl reverse transcriptase mix
16pl dNTP mix (1,25mM)
0.2pl Taq DNA polymerase (5000U/ml)
2x1 Opl primers (50pg/ml) - approximately 75pmol of each
8pl assay buffer (1 Ox)
31.8pl autoclaved water
The reaction mix was vortexed and mineral oil (50pl) was layered on top,
and pulsed in a microfuge. Using a Hybaid Thermal Reactor (Teddington,
UK) reaction mixtures underwent denaturation at 94°C for 1 minute,
annealing at 55°C for 1.5 minutes and extension at 72°C for 3.5 minutes, for
a total of 40 cycles. The products were then size separated on a 2% agarose
gel.
ii) cDNA Digestion with Bgl I
GM-CSF PCR products were characterised by the ability of Bgl 1 to
cleave the 170 bp product into two smaller products of 123 and 47 bp. A
restriction digest was carried out by mixing:
20pl PCR product
5pl Enzyme buffer (10x)
24pl Autoclaved water
1 pi Bgl I
This mixture was vortexed and then incubated at 37°C for 1 hour.
iii) Analysis of Genomic DNA contamination
In order to demonstrate that GM-CSF PCR products were due to RNA
and not genomic DNA the presence of genomic contamination was analysed
by amplifying 1 pg RNA without reverse transcription. Therefore the 20pl of
RT mix in the PCR reaction was replaced with a solution containing 1pg
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RNA and amplified as before. Any genomic contaminants would produce a
955 bp product, since the GM-CSF primers span two introns.
iv) Size Fractionation Of PCR Products
PCR products were size fractionated on a midi gel apparatus
(Northumbria Biologicals Ltd., Cramlington, UK). This was assembled after
cleaning with 75% ethanol and rinsing in TBE.
A 2% gel (w/v) was cast by melting agarose in TBE (70ml), using a
microwave oven. While the solution was cooling 1 jji of ethidium bromide was
added. When the gel solution reached hand heat it was poured into the gel
mould and left to set for 30 minutes. Once set, the comb was removed and
the gel was placed in the tank filled with TBE.
PCR product (27pl) was mixed with DNA gel loading dye (3pl) and
loaded into a sample well using a Gilson pipette along with a 100 base pair
ladder (30pl).
The gel was then run at 50V for 4-5 hours after which it was illuminated
by a TM-20 transilluminator (UVP Ltd., Cambridge) and photographed with





The number of viable cells was counted by mixing 0.5ml of single cell
suspension to 0.5ml of trypan blue (0.5% NaCI + 0.5% Trypan blue, w/w/v in
distilled water). A sample of this solution was then carefully loaded onto a
haemocytometer and the viable cells were counted (non-viable cells stained
blue). Cell number was calculated using the following equation:
(No. cells counted/No. squares on haemocytometer counted) x 204
b) Protein Analysis
i) Bradford assay (Bradford 1976)
A stock solution of BSA (160pg/ml) was prepared and serially diluted to
give 1ml volumes of 16, 12, 8, 6, 4, 2pg/ml standards, these were used to
produce a standard curve. Distilled water or reaction medium was used as a
blank and for diluting, as appropriate.
Each standard or sample (0.8ml) was added to Bradford reagent
(0.2ml) and vortexed (usually carried out in triplicate). These solutions were
left for a period of 5-60 minutes after which the absorbance at 595nm was
read on a spectrophotometer (Pye Unicam 550, Cambridge, UK).
Samples were diluted and added to reagent so that their absorbance
values fitted on the curve (and also to check that dilution of the sample led to
dilution of protein concentration measured). Protein concentrations were
read from the standard curve.
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ii) Absorbance at 280nm
If a sample contained a chemical which interfered with the Bradford
reagent (i.e., if the dilutent did not produce a standard curve or produced an
emulsion), protein concentration was measured at 280nm. Solutions for a
standard curve were prepared as for the Bradford assay.
c) Quantification of RNA and DNA
Samples of RNA or DNA solutions (1pl) were added to depc treated
water (1ml). The absorbance of this solution was then read in a
spectrophotometer (Pye Unicam 550, Cambridge, UK) at 260nm or 280nm.
Concentrations were calculated as indicated below.
i) RNA
Using the following equations the concentration and purity of RNA solutions
were calculated:
At 260nm one OD unit is equivalent to 40pg/ml of RNA
Pure RNA samples have a 260/280 absorbance ratio of 1.8-2.0
(values below 1.6 indicate the sample is badly contaminated
with protein).
ii) DNA
The concentration of DNA samples were calculated as follows:
At 260nm one OD unit is equivalent to 50pg/ml of double stranded DNA.
At 260nm one OD unit is equivalent to 40pg/ml of single stranded DNA.
iii) Oligonucleotide
The concentration of oligonucleotide samples were calculated as follows:





To test whether or not the means of two independent groups were
significantly different, statistics were calculated using the students unpaired
t-test to calculate p values. This test assumed that the samples analysed
had normal distributions. If the samples were judged to have non-parametric
distributions then statistics were calculated with the Mann-Whitney test.




The results in this chapter are presented in the following sections:
3.1 The effects of osteoblast-like cell conditioned medium on prostate cell
lines.
3.2 Characterisation of osteoblast-like cell conditioned medium.
3.3 The effects of haematopoietic growth factors on prostate cell lines.
3.4 Evidence that GM-CSF may or may not be responsible for the OBCM
stimulation of prostate cell lines.
3.5 Secretion of GM-CSF by prostate cell lines.
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3.1 The Effects Of Osteoblast-like Cell Conditioned
Medium On Prostate Cell Lines
a) Growth of prostate cancer cell lines in osteoblast-like cell
conditioned medium and bone marrow conditioned medium
In order to understand how prostate cancer is stimulated by factors in
the .bone environment, initial experiments looked at the effects of media
conditioned (CM) by primary cultures of human osteoblast-like cells (OB) and
bone marrow (BM), on the growth of prostate carcinoma cell lines.
PC-3 and DU145 cells were incubated for 3 days in the presence of
OBCM (figure 1) or BMCM (figure 2), both diluted to 50% with serum free
medium. Following the incubation, growth was measured by tritiated
thymidine uptake and compared to growth in serum free medium.
Figure 1 shows the effects of CM collected from three different
osteoblast cultures (L, R, P). All stimulated the growth of both DU145 and PC-
3 cells when compared to controls of serum free medium. Stimulations were
in the order of 1.8 to 3 fold, and all were statistically significant, p values are






























Figure 1: The Growth of Prostate Cell Lines In Osteoblast-like Cell Conditionec
Medium. Cells (DU145 or PC-3) were plated (1000/well) in normal growth medium
and then grown for 48 hours in SFM. Cells were subsequently incubated in 50%
OBCM (open) or a control of SFM (hatched) for a period of three days. Growth was
then assessed by tritiated thymidine uptake. OBCM was taken from culture L, R or P
Values are expressed as means (n=6) ± sd. p values are indicated if growth im
OBCM was significantly different to growth in SFM. * p<0.0025, **p<0.0005
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The results in table 1 summarise all the studies that have investigated
the effect of 50% OBCM on DU145 and PC-3 cell growth. Stimulation was
observed from all the five conditioned media tested. The table shows that
media conditioned by one individual osteoblast culture could reproducibly and
repeatedly stimulate both prostate cell lines. All OBCM stimulated DU145
growth roughly by the same degree, this stimulation had a mean (±sd) value
of 2.3 (±0.3) fold. PC-3 cells were also stimulated by approximately the same
degree, the mean value of which was 3.2 (±0.6) fold. These results
demonstrate that PC-3 cells were usually stimulated to a greater extent than
DU145 cells. Statistical analysis revealed that the mean value of PC-3 cell
growth stimulation was significantly (p<0.0005) greater than that of DU145
cells.
In contrast to OBCM, media conditioned by red bone marrow had no
significant (p>0.05) effects on the growth of DU145 or PC-3 cells (figure 2).
This effect was reproduced with media conditioned by three different bone
marrow cultures (V, P, T).
Previous work by Charkal-Roy et al (1989) showed that BMCM did
stimulate prostate cell line growth in the presence of 1% FCS. Therefore, the
experiment illustrated in figure 2 was repeated, but the BMCM was
supplemented with either 1% FCS or 5% FCS, to establish whether or not
FCS could produce synergistic growth effects with BMCM. However, as the
results in figure 3 indicate when 'BMCM (V)' was supplemented with 1% or
5% FCS there were still no stimulatory effects on DU145 growth.
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Table 1: The Growth of Prostate Cell Lines In Osteoblast-like Cell
Conditioned Medium.
Cells were grown in 50% OBCM as indicated in the legend of figure 1.
Values are expressed as means (n=6). Standard deviations were <15% of the mean.
Cell Line OB OBCM Control Stimulation
Culture (dpm) (dpm) (CM/Control)








L 2500 1500 1.7
O 2400 900 2.7
Q 3900 1400 2.8








L 1600 900 1.8
0 3900 1000 3.9




























Figure 2: The Growth of Prostate Cell Lines In Bone Marrow Conditioned
Medium. Cells (DU145 or PC-3) were plated (1000/well) and then grown in SFM
Cells were subsequently incubated in 50% BMCM (hatched) or a control of SFM
(open) for a period of three days. BMCM was collected from culture V, P or T
Growth was then assessed by tritiated thymidine uptake. Values are expressed as

























SFM 1% FCS 5% FCS
Figure 3: Growth of Prostate Cell Lines In Bone Marrow Conditioned Medium
Diluted in Media Containing FCS. DU145 were plated (1000/weII) and then grown
in SFM. Cells were subsequently incubated in 50% (V) BMCM (stripes) diluted with
either SFM or SFM plus FCS to a final dilution of 1% or 5% FCS. Control cells (open
were grown in the respective media used for diluting the BMCM. Cells were grown
for a further three days after which cell number was assessed by tritiated thymidine
uptake. Values are expressed as means (n=6) ± sd.
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b) Dose Response Experiments of Prostate Cell Lines To
Osteoblast-iike Cell Conditioned Medium
To investigate further the stimulatory activity of OBCM on prostate
cancer cell line (DU145, PC-3 and LNCaP) growth, the effect of increasing
dose was examined. Medium conditioned by the osteoblast culture, U, was
serially diluted with SFM and each cell line was exposed to all dilutions for a
period of 3 days.
The growth of both DU145 (figure 4a) and PC-3 cells (figure 4b)
responded in a dose dependent fashion with increasing concentrations of
OBCM. DU145 cell growth was increasingly stimulated as the concentration
of OBCM increased from 0 to 6.25%, greater concentrations caused little
further increase. However, only concentrations of 6.25% and above
significantly (p<0.025) stimulated DU145 growth, compared to growth in
serum free medium. Similarly, PC-3 cell growth was increasingly stimulated
by concentrations of OBCM from 0 to 12.5%, with higher concentrations
producing no further stimulation. The growth stimulation of PC-3 cells was
only significant at concentrations of 12.5% and above (p<0.05).
In addition to studies with hormone insensitive cell lines, the effect of
OBCM on the androgen sensitive cell line, LNCaP, was studied. Figure 4c
illustrates that 3% OBCM had a slight inhibitory effect on LNCaP growth,
though this wasn't significant. Increasing doses of OBCM did not affect
growth until at concentrations of 12.5% and greater, growth was significantly
(p<0.05) stimulated. All stimulatory doses produced a 1.3 fold increase of
growth compared to control levels.
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Figure 4a: Dose Response of DU145 Cells To Osteoblast-like Cell Conditioned
Medium. DU145 cells were plated (1000/well) and grown in SFM. Cells were
subsequently incubated in serial dilutions of OBCM (diluted with SFM) or a control o'
SFM, for a period of three days after which growth was measured by tritiatec
thymidine uptake. Values are expressed as means (n=6) ± sd. p values are indicatec






























Figure 4b: Dose Response of PC-3 Cells To Osteoblast-like Cell Conditioned
Medium. PC-3 cells were plated (1000/well) and then grown in SFM. Cells were
subsequently incubated in serial dilutions of OBCM (diluted with SFM) or a control o
SFM, for a period of three days after which growth was measured by tritiatec
thymidine uptake. Values are expressed as means (n=6) ± sd. p values are indicatec
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Figure 4c: Dose Response of LNCaP Cells To Osteoblast-like Cell Conditioned
Medium. LNCaP cells were plated (5000/well) in normal growth medium. After 48
hours the cells were incubated in serial dilutions of OBCM (diluted with norma
growth medium) or a control of normal growth medium, for a period of five days afte
which growth was measured by cell counts. Values are expressed as means (n=3) ±




The results presented in figures 4a, 4b and 4c are typical of the dose
dependent effects observed when prostate cell lines are incubated with media
conditioned by other osteoblast-like cell cultures. A further example, using
media conditioned by the osteoblast culture, P, is summarised in table 2.
These results indicate that in a manner similar to 'OBCM (U)', 'OBCM (P)'
stimulated PC-3 and DU145 cell growth in a dose dependent manner and
LNCaP cells were stimulated only by high doses of OBCM. Again, it is evident
that the magnitude of stimulation induced by conditioned media can vary with
different osteoblast cultures, but the overall pattern between the cell lines
remains the same - PC-3 cells were always stimulated to the greatest extent
(3-3.6 fold), followed by DU145 cells (2.1-3.3 fold) and finally LNCaP cells
(1.3-1.5 fold).
Table 2: Dose Response of Prostate Cell Lines To Osteoblast-like Cell
Conditioned Medium (P).
Cells were plated and exposed to 'OBCM (P)' as described in the legends for
figures 4a, 4b and 4c. Values in bold indicate the mean growth stimulation as a
multiple of growth in OBCM/growth in control. Within the brackets are the mean
value (n=6) of dpm (DU145 and PC-3) or cell counts/well (for LNCaP) ± sd. p values
are indicated if growth in OBCM was significantly different to growth in the control.
% PC-3 DU145 LNCaP
OBCM Growth Stimulation Growth Stimulation Growth Stimulation
(P) CM/Control (dpm±sd) CM/Control (dpm±sd) CM/Control (cells/well+sd)
0 0 (1500±145) 0 (2180±210) 0 (15000±1500)
3.125 1.7 (2500±190) 1.38 (3040±500) 1.07 16000±2000)
p<0.0025
6.25 2.6 (3900±400) 1.67 (3680±195) 0 (15000±2000)
p<0.0005 p<0.0025
12 2.8 (4250±200) 1.75 (3850±370) 1.33 (20000±1000)
p<0.0005 p<0.0025 p<0.01
25 3.3 (5000±450) 1.85 (4050±400) 1.53 (23000±1500)
p<0.0005 p<0.0005 p<0.0025




c) The Effects of Time On DU145 and PC-3 Growth In
Osteoblast-like Cell Conditioned Medium
The effect of time on the OBCM stimulation of DU145 and PC-3 cell
growth was studied by incubating both cell lines in 50% 'OBCM (R)' and
measuring growth every 24 hours for a period of 4 days.
Figure 5a shows that DU145 growth steadily increased over 4 days in
both serum free medium and OBCM. When the cells were plated at a density
of 1000 cells/well the growth in OBCM was greater than that in serum free
medium on all days and this stimulation became significant on day 3 and 4
(p<0.0005). Similar results were found if the cells were plated at 2000
cells/well. At this density stimulation became significant on day 2 and
thereafter (p<0.0005).
PC-3 cell growth (figure 5b) was also stimulated by OBCM (in
comparison to growth in SFM) over the 4 day period whether plated at 1000
or 2000 cells/well. Growth stimulation became significant (p values indicated
on the graph) on day 2 and thereafter at both plating densities.
d) The Effects of Time On Prostate Cell Lines Exposed to
Human Skin Fibroblast Cell Conditioned Medium
To determine if the growth stimulation of prostate cancer cell lines
induced by OBCM was specific to osteoblastic mitogens, the growth effects of
media conditioned by human, primary skin fibroblasts was investigated. Skin
fibroblast CM was diluted to 50% with SFM and exposed to prostate cell lines.
This dilution of skin fibroblast CM was used since previous experiments with
OBCM showed that this concentration of CM could significantly stimulate
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Figure 5a: DU145 Growth Curve In Osteoblast-like Cell Conditioned Medium
DU145 cells were plated (1000 or 2000/well). Cells were subsequently incubated in
50% OBCM ( ) or a control of SFM ( ). Growth was measured by tritiatec
thymidine uptake every 24 hours for a further 4 days. Values are expressed as
means (n=6). Standard deviations were <10% of the mean, p values are indicated i




Figure 5b: PC-3 Growth Curve In Osteoblast-like Cell Conditioned Medium.
PC-3 cells were plated (1000 or 2000/well). Cells were subsequently incubated in
50% OBCM ( ) or a control of SFM ( ). Growth was measured by tritiatec
thymidine uptake every 24 hours for a further 4 days. Values are expressed as
means (n=6). Sd were <10% of the mean, p values are indicated if growth in OBCIV






Both DU145 (figure 6a) and PC-3 cells (figure 6b) showed increased
growth with increasing time in culture, however there was no difference in the
growth of the cells whether cultured in 50% skin fibroblast CM or serum free
medium.
These results indicate that although the growth of DU145 and PC-3
cells was stimulated by 50% OBCM, growth was unaffected by 50% skin
fibroblast conditioned medium.
e) The Effect Of Conditioned Media From A Variety Of Cell
Lines On DU145 and PC-3 Cell Growth
The specificity of osteoblast-derived factors to stimulate prostate
cancer cell line growth, was investigated further by analysing the effects of
cells from other potential, prostate metastatic sites. Media conditioned by cell
lines derived from bladder (RT112), lung (HF19) and kidney (ACHN)
carcinomas were collected and diluted to 50% with serum free medium. The
effect of exposing DU145 (figure 7a) or PC-3 (figure 7b) cells to each of these
media, for 3 days was assessed.
Media conditioned by bladder, lung, and kidney cell lines showed no
significant stimulatory effects on DU145 (figure 7a) or PC-3 cell growth (figure
7b) when compared to growth in serum free medium. In the same
experiments, the growth of both DU145 and PC-3 cells was significantly
(p<0.0005) stimulated by 50% 'OBCM (Q)'. The growth of DU145 and PC-3
cells in OBCM increased to 2.3 and 3.3 fold (respectively) the levels in SFM.
These results are typical of those produced on two other occasions
(summarised in table 3), and together indicate that 50% CM from bladder,





Figure 6a: DU145 Growth Curve In Human Skin Fibroblast Conditioned
Medium. DU145 cells were plated (1000/well) and then grown in SFM. Cells were
subsequently incubated in either 50% skin fibroblast CM ( ) or a control of SFIV
( ). Growth was measured by tritiated thymidine uptake every 24 hours for £
further 4 days. Values are expressed as means (n=6). Standard deviations were




Figure 6b: PC-3 Growth Curve In Human Skin Fibroblast Conditioned Medium
PC-3 cells were plated (1000/well) and then grown in SFM. Cells were subsequently
incubated in 50% skin fibroblast CM ( ) or a control of SFM ( ). Growth was
measured by tritiated thymidine uptake every 24 hours for a further 4 days. Values


























Control RT112 HF19 ACHN OBCM
Figure 7a: The Growth of DU145 Cells In Conditioned Medium From A Variety
Of Cell Lines. DU145 cells were plated (1000/well) and then grown in SFM. Cells
were subsequently incubated in either 50% cell line CM (RT112, HF19 or ACHN) or
a control of SFM or 50% OBCM for a period of three days. Growth was ther
assessed by tritiated thymidine uptake. Values are expressed as means (n=6) ±sd. p





























Control RT112 HF19 ACHN OBCM
Figure 7b: The Growth of PC-3 Cells In Conditioned Medium From A Variety O
Cell Lines. PC-3 cells were plated (1000/well) and then grown in SFM. Cells were
subsequently incubated in either 50% cell line CM (RT112, HF19 or ACHN) or a
control of serum free medium or 50% OBCM for a period of three days. Growth was
then assessed by tritiated thymidine uptake. Values are expressed as means (n=6)
±sd. p values are indicated if growth in CM was significantly different to that in SFM.
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Table 3: The Growth of Prostate Cell Lines In ConditionedMedium From
A Variety Of Cell Lines.
Cells were plated and exposed to 50% cell line CM as described in the legends for
figures 7a and 7b. Values are expressed as means (n=6) and sd were <15% of the
mean. The magnitude of either stimulation or inhibition (growth in CM/growth in
SFM) is shown in brackets.
Cell Line SFM RT112 CM HF19 CM ACHN CM
dpm dpm dpm dpm
DU145 1900 1750 (0.92) 1800 (0.95) 2100 (1.10)
DU145 2100 2100 (0.00) 2000 (0.95) 2150 (1.02)
PC-3 1600 1750 (1.09) 1550 (0.97) 1500 (0.94)
PC-3 2500 2550 (1.02) 2400 (0.96) 2350 (0.94)
f) The effect of osteoblast-like cell CM on liver, bladder and
breast cell lines.
OBCM was assessed for its ability to stimulate cancers, other than of
prostate origin, which are known to metastasise to bone. 50% 'OBCM (L)' was
exposed to cell lines derived from human liver epithelial cells (CHANG),
bladder epithelial carcinoma (RT112) or breast epithelial carcinosarcoma
(Hs578T) cell lines. Growth was measured, after 3 days exposure to OBCM
by tritiated thymidine uptake. Figure 8 demonstrates that 50% 'OBCM (L)' had
no significant effects on CHANG, RT112 or Hs578T cell growth, whilst still
producing a 1.7 fold increase in DU145 cell growth (in comparison to SFM).
This experiment was reproduced using CM from a different osteoblast culture
(U). The results obtained are summarised in table 4. These demonstrated that
the growth of CHANG, RT112 and Hs578T cells were again unaffected by






























CHANG RT112 Hs578T DU145
Figure 8: The Growth of Liver, Bladder and Breast Cell Lines In Osteoblast-like
Cell Conditioned Medium. RT112 (bladder) or CHANG (liver) or Hs578T (breast)
cells were plated (1000/well) in normal growth medium and then grown in SFM. Cells
were subsequently incubated in 50% 'L OBCM' (open) or a control of SFM (hatched]
for a period of three days. Growth was then assessed by tritiated thymidine uptake
Values are expressed as means (n=6) ± sd. p values are indicated if the growth ir
OBCM was significantly different to that in SFM.
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Table 4: The Growth of Liver, Bladder and Breast Cell Lines In
Osteoblast-like Cell ConditionedMedium.
RT112 (bladder) or CHANG (liver) or Hs578T (breast) cells were plated and
exposed to 50% 'OBCM (U)' as described in the legend for figure 8. Values are
expressed as the mean of six samples ± sd.
Cell Line 50% U OBCM Control
(dpm ± sd) (dpm ± sd)
RT112 1600 ±100 1650±190
Hs578T 1660 ±130 1890 ±200
CHANG 1010 ±170 1100 ±150
DU145 2300 ± 260 1100± 150
3.2 Characterisation of osteoblast-like cell
conditioned medium
The results so far obtained have demonstrated that OBCM can
stimulate the growth of prostate cell lines PC-3, DU145 and LNCaP. In
contrast, red BMCM from proximal femora and skin fibroblast CM, diluted to
50% with SFM, did not stimulate the same prostate cancer cell lines. CM
(also 50% dilute) from kidney, bladder or lung cell lines were also ineffective.
Additionally, the growth of cell lines derived from liver, bladder and breast
cancers were unaffected by incubation with 50% OBCM.
To characterise the nature of the prostate stimulatory component(s) in
OBCM four studies were carried out;
i) heating the OBCM to 80°C for one hour
ii) incubation of OBCM with citric acid-phosphate buffers of different
pH
iii) determining the effect of 1,25 (OH)2 vitamin D and DHT on
production and stimulatory activity
iv) molecular weight fractionation with 'centricon' filters
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a) Heat Treatment of OBCM
The effect of heat treatment on OBCM, was determined by heating
each of three different OBCM (R, T, V) to 80°C for one hour (Mohan et al
1986). Their ability to stimulate DU145 growth was then assessed using
thymidine uptake.
Figure 9 shows that prior to heat treatment each OBCM was capable
of stimulating DU145 growth in comparison to SFM. Flowever after heat
treatment growth was partially reduced (T) or reduced to levels less than the
control (R and V) . The reduction of stimulation was significant (p<0.0005) in
each case.
b) Acid Treatment of OBCM
The effect of low pFH on OBCM was judged by incubating U OBCM in
citric acid-phosphate buffers of different acidities (pH 2.6, 4.6, 6.6 and 7.6) for
one hour. The pH was then returned to 7.6 with BSA solution and the ability of
each solution to stimulate DU145 growth was again assessed with thymidine
uptake.
The results shown in figure 10 indicate that OBCM treated with a buffer
of pH 7.6 or 6.6 retain their stimulatory activity over DU145 growth. If OBCM
was treated with a buffer of pH 4.6 or 2.6 the stimulatory activity was lost and
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Figure 9: The Effect of Heat Treatment on Osteoblast-like Cell Conditionec
Medium. DU145 cells were plated (1000/well) and then grown in SFM. The cells
were subsequently grown in a control of SFM (stripes) or normal 50% OBCM (open
or 50% OBCM heat treated (hatched), for a period of 3 days. Growth was assessec
by tritiated thymidine uptake. Values are expressed as the mean of six samples ±sd
p values are indicated if growth in untreated OBCM was significantly different frorr
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Figure 10: The Effect of Acidic Buffers on Osteoblast-like Cell Conditionec
Medium. DU145 cells were plated (1000/well) and then grown in SFM. Cells were
subsequently grown in a control of SFM (stripes) or 50% OBCM (open) treated with
a citric acid-phosphate buffer (pH 2.6-7.6), for a period of 3 days. Growth was




c) The effects of DHT and 1,25 (0H)2 Vitamin D On OBCM
Stimulatory Activity
To characterise further the prostate stimulatory factors in OBCM, the
effects of hormones which target either prostate or bone (DHT and 1,25
(OH)2 vitamin D respectively) were examined. Two investigations were
carried out:
1) To gauge the effect of adding 10nM DHT (Horoszewicz et al 1983) or
10nM 1,25 (OH)2 vitamin D (Beresford et al 1984, Murray et al 1987)
to OBCM, and its subsequent effect on the growth stimulation of
DU145 cells.
2) To determine whether the growth of DU145 cells is influenced by CM
collected from osteoblasts grown in the presence of either 10nM DHT
or 10nM 1,25 (OH)2 vitamin D.
Figure 11a and 11b illustrate that DU145 growth was stimulated by 50%
'OBCM (T)' in comparison to growth in SFM. Growth stimulation was
significant on day 2 and thereafter (p values are indicated on the graphs).
Supplementation of 50% OBCM or SFM with either 10nM DHT (figure 11a) or
10nM 1,25 (OH)2 vitamin D (figure 11b) had no effect on the level of DU145
growth in either medium. DU145 growth was also unaffected by media
conditioned by osteoblasts grown in the presence of 10nM DHT (figure 11a)
or 10nM 1,25 (OH)2 vitamin D (figure 11 b).
These results are typical of those produced on other occasions,
indicating that the production of DU145 stimulatory factors from osteoblast-
like cells is unaffected by 10nM DHT or 10nM 1,25 (OH)2 vitamin D. Also the





Figure 11a: The Effect of Dihydrotestosterone on DU145 Growth In Osteoblast-
like Cell Conditioned Medium. DU145 cells were plated (1000/well) and then
grown in SFM. Cells were subsequently incubated in one of five separate mediums:
SFM (- - -); 10nM DHT + SFM (-♦- -); 50% OBCM ( -); 10nM DHT + 50% OBCM (
—♦—); 50% OBCM collected from OB grown in 10nM DFIT (—•—■). Growth was
measured by tritiated thymidine uptake every 24 hours for 4 days. Values are
expressed as means (n=6). Sd were <10% of the mean. P values refer to the
significant differences of growth in SFM (—) compared to OBCM ( ).




Figure 11b: The Effect of 1,25 (OH)2 vitamin D on DU145 Growth In Osteoblast
like Cell Conditioned Medium. DU145 cells were plated (1000/well) and then
grown in SFM. Subsequently cells were incubated in one of five separate mediums:
SFM (---); 10nM 1,25 (OH)2 vitamin D + SFM 50% OBCM ( -); 10nM 1,25
(OH)2 vitamin D + 50% OBCM (—♦—-); 50% OBCM collected from OB grown ir
10nM 1,25 (OH)2 vitamin D (—•—). Growth was measured by tritiated thymidine
uptake every 24 hours for a further 4 days. Values are expressed as means (n=6)
Sd were <10% of the mean. P values refer to the significant differences of growtt
between SFM (—) and OBCM ( •). * p<0.05, *** p<0.0005.
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d) Molecular Weight Fractionation of Osteoblast-like Cell
Conditioned Medium
50% 'OBCM (U)' was sequentially filtered through a set of four
'centricon' filters with decreasing molecular weight pore sizes (100Kd, 30Kd,
10Kd and 3Kd) to crudely establish the molecular weights of prostate
mitogens in OBCM. The filters produced five molecular weight fractions of
OBCM; '>1 OOKd', '<100Kd', '<30Kd', *<10Kd' and '<3Kd'. Each of these
fractions was tested for its ability to stimulate DU145 growth. SFM was
similarly filtered to provide five control fractions.
Typical results are shown in figure 12. Unfractionated OBCM
stimulated DU145 growth 2.7 fold (p<0.0005) compared to unfractionated
SFM. The level of this stimulation decreased only slightly when the cells were
incubated in the fraction ">1 OOKd'. Flowever stimulatory activity significantly
(p<0.0005) decreased to 1.8 fold when the cells were incubated in the fraction
'<100Kd'. DU145 cells grown in the fraction '<30Kd' showed no growth
stimulation above control levels. This too was a significant (p<0.05) decrease
in stimulatory activity compared to unfractionated OBCM or the fraction
'<1 OOKd'. The fractions of OBCM '<1 OKd' and '<3Kd' both had no stimulatory
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Figure 12: Molecular Weight Fractionation Of Osteoblast-like Cell Conditionec
Medium. DU145 cells were plated (1000/well) and then grown in SFM. Cells were
subsequently incubated in a control of SFM (diagonals) or 50% OBCM (open), for £
period of 3 days. The media were either unfractionated (total) or had beer
sequentially passed through a series of filters with decreasing molecular weight cut¬
off points (100Kd, 30Kd, 10Kd and 3Kd). Growth was assessed by tritiated thymidine
uptake. Values are expressed as the mean value (n=6) +sd. p values are indicated il
the growth of DU145 cells in the OBCM fraction was significantly different to growth
in the SFM fraction. * p<0.0005
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The precision of the filters was assessed by silver staining. A 7.5%
polyacrylamide gel was run with the following 1ml samples; SFM,
unfractionated 50% OBCM, '>100Kd OBCM', '<100Kd OBCM' and '<30Kd
OBCM'. On completion of the run, the gel was silver stained to reveal the
protein bands, shown in plate 1. It illustrates the fraction '>100Kd' contained
proteins greater than 100Kd but also a few proteins less than 100Kd. The
fraction '<100Kd' contained no proteins greater than this molecular weight and
similarly the fraction '<30Kd' contained no proteins greater than 30Kd. This
indicates that although filtrates contain no proteins greater than their
molecular weight cut-off point, some of the proteins below this point were
retained on the filter (plate 1).
The molecular weight fractions which had stimulatory activity for
DU145 growth were '>100Kd' and '<100Kd'. These were characterised with
heat and acid treatment as for unfractionated OBCM (in figures 9 and 10).
The results shown in figure 13 indicate that unfractionated OBCM
significantly (p<0.0005) stimulated DU145 growth 2.6 fold greater than the
control values. The fraction '>100Kd' significantly stimulated DU145 growth
2.3 fold and this stimulatory activity decreased to control values if the fraction
was incubated at 80°C for 1 hour or incubated in a buffer at pH 4.6. In a
similar manner DU145 cells were significantly stimulated 1.4 fold (p<0.025) by
the fraction '<100Kd'. This stimulatory activity also decreased to control levels
if the fraction was heat treated at 80°C or incubated in buffer at pH 4.6.
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Plate 1: Silver Staining assessment of the validity of the Amicon Filters.
1ml samples of SFM (lane 2), 100% OBCM (lane 3), '>100Kd' fraction of OBCM
(lane 4), '<100Kd' fraction of OBCM (lane 5), '<30Kd' fraction of OBCM (lane 6)
were lyophilised to dryness and reconstituted in 50pl of 'blue juice' loading buffer.
These were loaded on a 7.5% SDS-PAGE with molecular weight markers 14.3-






























Figure 13: The Effect of Acidic Buffers and Temperature on the Stimulatory
Fractions Of Osteoblast-like Cell Conditioned Medium.DU145 cells were plated
(1000/well) and then grown in SFM. Cells were subsequently incubated in
unfractionated 50% OBCM (total) or MW fractions (>100Kd or <100Kd)or their
controls (stripes). Each fraction was either untreated 50% OBCM (open) or it hac
been previously heat treated (diagonals) or incubated at pH4.6 (hatched). Growth
was assessed after 3 days growth, by tritiated thymidine uptake. Values are
expressed as the mean (n=6) ±sd. p values are indicated if DU145 growth in
untreated OBCM was significantly different to growth in SFM.
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3.3 The Effects Of Haematopoietic Growth Factors On
Prostate Cell Lines
t
The results of sections 3.1 and 3.2 have indicated that the growth of
prostate cell lines can be stimulated by factors secreted from human
osteoblast-like cells and not by media conditioned with either bone marrow or
skin fibroblasts. To aid the identification of prostate stimulatory factors in
OBCM the effect of specific growth factors found in the bone environment
was tested. Haematopoietic growth factors are both produced, and have their
major biological effects in the bone marrow (Nicola 1989), and two of these
haematopoietic growth factors GM-CSF and G-CSF are already known to be
secreted by osteoblasts (Horowitz et al 1989, Felix et al 1991). Therefore,
GM-CSF and G-CSF plus two other haematopoietic growth factors, EPO and
IL-3 were investigated for prostate mitogenic effects. These four
haematopoietic growth factors were also of clinical interest, as they are used
to revive bone marrow after chemotherapy (Oster et al 1990, Moore 1990). If
the haematopoietic growth factors were found to stimulate the growth of
prostate cancer cell lines, this may indicate detrimental effects for tumour
growth in vivo.
a) Dose Response Experiments of Prostate Cell Line Growth
To Haematopoietic Growth Factors
Recombinant haematopoietic growth factors were diluted to varying
concentrations (based around values used clinically) with SFM plus 0.1%
BSA. Prostate cell lines were then exposed to each dilution for three days,




The growth of both DU145 (figure 14a) and PC-3 cells (figure 14b)
showed no response to medium supplemented with either rlL-3 (0.1-
1000mU/ml) or rG-CSF (0.1-1000U/ml), at any of the concentrations tested.
In contrast, both DU145 and PC-3 cells responded in a dose dependent
fashion to increasing concentrations of either rEPO or rGM-CSF. Increasing
concentrations of rEPO up to 1 mill/ml, and concentrations of rGM-CSF up to
0.1-11U/ml, increasingly stimulated the growth of DU145 or PC-3 cells.
Concentrations greater than these caused little further increase of growth
stimulation.
The maximum growth stimulation caused by rEPO (compared to
growth in controls) was 1.7 fold for DU145 cells and 3 fold for PC-3 cells. All
concentrations of rEPO significantly stimulated DU145 growth (p<0.0025) and
concentrations >1 Ill/ml significantly stimulated PC-3 cell growth (p<0.0025).
The maximum growth stimulation of DU145 and PC-3 cells due to
rGM-CSF was 1.9 fold and 3.4 fold, respectively, in comparison to control
levels. All doses of rGM-CSF, above 0.1 mil/ml, significantly stimulated both
PC-3 and DU145 cell growth (p<0.0025).
In contrast to the hormone insensitive cell lines the androgen sensitive
cell line, LNCaP (figure 14c), showed no significant response to medium
supplemented with rlL-3, rG-CSF or rEPO, at any of the concentrations
tested. Growth was significantly stimulated by medium supplemented with
rGM-CSF at doses of 5 and 50IU/ml (p<0.05), but not in a dose dependent
fashion. Both 5 and 50 Ill/ml of rGM-CSF stimulated the growth of LNCaP
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Figure 14a: Dose Response of DU145 Cells To Haematopoietic Growth
Factors. DU145 cells were plated (1000/well) and grown for 48 hours in SFM. Cells
were subsequently grown in SFM (+ 0.1%BSA) supplemented with increasing
concentrations of—°—rEPO (mlU/ml), —♦—rlL-3 (mU/ml), -o-- rGM-CSF (lU/ml) or
■ ■••• -rG-CSF (U/ml), for three days. Growth was assessed by tritiated thymidine
uptake. Values represent the mean value of six samples. Standard deviations were
<± 10% of the mean. *p<0.025.
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HGF (mU/ml or U/ml)
Figure 14b: Dose Response of PC-3 Cells To Haematopoietic Growth Factors.
PC-3 cells were plated (1000/well) and grown for 48 hours in SFM. Cells were
subsequently grown in SFM (+0.1%BSA) supplemented with increasing
concentrations of—°—rEPO (mlU/ml),—— rlL-3 (mU/ml), -o— rGM-CSF (lU/ml)
or ■■••■■•rG-CSF (U/ml), for three days. Growth was assessed by tritiated thymidine
uptake. Values represent the mean value of six samples. Standard deviations were
<± 10% of the mean. *p<0.025.
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Figure 14c: Dose Response of LNCaP Cells To Haematopoietic Growth
Factors. LNCaP cells were plated (5000/well) in complete medium. After 48 hours
the cells were exposed to fresh complete medium supplemented with increasing
concentrations of—°—rEPO (mlU/ml),—— rlL-3 (mil/ml), -o— rGM-CSF (Ill/ml)
or ••■•■■■rG-CSF (U/ml), for a period of five days. Growth was measured using eel
counts. Values represent the mean value of three samples. Standard deviations
were <±15% of mean. **p<0.05
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The dose response effects of haematopoietic growth factors on
prostate cell lines are typical of those produced on several other occasions
and a further example is given in table 5.
These results again indicate that none of the three prostate cell lines
responded in a significant manner to any dose of rlL-3 (0.1-1000mll/ml) or
rG-CSF (0.1-1000U/ml). PC-3 and DU145 cells were again stimulated in a
dose dependent fashion by both rGM-CSF (0.01-100IU/ml) and rEPO (0.01-
100mlU/ml). The magnitude of PC-3 and DU145 growth stimulation, caused
by rEPO (2.6 fold and 2.2 fold respectively) and rGM-CSF (3 fold and 2.3 fold
respectively) was similar to the previous experiment. As before, PC-3 cells
were stimulated to a greater extent than DU145 cells. LNCaP cells showed no
response to rEPO, whilst growth was significantly stimulated by higher doses
of rGM-CSF (>10IU/ml). In this experiment, LNCaP cells were stimulated to a
maximum of 2 fold by stimulatory doses of rGM-CSF (in comparison to
controls).
b) DU145 and PC-3 Growth Curve In 100mlU/ml rEPO and
100IU/ml rGM-CSF
Time course studies were undertaken to gauge the effects of
stimulatory concentrations of rEPO (100mlU/ml) and rGM-CSF (100IU/ml) on
the growth of DU145 (figure 15a) and PC-3 (figure 15b) cells over a series of
days. Growth was measured every 24 hours for 4 days using tritiated
thymidine uptake as an index of cell number.
132
Results
Table 5: Dose Response of Prostate cell lines To Haematopoietic
Growth Factors.
Prostate cells were plated and exposed to varying concentrations of HGFs, as
described in the legends for figures 14a, 14b and 14c. Values indicate the mean
growth stimulation as a multiple of growth in HGF/growth in control. For PC-3 and
DU145: sd <± 10% of the mean, n=6. For LNCaP: sd <± 15% of the mean, n=3.
ND = not done. *p<0.05, **p<0.0025, ***p<0.0005.
rG-CSF (Ill/ml) 0 0.01 0.1 1.0 10 100 1000
DU145 1 ND 0.97 0.97 1.2 0.9 0.9
PC-3 1 ND 1.1 1 0.9 1.1 1.2
LNCaP 1 1 1.2 1 1 1.2 ND
rlL-3 (mil/ml)
DU145 1 ND 1 1.2 0.9 1 1
PC-3 1 ND 1.2 1.3 1.3 1.3 1.3
LNCaP 1 1 1.1 1 1.1 1.1 1.1
rGM-CSF (lU/ml)
DU145 1 1 4** 1.4** 1.5** 1.6** 2.3*** ND
PC-3 1 1.4* 2 ** 2 g*** 2 ■j*** g*** ND
LNCaP 1 1.5 1.3 1.5 1.7* 2** ND
rEPO (mlU/ml)
DU145 1 1.4 1.9** 2** 2 ^** 2 2** ND
PC-3 1 1.6* 1.8** 2 ^*** 2.5*** 2 g*** ND



























Figure 15a: Time Course Study of DU145 Growth In Media Supplemented with
100!U/ml GM-CSF and 100mlU/ml EPO.
DU145 cells were plated (1000/well) and grown in SFM. Cells were subsequently
grown in either SFM ( ), or SFM supplemented with 100IU/ml GM-CSF ( ) or
100mlU/ml rEPO (—). Growth was assessed by tritiated thymidine uptake every 2




Figure 15b: Time Course Study of PC-3 Growth In Media Supplemented with
100IU/ml GM-CSF and 100mlU/ml EPO.
PC-3 cells were plated (1000/well) and grown in SFM. Cells were subsequently
grown in either SFM ( ), or SFM supplemented with 100IU/ml GM-CSF ( ) or
100mlU/ml rEPO (—). Growth was assessed by tritiated thymidine uptake every 2^




Figure 15a shows that DU145 growth increased over 4 days in all three
media tested (i.e., SFM or SFM supplemented with either rGM-CSF or rEPO).
Growth in rGM-CSF or rEPO became significantly greater than growth in SFM
on days 3 and 4 of culture (p<0.0005). PC-3 cell growth (figure 15b) was
stimulated by rEPO and rGM-CSF on all 4 days in culture. The stimulation
caused by SFM supplemented with rEPO (100mlU/ml) became significant on
day 2 and thereafter (p values indicated on the graph). SFM supplemented
with rGM-CSF (100IU/ml) significantly stimulated growth on days 2 and 3.
Growth was not assayed further than 4 days in culture because the cells
became confluent after this time and were therefore no longer in a log phase
of growth.
c) Antibody Inhibition of GM-CSF Stimulated DU145 Growth
To test whether the growth stimulation of prostate cell lines by serum
free medium supplemented with 100IU/ml rGM-CSF was specific to rGM-
CSF, the HGF was pre-incubated with antibody, before exposing to DU145
cells. The antibody used was a mouse monoclonal raised against human GM-
CSF.
Figure 16 illustrates the effect on DU145 growth when the cells were
incubated with serum free medium supplemented with increasing
concentrations of anti-GM-CSF mAb with or without prior incubation with
100IU/ml rGM-CSF. In a manner similar to previous experiments, when no
antibody was present DU145 growth was significantly (p<0.025) stimulated
2.2 fold when exposed to GM-CSF, in comparison to growth in SFM.
Increasing concentrations of antibody had no effect on this growth stimulation
until 20ng/ml, which caused the stimulation to decrease by 58%.
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Figure 16: Antibody Inhibition of GM-CSF Stimulated DU145 Growth.
DU145 cells were plated (1000/well) and grown in SFM. Cells were subsequently
incubated with increasing concentrations of GM-CSF mAb, as indicated. Antibody
was previously incubated for 1 hour at 37°C with (-•—) or without (■■••■■■) 100IU/m
GM-CSF. Cells were grown in these media for 3 days after which growth was




Additional concentrations of antibody caused the growth stimulation to
decrease further, and with 2|jg/ml of antibody the stimulation of DU145
growth by 100IU/ml rGM-CSF was completely inhibited.
Incubation of DU145 cells in medium supplemented only with
increasing concentrations of mAb showed no effect on growth. The highest
concentration of mAb tested (20pg/ml) appeared to inhibit basal growth. This
inhibition was not significant compared to growth in serum free medium alone,
but was significantly reduced (p<0.05) compared to growth in medium
supplemented with 2pg/ml of mAb.
In an identical experiment, a non-specific mAb (mouse, lgG-|, raised
against a fetoprotein) showed no inhibition of the GM-CSF stimulation (figure
17) emphasising the specificity of GM-CSF to stimulate DU145 growth.
These experiments indicate that serum free medium supplemented
with 100IU/ml rGM-CSF could stimulate the growth of DU145 cells and that
this could be prevented with 2pg/ml of mAb raised against human GM-CSF.
No similar experiment was performed for EPO since an antibody capable of
inhibiting biological activity was unavailable at the time these experiments
were performed. This also prevented further experiments with EPO, and
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Figure 17: The Effect of a Non-specific Antibody on GM-CSF Stimulated DU145
Growth. DU145 cells were plated (1000/well) and grown in SFM. Cells were
subsequently incubated with increasing concentrations of a fetoprotien mAb, as
indicated. Antibody was previously incubated for 1 hour at 37°C with (—•—) or
without (•■•••■•) 100IU/ml GM-CSF. Cells were grown in these media for 3 days aftei




3.4 Is GM-CSF Responsible For The OBCM Growth
Stimulation Of Prostate Cell Lines?
Osteoblast-like cell CM, rEPO and rGM-CSF have all been found to
stimulate the growth of prostate cell lines. Since GM-CSF is known to be
secreted by osteoblast cells (Florowitzef al 1989), studies were carried out to
establish whether GM-CSF or EPO or other factors could be the stimulatory
agents found in OBCM.
The cumulative effects of 50% OBCM, 100IU/ml rGM-CSF and
100lmU/ml rEPO on DU145 growth were studied. Typical results are shown in
figure 18.
SFM supplemented with 100mlU/ml rEPO stimulated growth 1.9 fold
compared to control levels of SFM. Medium containing 100IU/ml rGM-CSF
stimulated growth 2.2 fold, and 50% OBCM stimulated growth 2.8 fold. All of
these were significant (p<0.03). If medium was supplemented with any
combination of growth factor or OBCM there were no significant additive
effects on the growth stimulation of DU145 cells. Although growth in
100mlU/ml of rEPO was significantly less than growth in OBCM, growth in a
solution containing both was not significantly different from growth in either
solution alone. This suggests that all three agents were stimulating the growth
of the DU145 cells to their maximum or that EPO or GM-CSF are already
present in the OBCM. To clarify this, the presence of GM-CSF in OBCM was
examined by incubating OBCM with the antibody raised against GM-CSF, to
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Figure 18: The Cumulative Effects Of rEPO, rGM-CSF and OBCM on the
Growth of DU145 Cells. DU145 cells were plated (1000/well) and grown in SFM
Cells were subsequently incubated in SFM supplemented with 100mll)/ml rEPO (E)
100IU/ml rGM-CSF (G), 50% OBCM (O), or a combination as indicated. Cells were
grown in these media for 3 days after which growth was measured by tritiatec
thymidine uptake. Values represent the mean value (n=6) ± sd.
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From previous studies, the stimulation of DU145 cells by 100IU/ml
rGM-CSF (equivalent to 10ng/ml rGM-CSF) was inhibited with 2pg/ml of mAb
specific to GM-CSF. Other investigators have shown that CM taken from the
best natural sources contains 1-10ng/ml GM-CSF (Nicola 1989) therefore
2pg/ml of GM-CSF mAb was thought ample to inhibit any amounts of GM-
CSF secreted by the osteoblast-like cell cultures.
Subsequently DU145 cells were incubated with increasing
concentrations of OBCM (diluted in SFM) with or without pre-incubation with
2pg/ml of anti-GM-CSF mAb. These results are shown in figure 19 and
indicate that there was no significant difference between the growth of DU145
cells in OBCM with or without pre-incubation with anti-GM-CSF mAb.
Therefore the mAb demonstrated no significant inhibition of the stimulatory
action of OBCM. This result was similar when repeated with CM from a
different osteoblast-like cell culture.
The stimulatory fractions of OBCM (>100Kd and <100Kd), found in the
previous section (3.2 d), were also pre-incubated with 2pg/ml of anti-GM-CSF
mAb, before exposing them to DU145 cells (figure 20). The results indicated
that the fractions of OBCM >100Kd and <100Kd significantly stimulated
DU145 growth 2.3 fold and 1.4 fold, respectively (p values are indicated on
the graph). However, these growth stimulations were not inhibited by pre-
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Figure 19: GM-CSF Antibody Inhibition OBCM Stimulated DU145 Growth.
DU145 cells were plated (1000/well) and grown in SFM. Cells were subsequently
incubated in increasing concentrations of OBCM (diluted with SFM), as indicated
which were pre-incubated for 1 hour at 37°C with ( ) or without ( ) 2pg/m
GM-CSF mAb. Cells were grown in these media for 3 days, growth was ther























Figure 20: GM-CSF Antibody Inhibition of OBCM Stimulatory Fractions o
DU145 Growth. DU145 cells were plated (1000/well) and grown in SFM. Cells were
subsequently incubated in either fractions of OBCM >100Kd or <100Kd or in SFM
(stripes). The fractions had been pre-incubated for 1 hour at 37°C with (diagonal) oi
without (open) 2pg/ml GM-CSF mAb. Growth was assessed after 3 days exposure tc
the media by tritiated thymidine uptake. Values represent the mean value (n=3) ± sd
p values are shown if cell growth in the untreated OBCM fraction was significantly
different to growth in SFM.
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3.5 Secretion Of GM-CSF by Prostate Cell Lines
Various investigators have reported that GM-CSF can be secreted by
non-haematopoietic cells and may have a role in cancer progression (Takeda
et al 1991, Young et al 1992, Pekarek et al 1993). Therefore to investigate
further the involvement of GM-CSF in prostate cancer the next experiments
examined whether GM-CSF was produced from the prostate carcinoma cell
lines.
To determine if prostate cell lines can produce GM-CSF, the presence
of protein was analysed by immunohistochemistry, ELISA and Western
Blotting. GM-CSF gene transcripts were also investigated by RT PCR of total
RNA extracted from the prostate cell lines.
a) Immunohistochemical staining of cell lines with a mouse
monoclonal GM-CSF antibody
Cells which were ~ 50% confluent were immunohistochemically
stained to determine the presence of GM-CSF. Staining was kindly analysed
by Dr. David Hughes from the Pathology Dept., University of Edinburgh. The
following plates illustrate the pattern of DAB-peroxidase staining due to the
binding of a mouse mAb raised to human GM-CSF, after incubation with a
variety of cell lines:
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Results
Plate 2: Illustrates a negative control for DU145 cells, this was the entire
immunostain procedure without primary antibody. No positive staining
was evident, only the blue nuclear stain of haematoxylin. All other
cells were similarly stained so that comparisons of positive stains
could be made, however these were not included in the thesis since
they all indicated a negative result, identical to this plate.
Plate 3: Indicates positive staining of DU145 cells, produced when primary
antibody was included in the staining procedure. Positive staining was
seen throughout the cytoplasm.
Plate 4: PC-3 cells also showed positive staining which was more specific to
the perinuclear region. This type of staining is indicative of a secretory
protein.
Plate 5: The LNCaP cell line demonstrated no apparent positive staining,
above background levels.
Plate 6: Osteoblast-like cells were used as positive controls (they are known
to secrete GM-CSF [Horowitz et al 1989]). These cells showed
positive staining throughout the cytoplasm, which became stronger in
the perinuclear region.
Plate 7: The osteosarcoma cell line, MG63, was also used as a positive
control. This plate illustrates that a weak positive cytoplasmic and
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Plate 2: Blank Immunostain of DU145 Cells. 50% confluent DU145 cells underwent
immunostaining with no primary antibody and were counter stained with Mayers
haematoxylin. x10 magnification.
Plate 3: GM-CSF Immunostaining of DU145 Cells. 50% confluent DU145 cells were









Plate 4: GM-CSF Immunostaining of PC-3 Cells. 50% confluent PC-3 cells were
immunostained with GM-CSF mAb (1:200), and counter stained with Mayers haematoxylin.
x10 magnification.
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Plate 5: GM-CSF Immunostaining of LNCaP Cells. 50% confluent LNCaP cells were




Plate 6: GM-CSF Immunostaining of Osteoblast-like Cells. 50% confluent osteoblast-like
cells were immunostained with GM-CSF mAb (1:200), and counter stained with Mayers
haematoxylin. x10 magnification.
Plate 7: GM-CSF Immunostaining of MG63 Cells. 50% confluent MG63 cells were




A variety of cell lines derived from cancers other than prostate were
also tested for the presence of GM-CSF by immunostaining. The results are
summarised in table 6, an example of positive (HF19) and negative (CHANG)
staining are shown in plates 8 and 9 respectively.
Table 6: Immunohistochemical staining of cell lines with a mouse
monoclonal GM-CSF antibody
Cell Line Staining Plate
WISH (melanoma) Positive
CHANG (liver) Negative 9
RT112 (bladder) Negative
HEP2 (larynx) Negative
HF19 (lung) Positive 8
HQS (osteosarcoma) Negative
i) Analysis of the Specificity of GM-CSF Staining
To check the specificity of staining produced by the anti-GM-CSF mAb,
the mAb was pre-incubated with excess GM-CSF. The lowest titration of
antibody to produce a positive stain (1:800) was used in order that excess
concentrations of rGM-CSF could be added.
Results are shown for staining DU145 cells with; no antibody (plate
10), GM-CSF mAb (plate 11), GM-CSF mAb pre-incubated with excess GM-
CSF (plate 12), GM-CSF mAb pre-incubated with excess IL-3 (plate 13), GM-












Plate 8: GM-CSF Immunostaining of HF19 Cells. 50% confluent HF19 cells were
immunostained with GM-CSF mAb (1:200), and counter stained with Mayers haematoxylin.
x10 magnification.
Plate 9: GM-CSF Immunostaining of CHANG Cells. 50% confluent CHANG cells were
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Plate 10: Blank Immunostain of DU145 Cells. 50% confluent DU145 cells underwent
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Plate 11: GM-CSF Immunostaining of DU145 Cells. 50% confluent DU145 cells were




Plate 12: GM-CSF mAb Incubated with excess GM-CSF Immunostaining of DU145
Cells. 50% confluent DU145 cells were immunostained with GM-CSF mAb (1:800),
previously incubated with excess rGM-CSF and counter stained with Mayers haematoxylin.
x10 magnification.
Plate 13: GM-CSF mAb Incubated with excess IL-3 Immunostaining of DU145 Cells.
50% confluent DU145 cells were immunostained with GM-CSF mAb (1:800), previously
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Plate 14: GM-CSF mAb Incubated with excess EPO Immunostaining of DU145 Cells.
50% confluent DU145 cells were immunostained with GM-CSF mAb (1:800), previously




The results indicate that the positive staining of DU145 cells by GM-
CSF mAb can only be inhibited by prior incubation of the mAb with excess
GM-CSF. Pre-incubation with either EPO or IL-3 did not lead to inhibition of
the stain, indicating the staining is very specific to GM-CSF.
ii) Immunohistochemical GM-CSF Staining of Prostate Cancer Primary
Cultures and Tissue Sections
The positive staining of prostate cell lines (PC-3 and DU145) led to
further immunohistochemical investigations of prostate carcinoma primary
cultures and also prostate tissue sections.
Primary cultures of epithelia and fibroblasts were produced from
prostate chips which had been identified as carcinoma, from pathology
reports. These were stained with mAb specific to GM-CSF, in an identical
manner to the cell lines. The results were as follows:
Plate 15: Epithelial cultures of prostate cancer showed positive staining
throughout the cytoplasm, which became stronger in perinuclear and
nuclear regions.
Plate 16: Fibroblast cultures from the same prostate cancer chips showed no
evidence of staining.
These results were reproduced on one other occasion using 'chips' of
prostate carcinoma from a different patient.
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Plate 15: GM-CSF mAb Immunostaining of Primary Cultures of Prostate Carcinoma
Epithelia. 50% confluent prostate carcinoma epithelia cells were immunostained with GM-
CSF mAb (1:200) and counter stained with Mayers haematoxylin. x10 magnification.
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Plate 16: GM-CSF mAb Immunostaining of Primary Cultures of Prostate Carcinoma
Fibroblasts. 50% confluent prostate carcinoma fibroblast cells were immunostained with
GM-CSF mAb (1:200) and counter stained with Mayers haematoxylin. x10 magnification.
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Paraffin sections of prostate and tonsil tissue were also immunostained
with GM-CSF mAb:
Plate 17: This indicates the staining pattern of normal peripheral zone
prostate (34-40 year old). This area of the prostate was chosen since
it is the commonest site of carcinoma origin (McNeal et al 1988b). It
exhibited staining specific to the basement membrane (BM).
Plate 18: Benign prostatic hyperplasia sections indicated no specific
staining, though the double epithelial layer of the prostate ducts was
clearly seen.
Plate 19: Well differentiated carcinoma of the prostate (Gleason score 3)
exhibited no specific staining.
Plate 20: Poorly differentiated prostate carcinoma (Gleason score 9) showed
strong positive staining amongst the malignant epithelia, whereas the
stromal areas remained negative. Haematopoietic cells, visible in
small blood vessels, also stain strongly, providing an internal control.
Areas of smooth muscle also stained positively in both poor and well
differentiated carcinoma sections.
Plate 21: Tonsil lymph nodes were stained since they contain activated T-
lymphocytes and therefore, provided a positive control. Strong
positive staining was found mainly in the paracortex (the expected site
of activated T-lymphocytes) though weaker staining was also seen in
the endothelia.




Plate 17: GM-CSF mAb Immunostaining of Normal Peripheral Zone Prostate Gland.
Tissue sections of normal peripheral zone prostate were fixed in acetone, immunostained
with GM-CSF mAb (1:400) and counter stained with Mayers haematoxylin. x40
magnification.
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Plate 18: GM-CSF mAb Immunostaining of Benign Prostatic Hyperplasia Tissue
Sections. Paraffin sections of benign prostatic hyperplasia were immunostained with GM-
CSF mAb (1:400) and counter stained with Mayers haematoxylin. x40 magnification.
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Plate 19: GM-CSF mAb Immunostaining Well Differentiated Prostate Carcinoma Tissue
Sections. Paraffin sections of well differentiated prostate carcinoma were immunostained
with GM-CSF mAb (1:400) and counter stained with Mayers haematoxylin. x25 magnification.
Plate 20: GM-CSF mAb Immunostaining of Poorly Differentiated Prostate Carcinoma
tissue Sections. Paraffin sections of poorly differentiated prostate carcinoma were
immunostained with GM-CSF mAb (1:400) and counter stained with Mayers haematoxylin.
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Plate 21: GM-CSF mAb Immunostaining of Tonsil Tissue Sections. Paraffin sections of
human tonsil carcinoma were immunostained with GM-CSF mAb (1:400) and counter
stained with Mayers haematoxylin. x25 magnification.
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b) GM-CSF Immunoassay of Prostate Cell Line Conditioned
Medium
To assess whether or not the GM-CSF-like material detected in PC-3
and DU145 cultures was produced by these cells or not, media conditioned
by the cells was collected and analysed by ELISA. Medium conditioned by
confluent cultures of LNCaP, MG63, benign prostatic fibroblasts and
osteoblast-like cells was also investigated. The amount of GM-CSF-like
material in all CM was assayed using a commercial ELISA kit. The kit
antibody exhibited no cross-reactivity with TGFa, TGF(31, EPO, IL-3 or G-
CSF, at the concentrations indicated (table 7).
The results summarised in table 8 are typical of those produced in
three separate experiments, each time using a fresh sample of CM.
GM-CSF-like material was detected in pg quantities/pg protein of
media conditioned by PC-3 or DU145 cells. If either CM was diluted, the
levels of GM-CSF-like material detected were diluted in parallel. There were
no detectable levels of GM-CSF in LNCaP CM or benign fibroblast CM, whilst
it was found in media conditioned by the positive controls, MG63 and
osteoblast-like cells. No detectable levels of GM-CSF were found in serum
free medium.
c) Expression of GM-CSF-like Material By Western Blotting
The results so far have suggested that the prostate cell lines DU145
and PC-3 can produce GM-CSF-like material, this was further established by
analysing media conditioned by DU145 and PC-3 cell lines with Western blot.
Proteins in these conditioned media were size fractionated on a reducing
polyacrylamide gel, and, after blotting, GM-CSF protein bands were
specifically probed with a mAb.
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Table 7: Results indicating lack of ELISA antibody cross-reactivity.
The indicated concentrations of growth factors were tested with the ELISA
kit for the presence of GM-CSF.
Growth Factor Protein GM-CSF GM-CSF
(pg/ml) (pg/ml) (pg/pg protein)
TGF a 0.5 0 0
TGF IJ1 0.0005 0 0
EPO 0.08 0 0
IL-3 0.01 0 0
G-CSF 0.1 0 0
Table 8 : GM-CSF Immunoassay Of Prostate Cancer Cell Line
Conditioned Medium.
Cell lines and primary cultures were incubated in serum free medium for 24
hours. The conditioned medium was collected, filtered and tested for the presence of
GM-CSF using a commercial ELISA kit. Protein concentration of the CM was
assayed using the Bradford method. Values represent the mean ± standard
deviation, n=3 (for protein concentrations sd were <± 10% of the mean).
Conditioned media GM-CSF Protein GM-CSF
(pg/ml) (pg/ml) (pg/pg protein)
DU145 214 ± 1.6 130 1.7
" " diluted x2 110 ± 0.7 60 1.8
PC-3 535 ±4.7 210 2.5
" " diluted x2 282 ±2.5 107 2.6
LNCaP 0 140 0
BPH Fibroblasts 0 154 0
MG63 170 ±2.2 108 1.6
Osteoblast-like cell 21 ±0.4 150 0.14
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The results are shown in plate 22. Protein bands (immunoreactive with the
anti-GM-CSF mAb) were evident from media conditioned by PC-3 (B), DU145
(D), MG63 (F) and osteoblast-like cells (G). All these bands co-migrated with
a sample of recombinant GM-CSF (A), at 42.5Kd. No bands were apparent
from the LNCaP (C) cell line or benign prostate fibroblasts (E).
Repetition of the immunoblot with a different antibody (polyclonal
sheep-anti human GM-CSF) yielded the same results (plate 23). rGM-CSF
(lane A) again migrated at 42.5Kd together with protein bands from DU145
CM (B) and PC-3 CM (C). The second immunoblot reinforces the suggestion
that the bands are due to GM-CSF.
These bands were consistently produced with different batches of
conditioned media and with different dilutions of CM. In further support of
these results, a sample of rGM-CSF reconstituted in phosphate buffer plus
0.1% BSA also ran at 42.5Kd. The molecular weight of GM-CSF is 18-22Kd
(Wong et al 1985) therefore the peptide was apparently running as a dimer.
Since the electrophoresis was carried out under reducing conditions and the
samples boiled up to 15 minutes it is unlikely a dimer had formed, though this
cannot be ruled out. To check the protein was correctly reduced a loading
buffer was prepared as follows: 50mM Tris.CI pH6.8, 100mM dithiothreitol,
10% SDS, 0.1% bromophenol blue, 30% glycerol. Using different
concentrations of dithiothreitol (100, 200mM) and SDS (5 and 10%) the band
still did not run at 18-22Kd. Considering the sample of rGM-CSF was
originally reconstituted with 0.1% BSA, an adduct may have formed.
Plate 24 shows a polyacrylamide gel which was silver stained to show
the multitude of proteins present in all the conditioned media.
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Plate 22: Expression of GM-CSF in Prostate Cell Line CM Analysed by Western
Blot. Samples of media conditioned by cell lines were run on a 12% PAGE at
20mA and then immunoblotted with a GM-CSF monoclonal antibody. The lanes
are: A, rGM-CSF (25ng); B, PC-3 (10pg protein); C, LNCaP (50pg protein); D,
DU145 (50pg protein); E, benign prostate fibroblasts (17pg protein); F, MG63




Plate 23: Repetition of Western Blot With A Second GM-CSF Antibody.
Samples of media conditioned by cell lines were run on a 12% PAGE at 20mA and
then immunoblotted with a GM-CSF polyclonal antibody.
The lanes are: A, rGM-CSF (25ng); B, DU145 (1pg protein); C, PC-3 (5pg protein).
MW markers are indicated in Kd.
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Plate 24: Silver Stain Of Conditioned Media Separated On 12% Polyacrylamide
Gel. Samples of conditioned media were run on 12% PAGE and then silver stained
to develop the protein bands. The lanes are: A, DU145 (50pg protein); B, PC-3
(10pg protein); C, benign prostatic fibroblasts (17pg protein); D, MG63 (17pg
protein); E, osteoblast-like cell (10pg protein); F, LNCaP (17pg protein).
MW markers are indicated in Kd.
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d) PCR Amplification of GM-CSF Gene Transcripts In Prostate
Cell Lines
The production of GM-CSF by DU145 and PC-3 cells but not by
LNCaP was explored further by amplifying possible GM-CSF gene transcripts
in the three prostate cell lines with RT PCR.
Total RNA was extracted from DU145, PC-3, LNCaP and human blood
cells (used as a positive control). RNA was converted to cDNA by reverse
transcription, and then specific primers were used to expressly amplify GM-
CSF (illustrated in figure 21) and HPRT transcripts by PCR.
Plate 25 illustrates the PCR products from DU145 (A), PC-3 (B),
human blood cells (C) and LNCaP cells (D). All cells showed the expression
of the 280 base pair HPRT transcript product (lanes 1), which provided an
internal, PCR control. DU145, PC-3 and blood cells all showed the presence
of a 170 base pair product, the expected size of the GM-CSF transcript (lanes
2). These 170 base pair products could be specifically cleaved byBgl 1 to
produce two smaller fragments, 123 and 47 base pairs (lanes 3). This
cleavage was calculated from the GM-CSF cDNA sequence (Wong et al
1985). The ability of Bgl 1 to produce these two fragments provides good
evidence that GM-CSF transcripts had been amplified and were present in
these cells. These results were identically produced on three separate RNA
preparations.
The LNCaP cell line showed the expression of a 170 base pair product
(figure d, lane 2). However, this could not be cleaved by Bgl 1 even if the
enzyme concentration was increased six fold and the incubation time
increased to 12 hours. This result was also reproducible.
Using the genomic sequence of human GM-CSF (Kaushansky et al
1986) the primers were designed to span two introns, therefore any genomic
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contaminants (lanes 4) would produce 955 base pair products. Lanes 4
illustrate the presence of these contaminants in the PC-3, DU145 and blood
cell RNA preparations, no such product was found in the LNCaP. This
indicates that the 170 base pair products were due to the amplification of











Figure 21: Design of human GM-CSF PCR Primers
(Kaushansky et al 1986, Wong et al 1985)
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Plate 25: PCR amplification of GM-CSF and HPRT gene transcripts.
cDNA was prepared by reverse transcription of 1 pg total cellular RNA from the cell
lines DU145 (A), PC-3 (B), human blood cells (C) and LNCaP (D). This cDNA was
amplified by PCR using primers for HPRT (lanes 1) and GM-CSF (lanes 2). GM-
CSF products were specifically cleaved with Bgl 1 (lanes 3) and genomic
contaminants are shown in lanes 4. The products were size fractionated on a 2%




Malignant prostate cells grow slowly in the primary tumour, but, once
they metastasise to the bone, the growth rate increases. These metastases
are often destructive and therefore pose a greater health risk to the patient
than the primary tumour. 84% of prostate cancer patients develop skeletal
metastases (Berretoni & Carter 1986) which form osteoblastic lesions. Batson
(1940) first suggested that the formation of skeletal metastases could be
explained by the mechanical seeding of prostate cancer cells via the vertebral
venous system. However, this theory on its own does not explain the
increased growth rate of prostate cancer cells at secondary skeletal sites.
One explanation for this increased growth, is the presence of prostate
mitogens in the bone environment. In this way a preferential site would be
provided for tumour development, in comparison to other locations in the
body. Similarly, researchers have attributed the formation of osteoblastic
lesions to growth factors secreted by the invading prostate tumour cells.
Consequently, paracrine growth factors acting between osteoblasts and
prostate cancer cells may play an important role in the formation of prostate
skeletal metastases.
This study has concentrated on looking for soluble factors present in
the bone environment that are mitogenic for human prostate cancer cells.
This was investigated by assessing the effects of the following growth factors
or media on the growth of both hormone sensitive (LNCaP) and insensitive
(DU145 and PC-3) prostate carcinoma cell lines:
a) media conditioned by osteoblast-like cells
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b) media conditioned by red bone marrow from the proximal femur
c) media supplemented with recombinant haematopoietic growth
factors
Finally, the ability of prostate cancer cells to produce GM-CSF was
investigated, to ascertain if such a capability was important to the formation of
a skeletal metastasis.
Media Conditioned by Human Osteoblast-like Cells
Stimulates the Growth of Prostate Cancer Cell Lines.
The effect of soluble factors secreted by primary cultures of osteoblast-
like cells on prostate carcinoma cell line growth was examined. Osteoblasts
were cultured with a method, known from previous investigations, to produce
cells with osteoblast-like characteristics (Beresford et al 1983, 1984, 1986).
For the purpose of this thesis, therefore, osteoblast-like cells were
characterised by their ability to increase alkaline phosphatase production in
response to 1,25 (OFI)2 vitamin D. This was demonstrated by histochemical
staining and by colourimetric assay.
The studies presented within this thesis indicated that media
conditioned by primary cultures of human osteoblast-like cells could
significantly (p<0.05) stimulate the growth of the prostate cell lines DU145,
PC-3 and LNCaP in a dose dependent manner. This is a novel result and
found to be reproducible with a wide range of different osteoblast-like cell
cultures. This stimulatory activity showed some specificity to the osteoblast
since media conditioned by skin fibroblasts had no effect on the growth of
DU145 or PC-3 cells. This also suggested further that the stimulatory effects
of OBCM were due to osteoblast-like cells, since both the osteoblast and skin
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fibroblast derive from connective tissue fibroblasts (Beresford et al 1983,
1984,1986).
The cell lines used demonstrated different responses to the mitogens
in OBCM. PC-3 cell growth was consistently (and significantly) stimulated by
OBCM to a greater extent (3.2-3.9 fold) than DU145 cells (1.9-2.4 fold), when
compared to growth in serum free medium. The LNCaP cell line displayed
only a 1.3-1.5 fold stimulation of growth due to OBCM. This decreased
sensitivity maybe due to a number of factors:
a) The presence of FCS in the experimental medium may mean the growth
of LNCaP cells was already stimulated before the addition of OBCM.
Therefore FCS may mask any potential stimulatory effects of OBCM at
lower doses.
b) FCS may contain factors which are inhibitory to the prostate mitogens in
OBCM.
c) LNCaP cells may secrete factors which are antagonistic to OBCM
mitogens.
d) LNCaP cells may be less responsive to OBCM, because they possess
fewer receptors to the osteoblast mitogens, or a post-receptor
abnormality.
Some of these problems could be answered if PC-3 and DU145 cells were
cultured under exactly the same conditions as the LNCaP cell line (i.e., with
FCS). If the growth stimulation then became depressed in the presence of
FCS, this would suggest that FCS does mask the stimulatory effects of
OBCM. However, if the growth stimulation remained greater than that of




A difference in sensitivity of the three cell lines may have arisen due to
differences in the number and (or) type of mitogen(s) receptors, present on
each cell line. Prostate cell line growth has already demonstrated varying
sensitivity to TGFI3. for such reasons. Experiments have shown that TGFIi
inhibits the growth of DU145 and PC-3 cells but does not affect LNCaP
growth (Wilding et al 1989b). Although this effect is inhibitory, the pattern is
the same as for OBCM i.e., PC-3 and DU145 growth was affected whereas
LNCaP growth was unaffected. These differential responses were attributed
to the presence of TGFI2, receptors on PC-3 and DU145 cells but not on
LNCaP. PC-3 cells possessed more binding sites than DU145 cells and were
also inhibited to a greater extent than DU145 cells. This illustrates how the
presence or absence of growth factor receptors can dictate the growth
response of a cell.
Characterisation of OBCM
Pulsing the osteoblast-like cells with DHT or 1,25 (OH)2 Vitamin D did
not influence the production of prostate mitogens, nor had these two
hormones any synergistic effects with the mitogens, on prostate growth. The
prostate mitogenic activity induced by OBCM was however inhibited by heat
and acid.
Since high performance chromatography techniques were unavailable,
OBCM was crudely fractionated with 'Centricon filters'. This procedure
suggested the presence of two or more active components, with molecular
weights of >100Kd and 30-1 OOKd. To test the efficiency of filtering, the
various molecular weight fractions were run on a polyacrylamide gel and
analysed by silver staining. This indicated that filtration was not 100%
efficient. The staining revealed that some proteins with molecular weights less
than that of their filter cut-off point were retained on the filter. This meant that
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the decrease in growth stimulation observed when DU145 cells were
incubated in the OBCM fraction '<1 OOKd' compared to '>100Kd' could have
been due to:
a) the absence of stimulatory factors >1 OOKd (efficient filtering) or
b) the absence of stimulatory factors <100Kd, because they were retained
on the filter (inefficient filtering).
If the effect of (b) is a simple dilution of the stimulatory factors '<100Kd' and
not a loss of unknown paracrine interactions, then this should not affect any
stimulatory activity of the '<100Kd fraction'. This is presumed because the
dose response analysis of OBCM indicated that significant stimulation of
DU145 cells was achieved with concentrations of OBCM between 6.25-50%.
Since 50% OBCM was filtered, it would have to be greatly diluted (by
retention) to influence its stimulatory activity. Therefore the decrease in
DU145 stimulation in the fraction '<1 OOKd' is most likely due to loss of
stimulatory factors greater than 100Kd and not due to loss (dilution) of factors
<100Kd, i.e., the filters were accurate.
These results suggest that growth factors with molecular weights less
than 30Kd are unlikely to be the prostate mitogens in OBCM. With additional
time these studies could be confirmed by further fractionating the OBCM with
high performance liquid chromatography.
Site Specificity
The importance of osteoblast-derived factors in the production of
prostate skeletal metastases was investigated by examining the effects of
factors from other potential prostate metastatic sites. This was assessed by
the response of prostate cells to media conditioned by cell lines derived from
kidney, lung and bladder. The results demonstrated no stimulation of the
prostate cells by any of the three media (at 50% dilution). In support of these
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results, Charkal-Roy et al (1989) could find no significant response of PC-3
cells to media conditioned by human kidney, muscle or skin tissue. Therefore
prostate cell lines were more responsive to soluble factors produced by
osteoblast-like cells than factors produced by kidney, lung or bladder cell
lines. This characteristic may be a contributory factor to the metastasis of
prostate cancer to bone.
In similar, but reversed experiments the effects of exposing 50%
OBCM to cell lines derived from other cancers, metastasising to bone was
analysed (bladder, liver and breast). The results indicated that OBCM had no
effect on the growth of these cell lines, whilst still stimulating prostate cells.
Cancers of the bladder, liver and breast usually produce osteolytic lesions. If
this is a characteristic shared by their respective cell lines, then it may
indicate that the metastasis of prostate cancer to bone depends not only on
growth factors from the bone environment but also from the prostate cancer
cell. Further research on this preliminary data would help to establish whether
or not the selective metastasis of prostate to bone shows a dependency on
bi-directional paracrine effects between the osteoblast and the prostate
cancer cell. This study should include examination of media conditioned by a
wider range of cell lines, tumours and primary cultures derived from both
osteolytic and osteoblastic tumours.
Media Conditioned By Bone Marrow From Proximal Femora
Has No Effect On Prostate Cell Line Growth.
In addition to the studies on osteoblast-like cells, the effects of bone




Studies by Charkal-Roy et al (1989) have already shown that media
conditioned by bone marrow removed from infant sternum can stimulate the
growth of prostate cell lines, DU145 and PC-3. Later experiments attributed
some of this stimulatory activity to transferrin (Charkal-Rossi et al 1992).
Other researchers (Klose et al 1987) have however demonstrated that rat
BMCM inhibits the growth of rat prostate tumours.
To try and clarify the effect of BMCM on prostate cancers, this study
examined the effect of media conditioned by red bone marrow (from the
proximal femur) on the growth of prostate carcinoma cell lines. It was found
that both DU145 and PC-3 showed no growth response to this red BMCM, if it
was diluted 2 fold with SFM. This concentration of BMCM was used because
Charkal-Roy et al (1989) showed this dose caused maximal stimulation.
Additionally, our own studies with OBCM indicated that 50% conditioned
medium gave maximal response. Since Charkal-Roy et al (1989)
supplemented their cell growth experiments with 1% FCS (v/v), it was tested
whether or not supplementing the BMCM of these studies with 1% and 5%
FCS (v/v) could also produce stimulatory responses. However, the prostate
cell lines still showed no response to the BMCM collected in this study when
supplemented with FCS.
There are several factors which may account for the discrepancies
between this work and that of others, regarding the effects of BMCM on
prostate cancer cell growth. These are as follows:
i) Species
ii) Presence of transferrin
iii) Age
iv) Activity of bone marrow
Each of these will now be discussed in further detail.
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Firstly, the inhibitory effects of rat BMCM could be an effect confined to
the rat species (and previously discussed in the introduction). Secondly, the
studies by Charkal-Rossi et al (1992) demonstrating that transferrin was one
of the stimulatory components in their BMCM, may affect the results of this
study. They showed that maximum stimulation was reached with 10pg/ml of
transferrin. In view of the fact that the serum free culture technique employed
in this thesis contained 10mg/ml transferrin it seems likely that this level
would mask the stimulatory effects of this factor already present in the
BMCM. However, transferrin only accounts for part of the stimulatory
response induced by Charkal Roy's BMCM, therefore other factors must also
play a part.
There is a large difference in the age of the bone marrow used in both
studies. The red bone marrow in this thesis was predominantly obtained from
the proximal femora of elderly patients having hip replacements, whereas
Charkal-Roy's red marrow came from sternal fragments of children having
corrective surgery. The disease state of bone marrow from hip replacements
should not affect the results since hip replacements are usually required
because of arthritis. Arthritis is a disease which does not directly involve bone
cells or bone marrow but is caused by the loss of calcium and cartilage,
leading to bone thinning. Potentially therefore, the age of the bone marrow
may be a contributing factor. The site from which the bone marrow was
removed may also be important. In the adult, the active sites of the bone
marrow are the proximal ends of the femora and humeri, the sternum,
clavicle, vertebrae, ribs and skull (Harrison 1981), which are also major sites
for prostate skeletal metastases (Jacobs 1983). This implies that prostate
cancer spreads to sites of active bone marrow. The bone marrow in Charkal-
Roy's (1989) studies came from the sternum, whereas the bone marrow for
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these studies came from the proximal femur. Generally the bone marrow of
adult long bones is inactive therefore the advanced age of the specimens
used in this study may mean the marrow was inactive. The idea that active
bone marrow is important for stimulation is further reinforced by results from
Charkal-Roy et al (1989) who found no stimulation of prostate growth by
media conditioned with yellow bone marrow (haematopoietically inactive).
Therefore, stimulation of prostate cancer in the bone environment may be due
to the production of soluble mitogens from active bone marrow.
Alternatively, as prostate cancer only manifests in elderly males and
therefore the use of bone marrow from a child is less valid than the use of
marrow from an adult. Potentially therefore, the lack of stimulation seen by
the BMCM in this thesis is a more accurate portrayal of events in vivo, in
comparison to the results of Charkal-Roy et al (1989). This raises the
possibility that the stimulation of prostate cancer in the bone environment is
due to osteoblast derived mitogens and not bone marrow.
It is suggested that further work should investigate the following
aspects of BMCM stimulatory activity:
1) Using the BMCM prepared, as described in this thesis, diluted in serum
free media without transferrin, the effects of transferrin in BMCM on
prostate cell line growth could be assessed.
2) Assess how prostate cell line growth is affected by the age or activity of
bone marrow.
These experiments may help elucidate whether BMCM stimulates prostate
cell lines due to transferrin alone or due to other factors produced by active
bone marrow, or not at all.
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The Response Of Prostate Carcinoma Cell Lines To
Haematopoietic Growth Factors
Bone marrow and osteoblasts are rich in haematopoietic growth
factors, and since earlier studies have demonstrated that some of these HGF
can stimulate the growth of non-haematopoietic malignant cell lines (Dedhar
et al 1988, Block et al 1992, Young et al 1992, Berdel et al 1992), it was
decided to examine their effects on prostate carcinoma cell lines.
The studies presented show that medium supplemented with rGM-CSF
(0.01-100 lU/ml) stimulated the growth of DU145 and PC-3 cells in a dose
dependent manner. The growth stimulation could be inhibited with a
monoclonal antibody raised specifically to human GM-CSF, suggesting that
the prostate stimulatory activity was specific to GM-CSF. The growth of
LNCaP cells was stimulated at doses of rGM-CSF >5IU/ml, which indicated
decreased sensitivity in comparison to DU145 and PC-3. The reasons for this
decrease in sensitivity may be similar to those for OBCM having less effect
on LNCaP growth and could therefore be investigated in a similar manner.
Other authors have indicated decreased sensitivity to GM-CSF, with
increasing FCS concentration (Dedhar et al 1988, Berdel et al 1992). Serum
therefore appears to be the most likely reason for the decreased response of
LNCaP cells to rGM-CSF, though this remains to be made clear.
Medium supplemented with rEPO (0.1-1 OOmlU/ml) stimulated the
growth of DU145 and PC-3 cells. This conflicts with earlier studies by Berdel
et al (1991) who found no response from a prostate carcinoma cell line 'B' to
rEPO (0.01-100U/ml). The cell line was defined as being derived from a
prostatic carcinoma in their own laboratory. Therefore the characteristics of 'B'
may be different to those of PC-3 or DU145 and this could account for the
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differences in growth response to rEPO. In the same study Berdelef a/ (1991)
found no effect on the clonal growth of a wide range of cell lines derived from
human tumours in response to rEPO (e.g., lung, breast, stomach, renal,
ovarian and colorectal). Inhibition of the biological activity of rEPO with a
monoclonal antibody was not attempted because at the time these
experiments were conducted there was no suitable antibody.
The stimulation of prostate cancer cell lines by rEPO and rGM-CSF
lends support to the findings of other groups who have similarly shown that
the growth of non-haematopoietic malignant cell lines (breast, bladder, lung,
colorectal) can be stimulated by the haematopoietic growth factors, GM-CSF,
IL-3 and G-CSF (Dedhar et al 1988, Nakata et al 1991, Block et al 1992,
Young et al 1992, Berdelef al 1992). Much controversy exists in this field of
investigation since other research groups have found no such stimulatory
activity in response to the haematopoietic growth factors (Foulkeef al 1990,
EORTC 1991, Twentyman & Wright 1991, Guillaumeef al 1993). These latter
groups however often lacked (Guillaume et al 1993) or presented
unconvincing (EORTC 1991) positive controls. The positive controls
presented in the paper by the EORTC indicated significant stimulation of
growth when exposed to rGM-CSF. Flowever in comparison to some of their
claimed negative results, it is obvious that a number of these were stimulated
to similar magnitudes, as the positive controls, and also possessed smaller
deviations of error. This suggests that some of the non-haematological
malignancies were significantly stimulated by rGM-CSF.
Inconsistent results probably arose due to the use of different cell
growth assays (e.g., clonal growth, thymidine incorporation, cell counts
metabolic C02 production, MTT assay). The EORTC group made some
attempts to compare clonogenic, MTT and thymidine assays. They stated that
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GM-CSF had no effect on MCF-7 (breast carcinoma cell line) when assessed
by any of the three assays. The validity of this statement is however uncertain
due their unconvincing positive controls (discussed above). Results may also
vary due to different dose levels and sources of recombinant haematopoietic
growth factors (e.g., Sandoz, Amgen, Behringwerke, Glaxo). Deviation in the
characteristics of the same cell line between laboratories may also have
occurred. All of the above variations in experimentation need to be evaluated
in order to comprehend the real effect of haematopoietic growth factors on
non-haematopoietic malignancies. The problem of divergent cell lines may be
overcome by investigating in vivo experiments with athymic mice or by
examining the effects of haematopoeitic growth factors on primary cultures of
prostate cancer.
The studies presented have indicated that prostate cancer can be
stimulated by haematopoietic growth factors. The presence of haematopoietic
growth factors in bone marrow would therefore provide an advantageous site
for the secondary growth of a tumour. This idea is supported by other
experimental results. The lowest dose of rGM-CSF capable of stimulating PC-
3 and DU145 cell growth was found to be 0.1 Ill/ml (equivalent to 10pg/ml).
Results from ELISA experiments indicated that the bone cells (MG63 and
osteoblast-like cells) produce 21-170pg/ml of GM-CSF-like material, which
would be sufficient (i.e., >10pg/ml) to cause growth stimulation of prostate
cancer cells. A review by Nicola (1989) stated that natural sources produce
10ng/ml of GM-CSF. Therefore bone that is haematopoietically active and
producing quantities of GM-CSF as above, would provide a selective site for
the growth of prostate cancer cells, allowing the development of a metastatic
tumour. The possibility that prostate cancer is only stimulated by active bone
marrow has already been raised. Since haematopoiesis is a process largely
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controlled by haematopoietic growth factors, these growth factors may be
more specifically involved in the selective metastasis of prostate cancer to
active bone marrow.
This idea is further supported by the results of Charkal-Roy et al (1989)
who demonstrated that combinations of haematopoietic growth factors (IL-3,
M-CSF, G-CSF) could stimulate the growth of prostate carcinoma cell lines up
to 50% of that induced by BMCM. Also, recent experiments, investigating IL-1
have found that this growth factor is important for the formation of secondary
melanoma tumours in the bone marrow. Arguelloef al (1992) demonstrated
that the administration of IL-1 into mice increased the number of bone or bone
marrow metastases formed from melanoma cells. This effect was mediated
through the release of prostaglandins and haematopoietic growth factors such
as GM-CSF.
Therefore, experimental evidence is growing to suggest that prostate
cancer spreads to sites of active bone marrow because of the release of
soluble mitogens such as the haematopoietic growth factors.
Can GM-CSF account for the OBCM stimulation of prostate cell
lines?
The results reported in this thesis suggest that GM-CSF is produced
by osteoblasts, a characteristic of these cells previously reported (Horowitzef
al 1989). Whether or not this osteoblast-derived GM-CSF is responsible for
the prostate stimulatory activity of OBCM is debatable. Pre-incubation of
OBCM with concentrations of anti-GM-CSF mAb known to inhibit the rGM-
CSF induced stimulation of DU145 cells, had no effect on the DU145
mitogenic activity of OBCM. Other experiments could not find any additive
effects of DU145 growth stimulation when media containing EPO, GM-CSF or
OBCM were combined. This may mean that OBCM already contains GM-CSF
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and EPO. Immunological investigations showed that OBCM did contain GM-
CSF-like material, however, it is unlikely that OBCM contains EPO, since
EPO is a hormone normally produced by the kidney. However, the lack of
additive effects when media containing rEPO or rGM-CSF were combined
suggested that DU145 growth was instead stimulated to a maximum by all
three test media. Since these two solutions were originally devoid of each
other, an additive effect would have been expected if growth was sub-
maximal. It is unlikely therefore that GM-CSF on its own can account for the
prostate mitogenic activity of OBCM.
Potentially, GM-CSF is one of many factors produced by osteoblasts
which act in a synergistic fashion to stimulate prostate cancer growth.
Fractionation of the OBCM was carried out to try and clarify this. The two
stimulatory fractions of OBCM ('>100Kd' and '<100Kd') indicated no inhibition
of growth stimulation when incubated with the anti-GM-CSF mAb. Since GM-
CSF has a molecular weight of 22Kd (Wong et al 1985) and the stimulatory
fractions of OBCM had, approximately, molecular weights greater than 30Kd
the likelihood of GM-CSF being responsible for OBCM stimulatory activity is
less likely. However, analysis of OBCM for the presence of GM-CSF by
Western Blot indicated GM-CSF-like material (and recombinant GM-CSF) to
have a molecular weight of 42Kd. If this was due to dimerisation or an
interaction of GM-CSF with SFM then GM-CSF would appear in the
stimulatory fraction 30-1 OOKd.
The results presented have not been able to demonstrate whether or
not GM-CSF is in part responsible for the prostate stimulatory activity of
OBCM. However since both immunohistochemistry and ELISA suggested the
presence of GM-CSF-like material in OB cultures, it is likely to contribute to
this effect. The GM-CSF-like material produced by these cultures was not
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shown to have any biological activity therefore it cannot be ruled out that the
GM-CSF-like material was inactive.
Research has shown that Lewis-lung carcinoma cell lines can produce
GM-CSF (Young et al 1992). Therefore media conditioned by another lung
carcinoma cell line, HF19, might be expected to stimulate the growth of the
prostate carcinoma cell lines. Our immunohistochemical studies have
indicated that the lung cell line, HF19, was immunoreactive with an anti-GM-
CSF mAb. However media conditioned by this cell line showed no evidence
of stimulating PC-3 and DU145 cells. Unlike the experiments by Youngef al
(1992), we did not demonstrate that HF19 conditioned medium possessed
GM-CSF biological activity, therefore there may not be any active GM-CSF in
the medium. This would explain the lack of prostate cell line growth
stimulation. Alternatively, since immunostaining is a very sensitive procedure
the lung cells may be producing GM-CSF but not at great enough levels to
stimulate the prostate cell lines, or there may be other growth factors in the
HF19 conditioned medium which are antagonistic to the GM-CSF.
Secretion Of GM-CSF by Prostate Cell Lines
Experiments carried out by Young et al (1992) have shown that lung
carcinoma cell lines can not only respond to GM-CSF but also secrete this
haematopoietic growth factor. Further studies were therefore conducted to
investigate whether or not GM-CSF was produced by prostate cell lines.
Immunohistochemical analysis, showed immunoreactivity of anti-GM-
CSF mAb with DU145 and PC-3 cell cultures. The cell staining was specific to
the perinuclear region which is indicative of a secretory protein. This was
assumed because exogenous GM-CSF bound to its receptor would produce
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an even staining, not one confined to regions of the Golgi. The LNCaP cell
line showed no staining. In support of these results, osteoblast-like cells and
MG63 demonstrated positive staining. These two cell types were used as
positive controls because both have osteoblast characteristics, and
osteoblasts are known to secrete GM-CSF (Horowitz et al 1989). To
demonstrate the specificity of the anti-GM-CSF mAb, the positive stain of
DU145 cells was inhibited by pre-incubation of the antibody with excess rGM-
CSF. Pre-incubation of the antibody with either rlL-3 (which shares the same
ft receptor subunit as GM-CSF [Kitamuraef al 1991]) or rEPO, did not affect
the positive stain, indicating further the specificity of the antibody.
Prostate cancer primary cultures of both epithelial and fibroblastic cells
were immunostained with the anti-GM-CSF mAb. Epithelial cells showed
positive staining only. Although this result was reproduced on three different
prostate cancer tissues, the study would be more conclusive with greater a
number of tissue samples. A selection of malignant cell lines other than
prostate cancer (available in our laboratory) were similarly immunostained.
Positive staining was seen in melanoma and lung cell lines, these results
confirm those already reported by Young et al 1992. Negative results were
found for bladder, liver, osteosarcoma and larynx.
Media conditioned by the prostate cell lines was analysed by both
ELISA and Western blotting. These techniques indicated that GM-CSF-like
material was produced by both PC-3 and DU145 cells but not LNCaP. The
Western blot revealed a protein band which migrated with recombinant GM-
CSF. The protein band ran greater, unexpectantly. The correct molecular
weight is 18-22Kd (Wong et al 1985). This is unlikely to represent a partially
cleaved precursor protein, or state of glycosylation since the protein bands
migrated at the same molecular weight as the recombinant material. A dimer
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is unlikely since the blot was carried out under reducing conditions.
Nevertheless because the molecular weight is that of a dimer it cannot be
ruled out. It is possible that an adduct had formed between GM-CSF and BSA
or some other component of the medium.
To complement the immunological studies, GM-CSF gene expression
in the three prostate cell lines was investigated by RT PCR of total cellular
RNA. GM-CSF gene transcripts were identified in PC-3, DU145 and blood
cells. This was known from the presence of the expected 170bp product in all
three cell types, which could be specifically cleaved by theBgl 1 enzyme. The
products (and primers for PCR) were all calculated from the GM-CSF cDNA
sequence (Wong et al 1985, Kaushansky et al 1986). The LNCaP cell line
showed expression of the 170bp product but since this could not be cut with a
Bgl 1 enzyme, whether or not it was a GM-CSF gene product remains
uncertain. Since the primer sequences were long and therefore very specific it
is unlikely that a non-specific band occurred at 170bp. It may be that the T4
DNA polymerase introduced a mutant nucleotide into the Bgl 1 recognition
site, though this is unlikely since the result was repeatable. It is more
probable that the LNCaP cell line, used in our laboratory, already contains a
mutation which makes it resistant to digestion. The presence of a mutation
may also explain the absence of any GM-CSF protein. Further experiments
could answer this problem by sequencing the LNCaP 170bp product or
Southern blotting.
These results together provide strong evidence for the production of
GM-CSF by the prostate cancer cell lines PC-3 and DU145. LNCaP cells




Recent research by Guillaume et al 1993 demonstrated no GM-CSF
gene transcription by DU145 cells which disagrees with the results presented
here. They did however demonstrate the larynx cell line used in this thesis
showed no GM-CSF gene transcription which is in agreement with the
findings of this thesis. It seems likely that cytokine gene transcription is very
variable within cell lines and may be a function of passage number and clonal
changes. Pekarek et al 1993 have indicated that tumours of the same type
and lineage can have distinct cytokine mRNA expression patterns. Therefore
to correctly analyse cytokine expression in non-haematological malignancies
one should investigate the malignant tissues themselves.
Immunoreactivity of Prostate Tissue Sections With a GM-CSF
Monoclonal antibody.
To investigate the latter statement a number of prostate tissues of
varying disease states were immunostained with the anti-GM-CSF mAb.
Immunoreactivity of the antibody was found with poorly differentiated prostate
cancers but not well differentiated ones. Staining was also absent in benign
tissues. These results imply a connection between prostate cancer
progression and GM-CSF production. Staining of the poorly differentiated
cancer indicated positive staining only in areas of malignant epithelia and not
in stromal sites. This supports the results found from the primary cultures,
that GM-CSF-like material was produced from epithelial cells and not from
fibroblasts.
It was interesting to note that normal prostate peripheral zone tissue
indicated positive staining confined to basement membranes around the
secretory duct epithelia. The explanation of this is unknown, but it may be
attributed to the sequestration of GM-CSF-like material by
glycosaminoglycans in the extracellular matrix, in a manner similar to that
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seen within the bone marrow (Gordon et al 1987, Roberts et al 1988). The
sequestering of haematopoietic growth factors in this way is thought to
present them in a biologically active form for haematopoietic cells.
Again a greater number of prostate cancer tissue sections would help
to confirm whether GM-CSF production is linked to cancer progression. The
staining of actual metastatic tissue sections would help evaluate whether or
not GM-CSF-like material is secreted at secondary metastatic sites.
Positive staining of the malignant prostate tissues did not necessarily
mean these tissues produced GM-CSF. Flowever the fact that DU145 and
PC-3 cells showed the production of GM-CSF, by a number of experiments,
strongly supports the idea that cancer tissues also produced GM-CSF.
Bi-directional Growth
In the prostate gland, malignancy arises from aberrant growth control.
As discussed in the introduction, normal growth is under endocrine and
paracrine growth factor regulation. Under androgenic control, growth factors
from the stroma and epithelia interact so that the stimulatory effects of FGF
and EGF are balanced by the inhibitory effects of TGFI3> (Schuurmansef al
1991, Steiner 1993). During malignant growth the prostate cells become
androgen insensitive. Cells also become less sensitive to EGF and it is
thought that they switch to an autocrine stimulation of growth by TGFa
(Wilding et al 1989a, MacDonald et al 1990). Alteration of normal growth
factor action may affect local paracrine growth controls which are highly
dependent on one another. For example, the overexpression of TGFI3>1 in
prostate cancer (Steiner et al 1992) could affect the extracellular matrix
production from stroma, leading to tissue breakdown or decreased cell
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adhesion (Lyons & Moses 1990). These effects may be responsible for the
increasing propensity of a prostate cell to metastasise with increasing TGFI2.1
production (Steiner et al 1992). In a similar manner, the production of GM-
CSF-like material from malignant epithelia may have important growth or
structural effects on the surrounding stroma. Alternatively, the interaction of
GM-CSF with other growth factors may result in a more malignant phenotype.
Once the prostate cancer cell is able to metastasise to the bone,
prostate growth factors may have important effects on the normal growth of
the bone. The stimulation of prostate cancer cells in the bone environment
and the production of osteoblastic lesions, suggests a bi-directional paracrine
control of growth. The introduction of foreign mitogens from metastatic
prostate cells in the bone environment would appear to interfere with the
normal growth of the osteoblast causing a net increase in numbers.
Conversely bone derived mitogens cause uncontrolled proliferation of
prostate tumour growth. Increasing numbers of both cell types would
accelerate the effect.
The high levels of GM-CSF produced by the PC-3 cell line (2.5pg/pg
protein) may be implicated in the formation of osteoblastic lesions, since GM-
CSF is a known stimulator of osteoblast growth (Evans et al 1989).
The release of latent TGFI2> from Dunning rat tumours has also been
suggested as a potential factor causing osteoblastic lesions, since active
TGFG can also stimulate osteoblast-like cells and inhibit osteoclasts (Matuo et
al 1990, Chenu et al 1986). Recent results (Killian et al 1993) have indicated
that latent TGFI3. is activated by prostate specific antigen (a serine protease
specific to the prostate). This provides a unique mechanism for prostate cells
to increase osteoblast growth.
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There are several other growth factors which are released by prostate
cancer cells and are capable of stimulating osteoblast growth. These include
PDGF, IGF-I, IGF-II and FGF (Canalis 1981, Sitarasef al 1988, Canalis 1980,
Matuo et al 1988, Rodan et al 1987, Story et al 1989). As yet, no-one has
investigated these factors in relation to prostate-derived osteoblast mitogens.
Unknown prostate-derived osteoblastic mitogens have been identified
by several researchers. Koutsilieris et al (1987) identified a 10Kd peptide
produced from malignant tissue - obviously not GM-CSF nor TGFI3., whose
molecular weights are 22Kd and 25Kd respectively. Simpson et al (1985)
identified a 20Kd protein encoded by an mRNA fraction of 1800 bases. This
could be GM-CSF (encoded by 1200 nucleotide mRNA [Goughef al 1984])
but not TGFR (encoded by a 2500 nucleotide mRNA [Derynckef al 1988]).
Either TGFI3. or GM-CSF could be responsible for the 26-30Kd PC-3 derived
osteoblast mitogen, identified by Perkelef al (1990). However whether or not
GM-CSF or TGFI3. were responsible for these unknown mitogens was not
assessed.
The studies presented in this thesis, have indicated the potential for a
bi-directional control of growth between osteoblasts and prostate carcinoma
cells. The production of GM-CSF by prostate carcinoma cell lines can
stimulate osteoblasts and conversely osteoblast-like cell derived mitogens
can stimulate prostate cancer cells.
Gleave et al (1991) have already demonstrated such a bi-directional
effect using nude mice injected with LNCaP cells. LNCaP tumours were
induced most consistently when coinoculated with media conditioned by a
bone fibroblast cell line. In vitro, LNCaP conditioned medium could stimulate
the growth of the same bone fibroblast cell line. The results could be further
investigated using primary cultures of osteoblasts. As briefly discussed,
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analysis of bi-directional effects between cancers producing osteolytic or
osteoblastic tumours and bone cells may help establish if prostate skeletal
metastases are in part due to uncontrolled growth caused by paracrine
growth factors of prostate cancer and osteoblasts.
Is GM-CSF Involved In Cancer Progression?
GM-CSF has been implicated in the aetiology of several cancers
(Takeda et al 1991, Young et al 1992, Kohn et al 1993). For example, in lung
carcinoma cell lines it may act as an autocrine growth factor (Young et al
1992). Prostate cell lines and prostate tissue sections all exhibited differing
degrees of GM-CSF immunostaining. The more invasive cell lines produced
greater amounts of GM-CSF and only the more malignant tissues indicated
GM-CSF immunostaining. There were also variations in the sensitivity of the
prostate cell lines to exogenous GM-CSF.
It has to be stressed that these results are preliminary, since both the
number of tissue samples and cell lines do not allow the findings to be
statistically significant. Although the invasive potential of our prostate cell
lines was not investigated, previous research has indicated that the PC-3 cell
line is more invasive than DU145 cells (Albini et al 1987, Kozlowski et al
1984). PC-3 cells produced more GM-CSF than DU145 cells (2.5pg GM-
CSF/pg protein versus 1.7pg/pg) and they were also stimulated by rGM-CSF
to a greater extent (i.e., 3 fold versus 2.3 fold). This would suggest that
increased production of GM-CSF together with enhanced sensitivity (perhaps
through increased numbers of GM-CSF receptors) leads to a greater capacity
for autocrine growth and increased invasive potential. These results are
supported by the fact that LNCaP cells which are the least invasive and
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hormone sensitive, showed no production of GM-CSF-like material. Further
evidence from the immunostaining of prostate tissue sections indicated that
poorly differentiated prostate cancers are immunoreactive with an anti-GM-
CSF antibody. The same was not true for well differentiated cancer or benign
tissues. This too would imply that more malignant prostate cancers have a
greater ability to produce GM-CSF. These facts indicate that the production of
and the response to GM-CSF by prostate cancer may be connected to its
progression.
It has been suggested that the progression of a cancer to a hormone
insensitive state is assisted by the over expression of autocrine growth
factors (King 1990, Eaton & Davies 1991). In light of this, the production of
GM-CSF by prostate hormone insensitive cells (PC-3, DU145) but not by
androgen responsive cells (LNCaP), may indicate that GM-CSF production
aids the progression of prostate cancer to an hormone insensitive state. We
could begin to understand whether the production of GM-CSF is linked to the
loss of androgen sensitivity by a study of prostate cancer tissues which have
undergone androgen ablation.
GM-CSF has been linked to cancer progression in other tumours.
Takeda et al (1991) indicated that highly metastatic mouse tumours exhibit
both GM-CSF gene expression and the ability to secrete GM-CSF activity into
their culture medium. Non-metastatic mouse tumours had neither
characteristic. Young et al (1992) also linked the production of GM-CSF to
cancer progression in lung carcinoma cell lines. Using PCR analysis they
showed metastatic variants could produce GM-CSF whereas non-metastatic
variants could not.
M-CSF may also have a role in cancer progression. Results by
Filderman et al (1992) demonstrated that the invasive potential of breast and
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lung cell lines, expressing the c-fms oncogene product (mutant M-CSF
receptor), could be increased by exposure to M-CSF.
How could GM-CSF Increase Invasiveness?
Since GM-CSF has been implicated as a growth factor involved in the
progression of lung and now, prostate cancer, there must be a mechanism for
this to occur. Several possibilities exist:
a) Nerve growth factor-like proteins have shown a capacity to increase the
mobility of prostate cell lines (Djakiew et al 1989). GM-CSF has also
increased the mobility of melanoma cells (Kohn et al 1993) and Lewis lung
carcinoma cells (Young et al 1992). Therefore secretion of GM-CSF by
malignant prostate cells may increase their invasive potential by acting as
a motility factor.
b) It has been reported that the release of GM-CSF and IL-3 from Lewis lung
carcinoma cells can induce myelopoiesis and the appearance of bone
marrow derived immune-suppressor cells (Young et al 1991). Although no
similar research has been carried out on prostate cancer, it can be seen
that the secretion of GM-CSF by prostate cancer may have matching
effects and allow the tumour cell to avoid immune attack.
c) The secretion of various degradative enzymes and adhesive factors by
prostate cancer cells has been linked to their invasive potential (Keer et al
1991, Pajouh et al 1991, Haq et al 1992). Since Lewis-lung carcinoma cells
have shown an increased capacity to attach to and invade artificial
basement membrane if they produce GM-CSF (Young et al 1992), a similar
effect for the production of GM-CSF by prostate cancer should not be ruled
out.
d) TGFa is suspected to be an autocrine growth factor in prostate cell lines,
since it is known to be both produced from and stimulate prostate cancer
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cell line growth (Wilding et al 1989a). GM-CSF has the same prostate
growth characteristics and therefore may also act as an autocrine growth
factor. This idea will be discussed further in the next section.
Is GM-CSF An Autocrine Growth Factor?
GM-CSF has already been implicated as an autocrine growth factor in
Lewis-lung carcinoma (LLC) cells (Young et al 1992). These studies showed
that the invasive potential of LLC cells could be inhibited with an anti-GM-CSF
antibody and increased with exogenous GM-CSF. Using PCR analysis, they
found GM-CSF gene transcripts in the metastatic LLC cells.
The experiments of this thesis have shown that prostate cancer cell
lines are stimulated by exogenous GM-CSF and are also capable of
producing GM-CSF. High levels of anti-GM-CSF antibody (20pg/ml)
suggested some inhibition of the basal growth of DU145 cells. Therefore GM-
CSF could be acting as an autocrine growth factor in prostate hormone
insensitive cell lines. It would be important for further studies to demonstrate
that the GM-CSF-like material produced by these prostate cells possesses
GM-CSF biological activity. The lack of basal growth inhibition by the anti-
GM-CSF mAb may be due to the production of biologically inactive GM-CSF.
Other investigations with various prostate cancer models have
indicated that both TGFI2.1 (Steiner ef al 1992) and TGFa (Wilding et al
1989a) act as potential autocrine growth factors. Both these are likely to be in
the media conditioned by the prostate cell lines, but could not be the GM-
CSF-like material, because the ELISA antibody showed no cross-reactivity
with either.
GM-CSF Receptors
If GM-CSF is acting as an autocrine growth factor (or paracrine) the
logical progression to the experiments carried out so far would be to show the
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presence of receptors on the prostate carcinoma cell lines. The GM-CSF
receptor has two receptor subunits a and IT The a subunit has low affinity
and is specific to GM-CSF (Gearing et al 1989) whereas the I3> subunit is
shared with IL-3 (Kitamura et al 1991). When both subunits are bound to GM-
CSF it results in the formation of a 45Kd high affinity receptor.
Using ligand exchange analysis, the presence of GM-CSF receptors
was demonstrated in melanoma cells (Baldwin et al 1991, Kohn et al 1993).
The presence of both receptor units was also determined by RT PCR in cell
lines derived from cancers of the lung, head, neck, ovary, stomach and
kidney (Guillaume et al 1993). Both Guillaume et al (1993) and Baldwin et al
(1991) stated that the presence of GM-CSF receptor on the cell lines did not
confer the ability to proliferate in the presence of GM-CSF. Flowever the
results by Kohn et al (1993) indicated that the presence of GM-CSF receptors
on melanoma cells increased their capacity to migrate in response to GM-
CSF, an important characteristic for a metastatic cell. Guillaume (et al 1993)
indicated that DU145 cells possess only the a subunit and not the IT Since
they did not test whether the cells were responsive to GM-CSF it is uncertain
as to whether the a subunit on its own can produce growth stimulatory
effects. It is also possible that the DU145 cell line used in these experiments
had different characteristics to the one used in this thesis, due to clonal
divergence etc. The results of Guillaume et al (1993) indicated the presence
of GM-CSF receptors on non-haematopoietic cell lines and therefore the
potential for GM-CSF to affect a variety of other cancers.
Clearly, there is a need to examine the presence of GM-CSF receptors
in prostatic cells and relate their presence or absence to the cells capacity to




A number of events are thought to be important in the formation of a
site specific metastasis including: a) selective adhesion at the secondary site
due to specific cell adhesion molecules (Blood & Zetter 1990, Johnsonef al
1991, Haq et al 1992); b) tumour cell production of hydrolytic enzymes
capable of degrading the secondary organ's extracellular matrix (Zetter 1990);
c) the ability of a secondary organ to sustain and increase the growth of a
tumour cell depending on the growth factors it secretes (Nicolson et al 1986,
Charkal-Roy et al 1989).
The initial aim of this thesis was to investigate whether or not growth
factors present in the bone environment can stimulate the growth of prostate
cancer, and therefore promote the selective metastatic spread of prostate
cancer to skeletal sites.
Media conditioned by osteoblast-like cells or supplemented with rGM-
CSF or rEPO were all capable of stimulating the growth of prostate cancer
cell lines compared to control levels. Whereas media supplemented with rll_-3
or rG-CSF had no effect on growth. Similarly media conditioned by bone
marrow from proximal femora also had no stimulatory effect on prostate cell
line growth. These results and those of others suggest that the growth of
prostate cancer is stimulated by either
i) osteoblast-derived mitogens and not bone marrow, or
ii) osteoblast-derived mitogens and soluble mitogens from active bone
marrow (Klose et al 1987, Charkal-Roy et al 1989, Arguello et al 1992).
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The latter would help explain why prostate skeletal metastases are frequently
observed at sites with active marrow, and further implicates haematopoietic
growth factors in their formation.
Studies were extended to investigate whether or not the prostate cell
lines could secrete GM-CSF. DU145 and PC-3 (hormone insensitive) were
both found to produce GM-CSF at both protein and RNA levels. LNCaP
(hormone sensitive) cells did not show any GM-CSF protein production.
Immunostaining of prostate tissue sections and primary cultures
demonstrated that the production of GM-CSF-like material was restricted to
epithelial cells and not stroma. Investigation of malignant prostate tumour
sections showed the presence of GM-CSF-like material only in poorly
differentiated cancers and not in well differentiated. These studies imply that
GM-CSF production may be linked to the progression of prostate cancer,
possibly as an autocrine growth factor. Previous research has shown that
GM-CSF can stimulate osteoblastic growth (Evans et al 1989). Therefore the
production of GM-CSF by prostate cancer indicates a potential mechanism for
the formation of osteoblastic lesions.
Overall, the results demonstrated the growth stimulation of human
prostate cancer cell lines by soluble osteoblast-derived mitogens, rEPO and
rGM-CSF. These may be important factors required to establish prostate
metastases at skeletal sites. The production of GM-CSF by prostate
androgen insensitive, carcinoma cells could play a role in the formation of




Using the findings of this thesis and those of others (discussed in the
introduction) a metastatic cascade was drawn (figure 1) to illustrate how
prostate cancer may hypothetically spread to bone.



























FN - Fibronectin OB
E-Cad - E-Cadherin BM
NGF - Nerve growth factor-like protein
u-PA - urokinase type plasminogen activator
MMP-7 - matrix metalloproteinase-7
TGF a & b - Transforming growth factor alpha & beta





Prostate cancer cells detach from the primary tumour due to
decreased levels of the cell adhesion molecules, fibronectin and E-cadherin
(Schalken et al 1988, Bussemakers et al 1992). They become mobile due to
the secretion of motility factors such as nerve growth factor-like peptides or
bFGF and invade the circulation through the release of urokinase type
plasminogen activator and matrix metalloproteinase-7 (Djakiewef a/ 1993,
Pienta et al 1991, Hoosein et al 1991, Pajouh et al 1991). The malignant cells
evade the immune system by methods unknown and eventually adhere to
bone endothelial cells (Flaq et al 1992). Within the bone environment the
tumour cells are stimulated by soluble osteoblast-derived mitogens, EPO and
GM-CSF. Potentially they are also stimulated by soluble bone marrow-derived
mitogens, including transferrin and other factors unknown (Charkal-Royef al
1989, Charkal-Rossi et al 1992). The increased growth of prostate tumour
cells is enhanced by the autocrine stimulation of GM-CSF, TGFa and TGFG
(Wilding et al 1989a, Steiner et al 1992). Additionally, the production of GM-
CSF, TGFG and unknown mitogens will also act in a paracrine fashion to
stimulate osteoblast growth (Matuo et al 1990). Although some of the steps
detailed are now well established others need to be confirmed.
Implications For Therapy
The concentrations of haematopoietic growth factors used in the
experiments of this thesis were based upon those used in clinical treatments.
Haematopoietic growth factors are used to treat refractory anaemia and for
leukocyte recovery after cytotoxic chemotherapy (Oster et al 1990, Moore
1990). The results presented have shown that certain haematopoietic growth
factors can stimulate prostate cancer cell lines. This raises concern for the
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use of rGM-CSF following chemotherapy and the use of rEPO in managing
refractory anaemia in prostate cancer patients. Further research into their use
in cancer therapy is essential. There is a need to evaluate the effects of using
GM-CSF to revive bone marrow after chemotherapy of prostate cancer
patients in order to assess whether it is also encouraging the re-emergence of
skeletal metastases. This concern applies to all cancers treated with
haematopoietic growth factors, since mounting evidence indicates that these
growth factors do have roles to play in non-haematopoietic malignancies.
Further investigations are required to substantiate the preliminary evidence
that EPO can stimulate prostate cancer cell lines.
The results presented herein indicate that manipulation of GM-CSF
stimulatory activity within the bone environment might provide a therapy for
reducing prostate skeletal metastases.
Future Work
The results raise three major questions which require further research
in order to answer and develop these ideas.
1) Does prostate cancer metastasise to bone because of osteoblast factors
alone or also because of factors derived from active bone marrow?
Primarily this question could be investigated by pathological
observation of the exact sites that prostate skeletal metastases arise. Media
conditioned by bone marrow from a variety of skeletal sites and ages would
also require analysis. If prostate cell lines were stimulated only by active bone
marrow, the mitogenic activity should be fractionated to evaluate whether it
arises from transferrin alone or also from haematopoietic growth factors.
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Finally an investigation of whether the selective metastasis is aided by
a bi-directional enhancement of growth between the osteoblast and the
prostate cancer cells should be undertaken. This could be investigated by the
analysis of growth effects between osteoblasts and cells derived from cancers
producing osteolytic lesions compared to those producing osteoblastic
lesions.
2) Secondly, further investigation into whether the production of GM-CSF by
prostate cancer is related to malignant progression should be confirmed by
immunostaining a wider range of malignant and benign prostate tissues. If an
association was found between prostate cancer progression and GM-CSF
production this could be verified by RT PCR of fresh tumours. The use of in
situ hybridisation could identify GM-CSF gene transcripts in the same tissue
slides as those used previously for immunostaining. GM-CSF production in
fresh tumours or media conditioned by primary cultures could be quantified by
ELISA.
3) Finally, the presence of GM-CSF receptors on either prostate cancer cell
lines or malignant tissue should be investigated. RT PCR would provide a
means of initially identifying the subunits, and binding studies could be
accomplished by ligand exchange assay. Both a and G> subunits should be
examined and the presence of one or both related with the sensitivity of the
cell to exogenous GM-CSF.
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